<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001202.pub4" GROUP_ID="INCONT" ID="477499090210053541" MERGED_FROM="" MODIFIED="2013-05-06 22:03:51 +0100" MODIFIED_BY="Muhammad Imran Omar" NOTES="&lt;p&gt;Exported from Review Manager 4.3&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.6&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.6&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.6&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2013-05-06 22:02:03 +0100" NOTES_MODIFIED_BY="Muhammad Imran Omar" REVIEW_NO="0002" REVMAN_SUB_VERSION="5.2.1 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.2">
<COVER_SHEET MODIFIED="2013-05-06 22:03:51 +0100" MODIFIED_BY="Muhammad Imran Omar">
<TITLE MODIFIED="2011-01-07 10:50:35 +0000" MODIFIED_BY="Bary CM Berghmans">Electrical stimulation with non-implanted electrodes for urinary incontinence in men</TITLE>
<CONTACT MODIFIED="2013-05-06 22:03:51 +0100" MODIFIED_BY="Muhammad Imran Omar"><PERSON ID="8985" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Bary</FIRST_NAME><LAST_NAME>Berghmans</LAST_NAME><POSITION>Clinical epidemiologist, health scientist, pelvic physiotherapist</POSITION><EMAIL_1>bary.berghmans@maastrichtuniversity.nl</EMAIL_1><MOBILE_PHONE>0031653641238</MOBILE_PHONE><ADDRESS><DEPARTMENT>Pelvic care Center Maastricht</DEPARTMENT><ORGANISATION>Maastricht University Medical Centre</ORGANISATION><ADDRESS_1>PO Box 5800</ADDRESS_1><CITY>Maastricht</CITY><ZIP>6202 az</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+ 31 433 4373555</PHONE_1><FAX_1>+ 31 433 478914</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-05-06 22:03:51 +0100" MODIFIED_BY="Muhammad Imran Omar"><PERSON ID="8985" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Bary</FIRST_NAME><LAST_NAME>Berghmans</LAST_NAME><POSITION>Clinical epidemiologist, health scientist, pelvic physiotherapist</POSITION><EMAIL_1>bary.berghmans@maastrichtuniversity.nl</EMAIL_1><MOBILE_PHONE>0031653641238</MOBILE_PHONE><ADDRESS><DEPARTMENT>Pelvic care Center Maastricht</DEPARTMENT><ORGANISATION>Maastricht University Medical Centre</ORGANISATION><ADDRESS_1>PO Box 5800</ADDRESS_1><CITY>Maastricht</CITY><ZIP>6202 az</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+ 31 433 4373555</PHONE_1><FAX_1>+ 31 433 478914</FAX_1></ADDRESS></PERSON><PERSON ID="14227" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Erik</FIRST_NAME><LAST_NAME>Hendriks</LAST_NAME><EMAIL_1>erik.hendriks@epid.unimaas.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Epidemiology</DEPARTMENT><ORGANISATION>Maastricht University</ORGANISATION><ADDRESS_1>School CAPHRI</ADDRESS_1><CITY>Maastricht</CITY><ZIP>NL-6200 MD</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 43 3881428</PHONE_1><FAX_1>+31 43 3884128</FAX_1></ADDRESS></PERSON><PERSON ID="98310595332162355946110113105803" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Arnold</FIRST_NAME><LAST_NAME>Bernards</LAST_NAME><POSITION>Researcher</POSITION><EMAIL_1>A.t.m.bernards@planet.nl</EMAIL_1><MOBILE_PHONE>+33 652 621866</MOBILE_PHONE><ADDRESS><DEPARTMENT>Research &amp; Innovation</DEPARTMENT><ORGANISATION>Dutch Institute of Allied Health Care (Nederland Paramedisch Instituut: NPi)</ORGANISATION><ADDRESS_1>Amsterdamseweg 16</ADDRESS_1><CITY>Amersfoort</CITY><REGION>Utrecht</REGION><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+33 421 6100</PHONE_1><PHONE_2>+33 421 6190</PHONE_2></ADDRESS></PERSON><PERSON ID="5522" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Rob</FIRST_NAME><LAST_NAME>de Bie</LAST_NAME><POSITION>Professor of Physiotherapy Research</POSITION><EMAIL_1>ra.debie@maastrichtuniversity.nl</EMAIL_1><URL>http://www.cebp.nl</URL><ADDRESS><DEPARTMENT>Department of Epidemiology</DEPARTMENT><ORGANISATION>Maastricht University</ORGANISATION><ADDRESS_1>P.O. Box 616</ADDRESS_1><CITY>Maastricht</CITY><ZIP>6200 MD</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>31 43 388 2362</PHONE_1><PHONE_2>31 43 3882394</PHONE_2><FAX_1>31 43 3884128</FAX_1></ADDRESS></PERSON><PERSON ID="74740356430336605589110415170237" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Muhammad Imran</FIRST_NAME><LAST_NAME>Omar</LAST_NAME><POSITION>Managing Editor Cochrane Incontinence Review Group</POSITION><EMAIL_1>m.i.omar@abdn.ac.uk</EMAIL_1><EMAIL_2>drimran@yahoo.com</EMAIL_2><ADDRESS><DEPARTMENT>Academic Urology Unit</DEPARTMENT><ORGANISATION>University of Aberdeen</ORGANISATION><ADDRESS_1>Health Sciences Building (second floor)</ADDRESS_1><ADDRESS_2>Foresterhill</ADDRESS_2><CITY>Aberdeen</CITY><ZIP>AB25 2ZD</ZIP><REGION>Scotland</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 (0) 122 4438126</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2013-05-03 16:34:10 +0100" MODIFIED_BY="Muhammad Imran Omar" NOTES="&lt;p&gt;Minor update: 10/10/07&lt;/p&gt;&lt;p&gt;New studies found and included or excluded: 8/15/06&lt;/p&gt;" NOTES_MODIFIED="2013-05-03 16:34:10 +0100" NOTES_MODIFIED_BY="Muhammad Imran Omar">
<UP_TO_DATE>
<DATE DAY="21" MONTH="1" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="21" MONTH="1" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="21" MONTH="1" YEAR="2014"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="1998"/>
<REVIEW_PUBLISHED ISSUE="" YEAR=""/>
<LAST_CITATION_ISSUE ISSUE="5" YEAR="2013"/>
</DATES>
<WHATS_NEW MODIFIED="2013-05-06 21:55:48 +0100" MODIFIED_BY="[Empty name]"/>
<HISTORY MODIFIED="2013-05-03 16:41:56 +0100" MODIFIED_BY="[Empty name]"/>
<SOURCES_OF_SUPPORT MODIFIED="2013-03-28 15:23:13 +0000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2013-03-28 15:23:13 +0000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2013-03-28 15:23:13 +0000" MODIFIED_BY="[Empty name]">
<NAME>NIHR</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>The National Institute for Health Research (NIHR) is the largest single funder of the Cochrane Incontinence Group. </P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-05-06 22:02:03 +0100" MODIFIED_BY="Bary CM Berghmans">
<SUMMARY MODIFIED="2013-04-25 22:18:58 +0100" MODIFIED_BY="Bary CM Berghmans">
<TITLE MODIFIED="2011-12-09 09:00:34 +0000" MODIFIED_BY="Bary CM Berghmans">Electrical stimulation with non-implanted electrodes for urinary incontinence in men</TITLE>
<SUMMARY_BODY MODIFIED="2013-04-25 22:18:58 +0100" MODIFIED_BY="[Empty name]">
<P>Some men leak urine (urinary incontinence) when they cough or exercise (stress urinary incontinence) or when they have a sudden, compelling urge to pass urine (urgency urinary incontinence). Men may also need to pass urine more often than usual (frequency) or get up more than once at night to pass urine (nocturia). In men this may be due to an enlarged prostate gland or develop after surgery to removal the prostate. Men can contract their pelvic floor muscles to reduce or stop these symptoms. Electrical stimulation with non-implanted devices involves stimulation of these muscles with a painless electric current using surface electrodes on the skin or a probe placed into the anus. The aim is to make the pelvic floor muscles contract so that they become stronger and so better able to prevent leakage, or to make the muscle at the base of the bladder (the sphincter) contract more strongly to stop urine escaping. Electrical stimulation might also lessen the contractions of the bladder muscle to ease the sense of urgency and allow the bladder to hold more urine.</P>
<P>In this review, electrical stimulation was compared with no treatment, placebo treatment (dummy medical treatment) or any other single treatment. There was some evidence that electrical stimulation increased the effect of pelvic floor muscle training (exercises to strengthen the pelvic floor muscles) in the short term but not after six months. It was not possible to identify whether one treatment was more successful than another. There was, however, more discomfort or pain (adverse effects) with electrical stimulation than with pelvic floor muscle exercises alone. There was not enough information about whether and how electrical stimulation should be used, which type of person or problem it would be best for, and how much it would cost.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-04-25 22:49:29 +0100" MODIFIED_BY="Bary CM Berghmans">
<ABS_BACKGROUND MODIFIED="2013-04-25 22:49:24 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>Electrical stimulation with non-implanted devices is used for patients with different types of urinary incontinence and symptoms of urgency, frequency and nocturia. The current review focused on electrical stimulation with non-implanted devices for the treatment of urinary incontinence in men.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2013-04-25 22:49:29 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>To determine the effectiveness of electrical stimulation with non-implanted devices for men with stress, urgency or mixed urinary incontinence in comparison with no treatment, placebo treatment, or any other 'single' treatment. Additionally, the effectiveness of electrical stimulation with non-implanted devices in combination with another intervention was compared with the other intervention alone. Finally, the effectiveness of one method of electrical stimulation with non-implanted devices was compared with another method.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-04-15 12:18:00 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>We searched the Cochrane Incontinence Group Specialised Trials Register, which contains trials identified from the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, PreMEDLINE, and handsearching of journals and conference proceedings (searched 21 January 2012). We also searched other electronic and non-electronic bibliographic databases and the reference lists of the included studies as well as contacting researchers in the field to identify other relevant trials.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2013-02-15 11:20:27 +0000" MODIFIED_BY="Bary CM Berghmans">
<P>Randomized and quasi-randomized controlled trials.<BR/>
</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2013-04-25 22:17:59 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>Two review authors independently assessed all the identified trials for eligibility. Risk of bias was assessed using the Cochrane tool for determining bias. Disagreements were resolved by discussion, and a third review author was involved in the case of no consensus. Data were analysed using Cochrane methods.<BR/>
</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-04-25 22:18:22 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>Six randomized controlled trials (five full papers and one abstract) were included. There was considerable variation in the interventions used, study protocols, types of electrical stimulation parameters and devices, study populations and outcome measures. In total 544 men were included, of whom 305 received some form of electrical stimulation, and 239 a control or comparator treatment. The trials were mostly small and generally there was not sufficient information to assess risk of bias; only two trials used secure methods of randomization.</P>
<P>There was some evidence that electrical stimulation (ES) had a short-term effect in reducing incontinence compared with sham treatment (for example risk ratio (RR) at six months 0.38, 95% CI 0.16 to 0.87) but not at 12 months. Four trials evaluated the effect of adding PFMT to ES versus pelvic floor muscle training (PFMT) alone or with biofeedback. There was no evidence of a statistically significant difference in the number of men with urinary incontinence at three months (146/239, 61% for combined treatment versus 98/156, 63% with PFMT alone; RR 0.93, 95% CI 0.82 to 1.06). However, there were more adverse effects with combined treatment (23/139, 17% versus 2/99, 2% with PFMT alone; RR 7.04, 95% CI 1.51 to 32.94) and quality of life also seemed better with PFMT alone. One small trial did not detect statistically significant differences between two methods of administration of transcutaneous electrical stimulation (anal versus perineal) but the quality of life score was lower (better) in the anal stimulation group.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-03-29 14:36:08 +0000" MODIFIED_BY="Bary CM Berghmans">
<P>There was some evidence that electrical stimulation enhanced the effect of PFMT in the short term but not after six months. There were, however, more adverse effects (pain or discomfort) with electrical stimulation.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-05-06 22:02:03 +0100" MODIFIED_BY="Bary CM Berghmans">
<BACKGROUND MODIFIED="2013-04-25 22:51:48 +0100" MODIFIED_BY="Bary CM Berghmans">
<CONDITION MODIFIED="2013-04-25 22:50:17 +0100" MODIFIED_BY="[Empty name]">
<P>World wide, urinary incontinence in men is a common problem. In western countries, estimates of prevalence rates up to 65 years of age are between 0.9% and 5% (<LINK REF="REF-Campbell-2012" TYPE="REFERENCE">Campbell 2012</LINK>). In men over 50 years of age, after radical prostatectomy the prevalence of urinary incontinence varies between 5% and 60% (<LINK REF="REF-van-Kampen-2000" TYPE="REFERENCE">van Kampen 2000</LINK>; <LINK REF="REF-Wolin-2009" TYPE="REFERENCE">Wolin 2009</LINK>).</P>
<P>Male stress urinary incontinence is rare except after radical prostatectomy and transurethral resection of the prostate (TURP), which may cause both sphincter and local nerve injury leading to intrinsic sphincter deficiency or weakness of the urethra with stress urinary incontinence as a consequence (<LINK REF="REF-Gacci-2003" TYPE="REFERENCE">Gacci 2003</LINK>; <LINK REF="REF-Groutz-2000" TYPE="REFERENCE">Groutz 2000</LINK>; <LINK REF="REF-Hu-2003" TYPE="REFERENCE">Hu 2003</LINK>; <LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>; <LINK REF="REF-Palmer-2003" TYPE="REFERENCE">Palmer 2003</LINK>). As well as intrinsic sphincter deficiency, detrusor overactivity and poor compliance of the bladder neck may be factors related to urinary incontinence (<LINK REF="REF-Carlson-2001" TYPE="REFERENCE">Carlson 2001</LINK>; <LINK REF="REF-Groutz-2000" TYPE="REFERENCE">Groutz 2000</LINK>; <LINK REF="REF-Gudziak-1996" TYPE="REFERENCE">Gudziak 1996</LINK>; <LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>). In general, persistent stress urinary incontinence tends to occur only in a minority of men, mostly because of surgery of the prostate (<LINK REF="REF-Buckley-2008" TYPE="REFERENCE">Buckley 2008</LINK>). In the case of (persistent) urinary incontinence, this health problem has a major impact on their daily life activities and quality of life (<LINK REF="REF-Coyne-2012" TYPE="REFERENCE">Coyne 2012</LINK>).</P>
<P>Male detrusor overactivity, including urgency urinary incontinence, may be due to bladder outlet obstruction such as with benign prostatic hyperplasia (<LINK REF="REF-De-Nunzio-2003" TYPE="REFERENCE">De Nunzio 2003</LINK>; <LINK REF="REF-Dmochowski-2002" TYPE="REFERENCE">Dmochowski 2002</LINK>) or neurogenic disease (<LINK REF="REF-Steers-2002" TYPE="REFERENCE">Steers 2002</LINK>). Urgency urinary incontinence might also be a symptom related to many different health problems of the lower urinary tract, such as inflammation, infections, kidney stones and tumours.  </P>
<P>For urinary incontinence, detrusor overactivity or symptoms of urgency and frequency, treatment options vary between several surgical and conservative or non-surgical interventions, pharmaceuticals and non-pharmaceuticals (<LINK REF="REF-Abrams-2009" TYPE="REFERENCE">Abrams 2009</LINK>). In the algorithms of the International Consultation of Incontinence, electrical stimulation has been suggested as one of the first-line treatment options (<LINK REF="REF-Abrams-2009" TYPE="REFERENCE">Abrams 2009</LINK>).   </P>
</CONDITION>
<INTERVENTION MODIFIED="2013-04-25 22:51:48 +0100" MODIFIED_BY="[Empty name]">
<P>In the context of conservative therapy, electrical stimulation can be applied using surface electrodes (<LINK REF="REF-Appell-1998" TYPE="REFERENCE">Appell 1998</LINK>; <LINK REF="REF-Brubaker-2000" TYPE="REFERENCE">Brubaker 2000</LINK>; <LINK REF="REF-Goldberg-2000" TYPE="REFERENCE">Goldberg 2000</LINK>; <LINK REF="REF-Govier-2001" TYPE="REFERENCE">Govier 2001</LINK>; <LINK REF="REF-Hasan-1998" TYPE="REFERENCE">Hasan 1998</LINK>; <LINK REF="REF-Jabs-2001" TYPE="REFERENCE">Jabs 2001</LINK>; <LINK REF="REF-Siegel-1992" TYPE="REFERENCE">Siegel 1992</LINK>; <LINK REF="REF-van-Kerrebroeck-1998" TYPE="REFERENCE">van Kerrebroeck 1998</LINK>). Surface electrodes include:</P>
<P>(1) transcutaneous electrical stimulation (<LINK REF="REF-Berghmans-2002" TYPE="REFERENCE">Berghmans 2002</LINK>; <LINK REF="REF-Brubaker-2000" TYPE="REFERENCE">Brubaker 2000</LINK>; <LINK REF="REF-Jabs-2001" TYPE="REFERENCE">Jabs 2001</LINK>) or transcutaneous electrical nerve<I> </I>stimulation (TENS) via suprapubic, sacral or penile attachment of electrodes, anal plug electrodes, plantar or thigh and similar stimulation, and other placement of surface electrodes such as for interferential or maximum electrical stimulation;<BR/>(2) percutaneous electrical stimulation (<LINK REF="REF-Govier-2001" TYPE="REFERENCE">Govier 2001</LINK>; <LINK REF="REF-Janknegt-1997" TYPE="REFERENCE">Janknegt 1997</LINK>; <LINK REF="REF-van-Balken-2001" TYPE="REFERENCE">van Balken 2001</LINK>), e.g. posterior tibial nerve stimulation, electro-acupuncture, in general via insertion of a percutaneous needle electrode with another stick-on surface electrode placed near to the needle as the reference electrode.</P>
<P>There are two main types of electrical stimulation:</P>
<OL>
<LI>long-term or chronic electrical stimulation delivered below the sensory threshold aiming at detrusor inhibition by afferent pudendal nerve stimulation. The electrically evoked activity is suggested to result in reflex activation of hypogastric efferents and central inhibition of pelvic efferent mechanisms sensitive to low-frequency stimulation (<LINK REF="REF-Fall-1994" TYPE="REFERENCE">Fall 1994</LINK>). The device is used six to 12 hours a day for several months (<LINK REF="REF-Eriksen-1989" TYPE="REFERENCE">Eriksen 1989</LINK>);</LI>
<LI>maximal electrical stimulation using a high-intensity stimulus (just below the pain threshold). It aims to improve urethral closure. Fall (<LINK REF="REF-Fall-1991" TYPE="REFERENCE">Fall 1991</LINK>) suggested a direct and reflexogenic contraction of striated peri-urethral musculature. Detrusor inhibition by afferent pudendal nerve stimulation has also been suggested (<LINK REF="REF-Berghmans-2002" TYPE="REFERENCE">Berghmans 2002</LINK>). Maximal electrical stimulation is applied with short duration (15 to 30 minutes) several times a week (or one to two times daily using portable devices at home) (<LINK REF="REF-Yamanishi-1997" TYPE="REFERENCE">Yamanishi 1997</LINK>; <LINK REF="REF-Yamanishi-1998" TYPE="REFERENCE">Yamanishi 1998</LINK>; <LINK REF="STD-Yamanishi-2000a" TYPE="STUDY">Yamanishi 2000a</LINK>).</LI>
</OL>
<P>Parameters used in previous studies, that is current source, pulse width and duration, current intensity (range), stimulus frequency, pulse shape, time and total number of sessions and rest to work ratio, vary according to type of urinary incontinence and type of electrical stimulation. Berghmans (<LINK REF="REF-Berghmans-2002" TYPE="REFERENCE">Berghmans 2002</LINK>) reported that frequencies of 5 to 20 Hz are usually used for urgency urinary incontinence, 20 to 50 Hz for stress (post-prostatectomy) incontinence, and for mixed urinary incontinence around 20 Hz or high and low frequency alternately (<LINK REF="REF-Smith-2009" TYPE="REFERENCE">Smith 2009</LINK>). Pulse durations of 200 (<LINK REF="REF-Smith-2009" TYPE="REFERENCE">Smith 2009</LINK>), 300 (<LINK REF="STD-Yamanishi-2010" TYPE="STUDY">Yamanishi 2010</LINK>), 400 to 600 (<LINK REF="REF-Everaert-1999" TYPE="REFERENCE">Everaert 1999</LINK>) and 1000 &#956;sec (<LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>) have been reported for stress urinary incontinence, for detrusor overactivity 200 to 500 &#956;sec, and for mixed urinary incontinence depending on the dominant factor of the urinary incontinence (<LINK REF="REF-Berghmans-2002" TYPE="REFERENCE">Berghmans 2002</LINK>; <LINK REF="REF-Smith-2009" TYPE="REFERENCE">Smith 2009</LINK>). The pulse shape is generally rectangular, and biphasic pulses are preferred (<LINK REF="REF-Smith-2009" TYPE="REFERENCE">Smith 2009</LINK>). </P>
<P>In the literature, authors suggest that intermittent, short-term stimulation (maximal electrical stimulation) using a portable stimulation device for home-use should usually be used. In men, rectal or anal or surface electrodes can be used to apply electrical stimulation (ES). Surface electrodes can be positioned:</P>
<UL>
<LI>over the dorsal nerve of the penis (<LINK REF="STD-Yamanishi-2000a" TYPE="STUDY">Yamanishi 2000a</LINK>);</LI>
<LI>at the peri-anal region;</LI>
<LI>at the S3, S4 dermatome (<LINK REF="REF-Walsh-1999" TYPE="REFERENCE">Walsh 1999</LINK>);</LI>
<LI>at the tibial nerve (<LINK REF="REF-Amarenco-2003" TYPE="REFERENCE">Amarenco 2003</LINK>); or</LI>
<LI>over the quadriceps and hamstring muscles (<LINK REF="REF-Okada-1998" TYPE="REFERENCE">Okada 1998</LINK>).</LI>
</UL>
<P>For the treatment of post-prostatectomy incontinence, ES has been used in combination with pelvic floor muscle training (PFMT) but also on its own (<LINK REF="STD-Yokoyama-2004" TYPE="STUDY">Yokoyama 2004</LINK>). Normally, an anal or rectal electrode is used and the stimulation artificially stimulates the pudendal nerve and its branches to cause direct reflex responses of the urethral and peri-urethral striated muscles (<LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>). Frequencies of 5 to 20 Hz are recommended for urgency urinary incontinence, for example Yamanishi (<LINK REF="STD-Yamanishi-2000a" TYPE="STUDY">Yamanishi 2000a</LINK>) used 10 Hz. For stress (post-prostatectomy) urinary incontinence (<LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>; <LINK REF="STD-Wille-2003" TYPE="STUDY">Wille 2003</LINK>; <LINK REF="STD-Yamanishi-1998a" TYPE="STUDY">Yamanishi 1998a</LINK>; <LINK REF="STD-Yokoyama-2004" TYPE="STUDY">Yokoyama 2004</LINK>) 20 to 50 Hz is used.</P>
<P>Although a wide range of parameters has been claimed to be successful, the optimal set of parameters for each type of urinary incontinence has not been determined (<LINK REF="REF-Smith-2009" TYPE="REFERENCE">Smith 2009</LINK>). Duration of the stimulation varies according to the investigators, from 15 minutes/day (<LINK REF="REF-Amarenco-2003" TYPE="REFERENCE">Amarenco 2003</LINK>) to 15 minutes/twice daily (<LINK REF="STD-Wille-2003" TYPE="STUDY">Wille 2003</LINK>; <LINK REF="STD-Yokoyama-2004" TYPE="STUDY">Yokoyama 2004</LINK>), to 20 minutes three times/week (<LINK REF="STD-Hoffmann-2005" TYPE="STUDY">Hoffmann 2005</LINK>) to twice weekly (<LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>). As for the number of sessions needed, some authors have recommended at least 10 treatment sessions before the clinical effect was assessed (<LINK REF="REF-Fall-1998" TYPE="REFERENCE">Fall 1998</LINK>; <LINK REF="REF-Primus-1996" TYPE="REFERENCE">Primus 1996</LINK>). Others used a treatment episode of one month (electrical stimulator also used at home) (<LINK REF="STD-Yokoyama-2004" TYPE="STUDY">Yokoyama 2004</LINK>), four to six weeks (<LINK REF="REF-Amarenco-2003" TYPE="REFERENCE">Amarenco 2003</LINK>; <LINK REF="REF-Bent-1993" TYPE="REFERENCE">Bent 1993</LINK>; <LINK REF="REF-Plevnik-1986" TYPE="REFERENCE">Plevnik 1986</LINK>), 12 weeks (<LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>; <LINK REF="STD-Soomro-2001" TYPE="STUDY">Soomro 2001</LINK>) or three months (<LINK REF="STD-Wille-2003" TYPE="STUDY">Wille 2003</LINK>).</P>
<P>So far, no studies reporting on a comparison of ES protocols or the parameters specified above have been identified, so up to now it is completely unclear what the most appropriate ES protocol and parameters might be, and for which type of urinary incontinence they might be most suitable.</P>
</INTERVENTION>
<THEORY MODIFIED="2013-04-25 22:22:53 +0100" MODIFIED_BY="[Empty name]">
<P>ES of the pelvic floor aims at stimulating motor fibres of the pudendal nerve, which may elicit a direct contraction of the pelvic floor muscles or the striated peri-urethral musculature to support the intrinsic part of the urethral sphincter closing mechanism (<LINK REF="REF-Fall-1991" TYPE="REFERENCE">Fall 1991</LINK>; <LINK REF="REF-Scheepens-2003" TYPE="REFERENCE">Scheepens 2003</LINK>). As such, ES might contribute to compensation of a weak intrinsic sphincter but it is questionable whether or not ESwould be the first choice treatment option in such cases or would have any additional value to functional training (<LINK REF="REF-Berghmans-1998b" TYPE="REFERENCE">Berghmans 1998b</LINK>; <LINK REF="REF-Smith-2009" TYPE="REFERENCE">Smith 2009</LINK>).    </P>
<P>ES might also be used as a kind of biofeedback. As such, by stimulating awareness, it might help male patients with stress urinary incontinence and who lack conscious control how and where exactly to contract and relax the pelvic floor muscles to regain this control (<LINK REF="REF-Berghmans-1998a" TYPE="REFERENCE">Berghmans 1998a</LINK>). Although it is suggested that ES might be useful to train or strengthen the pelvic floor muscles (<LINK REF="REF-Sand-1995" TYPE="REFERENCE">Sand 1995</LINK>), or to strengthen the structural support of the urethra and the bladder neck (<LINK REF="REF-Plevnik-1991" TYPE="REFERENCE">Plevnik 1991</LINK>), these hypotheses are not well supported by scientific evidence so far.   </P>
<P>In patients with detrusor overactivity or symptoms of urgency and urgency urinary incontinence, ES can elicit direct contractions of the pelvic floor muscles. The contractions stimulate afferent fibres of the pudendal nerve going to the sacral spinal cord, which reflexively decrease the feeling or sensation of urgency and inhibit parasympathetic activity at the level of the sacral micturition centre in the sacral cord in order to reduce involuntary detrusor contractions and reflexively activate the striated peri-urethral musculature. Several authors have suggested that ES of these afferent nerve fibres influences remodelling of neuronal reflex loops, such as the detrusor inhibition reflex (<LINK REF="REF-Berghmans-2002" TYPE="REFERENCE">Berghmans 2002</LINK>; <LINK REF="REF-Fall-1994" TYPE="REFERENCE">Fall 1994</LINK>; <LINK REF="REF-Vodusek-1986" TYPE="REFERENCE">Vodusek 1986</LINK>; <LINK REF="REF-Weil-2000" TYPE="REFERENCE">Weil 2000</LINK>).  </P>
<P>Electrical stimulation may be used as stand-alone therapy or in combination with PFMT (<LINK REF="REF-Meaglia-1990" TYPE="REFERENCE">Meaglia 1990</LINK>; <LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>; <LINK REF="STD-Wille-2003" TYPE="STUDY">Wille 2003</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2013-04-25 22:23:20 +0100" MODIFIED_BY="[Empty name]">
<P>It has been postulated that by using ES in combination with PFMT, continence is regained more rapidly (<LINK REF="REF-Hirakawa-1993" TYPE="REFERENCE">Hirakawa 1993</LINK>; <LINK REF="REF-Salinas-1993" TYPE="REFERENCE">Salinas 1993</LINK>) and the duration of the application of ES is reduced when PFMT is augmented with ES (<LINK REF="REF-Campbell-2012" TYPE="REFERENCE">Campbell 2012</LINK>). </P>
<P>The aim of this systematic review was to assess the effects of ES in adult men with stress, urgency and mixed urinary incontinence, and combinations of types of urinary incontinence.</P>
<P>ES for urinary incontinence is the subject of more than one Cochrane review. In men, a Cochrane review (<LINK REF="REF-Campbell-2012" TYPE="REFERENCE">Campbell 2012</LINK>) reviewed a combination of PFMT and rectal ES for urinary incontinence after radical prostatectomy. ES with the use of implanted stimulation is the subject of a further Cochrane review (<LINK REF="REF-Herbison-2009" TYPE="REFERENCE">Herbison 2009</LINK>). Because we only deal with non-implanted electrodes in this review, there is no overlap with that review.</P>
<P>Definitions and classifications used in this review are according to the Standardization Committees of the International Continence Society (ICS) and the International Urogynecological Association (<LINK REF="REF-Abrams-2002" TYPE="REFERENCE">Abrams 2002</LINK>; <LINK REF="REF-Haylen-2010" TYPE="REFERENCE">Haylen 2010</LINK>; <LINK REF="REF-Messelink-2005" TYPE="REFERENCE">Messelink 2005</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2013-04-25 22:23:34 +0100" MODIFIED_BY="Bary CM Berghmans" NOTES="&lt;p&gt;&lt;span modified=&quot;2013-02-06 09:51:00 +0000&quot; class=&quot;inserted&quot; modified_by=&quot;[Empty name]&quot;&gt;For  the &lt;/span&gt;&lt;span modified=&quot;2013-02-06 09:52:00 +0000&quot; class=&quot;inserted&quot; modified_by=&quot;[Empty name]&quot;&gt;n&lt;/span&gt;&lt;span modified=&quot;2013-02-06 09:50:00 +0000&quot; class=&quot;inserted&quot; modified_by=&quot;[Empty name]&quot;&gt;ext u&lt;/span&gt;&lt;span modified=&quot;2013-02-06 09:51:00 +0000&quot; class=&quot;inserted&quot; modified_by=&quot;[Empty name]&quot;&gt;pdate&lt;/span&gt;&lt;span modified=&quot;2013-02-06 09:50:00 +0000&quot; class=&quot;inserted&quot; modified_by=&quot;[Empty name]&quot;&gt; we should consider including this further objective:&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2013-02-06 09:51:00 +0000&quot; class=&quot;inserted&quot; modified_by=&quot;[Empty name]&quot;&gt;6&lt;/span&gt;&lt;span modified=&quot;2013-02-06 09:50:56 +0000&quot; class=&quot;inserted&quot; modified_by=&quot;[Empty name]&quot;&gt;. Electrical stimulation with non-implanted devices in combination with another therapy versus the e&lt;/span&gt;&lt;span modified=&quot;2013-02-06 09:51:00 +0000&quot; class=&quot;inserted&quot; modified_by=&quot;[Empty name]&quot;&gt;lectrical stimulation alone&lt;/span&gt;&lt;/p&gt;" NOTES_MODIFIED="2013-04-25 22:23:34 +0100" NOTES_MODIFIED_BY="Bary CM Berghmans">
<P>The following comparisons will be considered, in men with stress urinary incontinence; detrusor overactivity with urgency urinary incontinence or men with symptoms of urgency, frequency and urgency urinary incontinence; or mixed urinary incontinence.</P>
<P>1. Electrical stimulation with non-implanted devices versus no treatment.</P>
<P>2. Electrical stimulation with non-implanted devices versus placebo treatments.</P>
<P>3. Electrical stimulation with non-implanted devices versus other 'single' treatments (e.g. a physical therapy such as pelvic floor exercises, a pharmaceutical such as an anticholinergic, or a type of surgery).</P>
<P>4. Electrical stimulation with non-implanted devices in combination with another therapy versus the other therapy alone (e.g. pelvic floor muscle training).</P>
<P>5. One method of providing electrical stimulation with non-implanted devices (e.g. anal plug electrodes) versus another method (e.g. transcutaneous electrical nerve stimulation (TENS).</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-04-25 22:51:50 +0100" MODIFIED_BY="Bary CM Berghmans">
<SELECTION_CRITERIA MODIFIED="2013-04-25 22:25:39 +0100" MODIFIED_BY="Bary CM Berghmans">
<CRIT_STUDIES MODIFIED="2013-04-25 22:23:57 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>Randomized and quasi-randomized controlled trials of surface electrical stimulation (ES) for the management of urinary incontinence were included. Other forms of clinical trials were excluded. As well as trials reported as full-text, we also included trials of which only abstracts were available.   </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-01-22 11:56:42 +0000" MODIFIED_BY="Bary CM Berghmans">
<P>Adult men with: stress urinary incontinence; detrusor overactivity with urgency urinary incontinence or symptoms of urgency, frequency and urgency urinary incontinence; or mixed urinary incontinence.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2013-04-25 22:24:50 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>One arm of the study must have used ES with non-implanted devices to provide stimulation to the nerves or muscles of the pelvic floor or the bladder, or both, according to a standardised protocol. Any type of non-implanted device was included.</P>
<P>Setting (hospital, office, at home), intensity (both level of electrical current and duration and frequency of stimulation) and method (surface, anal, percutaneous) of stimulation were taken into account.</P>
<P>Comparator interventions included:</P>
<UL>
<LI>pelvic floor muscle training (PFMT),</LI>
<LI>bladder training,</LI>
<LI>drugs such as serotonin-noradrenaline reuptake inhibitors (SNRIs), anticholinergics,</LI>
<LI>surgery,</LI>
<LI>implantable electrical stimulation systems.</LI>
</UL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-04-25 22:25:39 +0100" MODIFIED_BY="Bary CM Berghmans">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2013-04-25 22:25:14 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">Men&#8217;s observations</HEADING>
<P>- self report of urinary incontinence</P>
</SUBSECTION>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2013-04-25 22:25:39 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">Quantification of symptoms</HEADING>
<P>- pad changes (voiding diary)</P>
<P>- frequency symptoms (voiding diary)</P>
<P>- urgency symptoms (voiding diary)</P>
<P>- incontinent episodes (voiding diary)</P>
<P>- standardised pad tests (24-hr, 1-hr, 20-min) measuring grams of involuntary loss of urine (continuous)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Health status measures</HEADING>
<P>- condition-specific quality of life (QOL) e.g. Incontinence Quality of Life (IQOL) Questionnaire</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Clinician&#8217;s observations</HEADING>
<P>- observation of urinary incontinence</P>
<P>- urodynamic measurements and studies</P>
<P>- pelvic floor muscle function and strength</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Health status measures</HEADING>
<P>- general health status e.g. Short Form 36 (<LINK REF="REF-Ware-1993" TYPE="REFERENCE">Ware 1993</LINK>)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse effects</HEADING>
<P>- tissue damage</P>
<P>- exhaustion of stimulated muscle fibres</P>
<P>- pain, discomfort</P>
<P>- infection of the lower urinary tract</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Health economics</HEADING>
<P>- cost of interventions</P>
<P>- resource implications of differences in outcome</P>
<P>- formal economic analysis (e.g. cost-effectiveness and cost utility)<BR/>
</P>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-04-25 22:51:50 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>We did not impose any language or other limits on the searches described below.</P>
<ELECTRONIC_SEARCHES MODIFIED="2013-04-25 22:25:57 +0100" MODIFIED_BY="[Empty name]">
<P>Relevant trials have been identified from the Specialised Register of controlled trials of the Cochrane Incontinence Group. This Register includes trials identified from searches in the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, PreMEDLINE, CINAHL, and by handsearching of journals and conference proceedings. The methods used to derive the Register, including the search strategy, are described under the Group's <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/INCONT/frame.html">module</A> in <I>The Cochrane Library</I>. Date of last search: 21 January 2012.</P>
<P>Additional trials have been sought by the authors from a broader search of computerized bibliographic databases (EMBASE, the Excerpta Medica <A HREF="http://www.excerptamedica.com/">website</A>, the Dutch National Institute of Allied Health Professions, and the database of the Cochrane Rehabilitation and Related Therapies Field at Maastricht University), from 1980 to 21 January 2012. The keywords used were: incontinence, urinary incontinence, detrusor instability, detrusor overactivity, bladder, overactive bladder, stress incontinence, urge incontinence, mixed incontinence, urgency, frequency, nocturia, physiotherapy, physical therapy, conservative management, conservative therapy, non-surgical stimulation, electrostimulation, neuromuscular stimulation, electrical stimulation, electrotherapy, RCTs, controlled trials, evaluation, effectiveness, efficacy and outcomes.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2013-04-25 22:51:50 +0100" MODIFIED_BY="[Empty name]">
<P>One non-electronic bibliographic database was also searched: Physiotherapy Index (up to September 2011), using the search terms given above. In addition, published abstracts presented at the International Continence Society, the European Association of Urology, the American Urogynaecology Society, and the American Urological Association have been reviewed (from 2000 to 2012) and cross-referenced to find if a full-length report has been published. Known trialists and other experts in the field have been contacted to ask for possible relevant trials, published or unpublished. Additional trials have been sought from the reference lists of included studies.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-04-25 22:28:21 +0100" MODIFIED_BY="Bary CM Berghmans">
<STUDY_SELECTION MODIFIED="2013-04-25 22:26:32 +0100" MODIFIED_BY="[Empty name]">
<P>Only randomized and quasi-randomized controlled trials were included. Two review authors independently screened the list of titles and abstracts generated by our search. Full-text articles of potentially relevant studies were retrieved. Two review authors independently assessed the full-text articles for eligibility. We contacted study investigators as required. Any differences of opinion were resolved by discussion or involvement of a third party. Studies formally considered for the review but excluded were listed with reasons given for their exclusion.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-04-25 22:26:52 +0100" MODIFIED_BY="[Empty name]">
<P>Data extraction of the included studies was performed independently by two of the review authors (BB and EH) using a standardised form. Any disagreement was resolved by discussion or by consulting a third party (RdB or MO). Where there was insufficient information regarding the primary outcome in the published reports, study authors were contacted. For data entry, performed by BB and EH, Review Manager software (RevMan 5.2) was used. Processing of the included data of trials was according to the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<P>Data were grouped by type of incontinence.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2013-04-25 22:27:16 +0100" MODIFIED_BY="[Empty name]">
<P>The risk of bias in the included studies was assessed using the Cochrane risk of bias assessment tool (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). This included:</P>
<UL>
<LI>sequence generation,</LI>
<LI>allocation concealment,</LI>
<LI>blinding of participants or therapists,</LI>
<LI>blinding of outcome assessors,</LI>
<LI>completeness of outcome data,</LI>
<LI>selective outcome reporting, and</LI>
<LI>other potential sources of bias. </LI>
</UL>
<P>Two of the review authors (BB and EH) independently assessed these domains. Any differences of opinion were resolved by consensus or by consulting a third party (MO).</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-04-25 22:27:26 +0100" MODIFIED_BY="[Empty name]">
<P>Analyses were based on available data from all included trials relevant to the comparisons and outcomes of interest. For trials with multiple publications, only the most up-to-date or complete data for each outcome were included. Meta-analysis was undertaken where data were available from more than one study assessing the same outcome. A fixed-effect model was used for calculations of pooled estimates and their 95% confidence intervals. For categorical outcomes we related the numbers reporting an outcome to the numbers at risk in each group to calculate a risk ratio (RR) with 95% confidence interval (CI). For continuous variables we used means and standard deviations to calculate a mean difference (MD) with 95% confidence interval. If similar outcomes were reported on different scales, we calculated the standardised mean difference (SMD). We reversed the direction of effect, if necessary, to ensure consistency across trials. If data to calculate RRs or MDs were not given, we utilised the most detailed numerical data available to calculate the actual numbers or means and standard deviations (for example test statistics, P values).</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2013-04-25 22:27:40 +0100" MODIFIED_BY="[Empty name]">
<P>The primary analysis was per man randomised.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2013-04-25 22:27:40 +0100" MODIFIED_BY="[Empty name]">
<P>The data were analysed on an intention-to-treat basis, as far as possible, meaning that all participants must be analysed in the groups to which they were randomised. If this was not the case, we considered whether the trial should be excluded. Attempts were made to obtain missing data from the original trialists. However, if this was not possible, data were reported as given in the studies, except if there was evidence of differential loss to follow up from the randomised groups. In that case, the use of imputation of missing data was considered. If trials reported sufficient detail to calculate mean differences but gave no information on associated standard deviations (SD), the outcome was assumed to have a standard deviation (SD) equal to the highest SD from other trials within the same analysis.  </P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-04-25 22:27:50 +0100" MODIFIED_BY="[Empty name]">
<P>Trials were only combined if they were thought to be clinically similar. Heterogeneity between studies was assessed by visual inspection of plots of the data, the &#967;<SUP>2</SUP> test for heterogeneity and the I<SUP>2</SUP>statistic (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>; <LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We defined the thresholds for interpretation of the I<SUP>2</SUP> statistic according to the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2013-04-25 22:27:58 +0100" MODIFIED_BY="[Empty name]">
<P>In view of the difficulty of detecting and correcting for publication bias and other reporting biases, the authors aimed to minimise their potential impact by ensuring a comprehensive search for eligible studies and by being alert for duplication of data.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2013-04-25 22:28:09 +0100" MODIFIED_BY="[Empty name]">
<P>Trials were combined if interventions were similar, based on clinical criteria. To combine trial data, a meta-analysis was conducted and a fixed effect model approach to the analysis was used unless there was evidence of heterogeneity across studies.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2013-04-25 22:28:21 +0100" MODIFIED_BY="[Empty name]">
<P>Data were subgrouped, if possible, by the type of underlying urinary incontinence or lower urinary tract symptoms:</P>
<UL>
<LI>stress urinary incontinence;</LI>
<LI>detrusor overactivity with urgency urinary incontinence or symptoms of urgency, frequency and urgency urinary incontinence; or</LI>
<LI>mixed urinary incontinence (both stress and urgency urinary incontinence).</LI>
</UL>
<P>If heterogeneity between trials was sufficiently large, an investigation to identify its causes was conducted. The investigation of heterogeneity addressed populations and interventions in the individual trials. The investigation could also include subgroup analyses, meta-regression and sensitivity analyses. If heterogeneity remained after appropriate investigation and possible removal of outlying trials, a random-effects model was used in the meta analysis.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2013-01-22 11:56:42 +0000" MODIFIED_BY="[Empty name]">
<P>The effects of including or excluding trials at high risk of bias were investigated by means of sensitivity analyses.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-04-25 22:51:52 +0100" MODIFIED_BY="Bary CM Berghmans">
<STUDY_DESCRIPTION MODIFIED="2013-04-25 22:51:52 +0100" MODIFIED_BY="Bary CM Berghmans">
<SEARCH_RESULTS MODIFIED="2013-04-25 22:28:38 +0100" MODIFIED_BY="[Empty name]">
<P>Our search strategy yielded 20 potentially eligible studies. All 20 studies were deemed to study ES protocols. For assessment of ES effect only six trials (five full publications: <LINK REF="STD-Hoffmann-2005" TYPE="STUDY">Hoffmann 2005</LINK>; <LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>; <LINK REF="STD-Wille-2003" TYPE="STUDY">Wille 2003</LINK>; <LINK REF="STD-Yamanishi-2010" TYPE="STUDY">Yamanishi 2010</LINK>; <LINK REF="STD-Yokoyama-2004" TYPE="STUDY">Yokoyama 2004</LINK>; 1 abstract: <LINK REF="STD-Ceresoli-2002" TYPE="STUDY">Ceresoli 2002</LINK>) could be included, whereas 14 studies were excluded. Closer investigation demonstrated that the abstract of Yamanishi 2006 and the full publication of <LINK REF="STD-Yamanishi-2010" TYPE="STUDY">Yamanishi 2010</LINK> were the same trial. The randomized clinical trial (RCT) of Yokoyama (<LINK REF="STD-Yokoyama-2004" TYPE="STUDY">Yokoyama 2004</LINK>) was included but data were not usable as they were not presented in a format usable in the tables of comparison. The literature assessment process is documented with a PRISMA flow chart (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2013-04-25 22:51:52 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Trial populations</HEADING>
<P>All six included trials involved patients after radical prostatectomy. In total, 544 men were included of whom 305 received some form of ES and 239 a control or comparator treatment.</P>
<P>The trials were conducted at different time points:</P>
<UL>
<LI>
<LINK REF="STD-Wille-2003" TYPE="STUDY">Wille 2003</LINK> recruited candidates pre-operatively,</LI>
<LI>
<LINK REF="STD-Hoffmann-2005" TYPE="STUDY">Hoffmann 2005</LINK> shortly after surgery,</LI>
<LI>
<LINK REF="STD-Yokoyama-2004" TYPE="STUDY">Yokoyama 2004</LINK> 11 to 15 days post-operatively,</LI>
<LI>
<LINK REF="STD-Yamanishi-2010" TYPE="STUDY">Yamanishi 2010</LINK> three weeks post-operatively,</LI>
<LI>
<LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK> more than eight weeks after surgery, and</LI>
<LI>
<LINK REF="STD-Ceresoli-2002" TYPE="STUDY">Ceresoli 2002</LINK> post-operatively without specification when exactly.</LI>
</UL>
<P>This means that the study population of <LINK REF="STD-Wille-2003" TYPE="STUDY">Wille 2003</LINK> might have consisted of men with and without urinary incontinence after radical prostatectomy, while in the other studies only patients with urinary incontinence after radical prostatectomy were included. So, based upon status of incontinence, study populations might already have been heterogeneous.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Trial interventions</HEADING>
<P>The following interventions or management strategies were included:</P>
<UL>
<LI>transcutaneous (anal) electrical nerve stimulation (<LINK REF="STD-Hoffmann-2005" TYPE="STUDY">Hoffmann 2005</LINK>; <LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>; <LINK REF="STD-Wille-2003" TYPE="STUDY">Wille 2003</LINK>; <LINK REF="STD-Yamanishi-2010" TYPE="STUDY">Yamanishi 2010</LINK>; <LINK REF="STD-Yokoyama-2004" TYPE="STUDY">Yokoyama 2004</LINK>);</LI>
<LI>transcutaneous (perineal) electrical nerve stimulation (<LINK REF="STD-Hoffmann-2005" TYPE="STUDY">Hoffmann 2005</LINK>);</LI>
<LI>transcutaneous (not specified) electrical nerve stimulation (<LINK REF="STD-Ceresoli-2002" TYPE="STUDY">Ceresoli 2002</LINK>);</LI>
<LI>pelvic floor muscle training (PFMT) (<LINK REF="STD-Ceresoli-2002" TYPE="STUDY">Ceresoli 2002</LINK>; <LINK REF="STD-Hoffmann-2005" TYPE="STUDY">Hoffmann 2005</LINK>; <LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>; <LINK REF="STD-Yokoyama-2004" TYPE="STUDY">Yokoyama 2004</LINK>; <LINK REF="STD-Wille-2003" TYPE="STUDY">Wille 2003</LINK>);</LI>
<LI>PFMT plus biofeedback (<LINK REF="STD-Wille-2003" TYPE="STUDY">Wille 2003</LINK>);</LI>
<LI>extracorporeal magnetic innervation or stimulation (<LINK REF="STD-Yokoyama-2004" TYPE="STUDY">Yokoyama 2004</LINK>);</LI>
<LI>placebo treatment (sham stimulation) (<LINK REF="STD-Yamanishi-2010" TYPE="STUDY">Yamanishi 2010</LINK>).</LI>
</UL>
<P>The specific study characteristics (participants, interventions, etc.) of the six included RCTs are presented in the table <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Electrical stimulation (ES) protocols</HEADING>
<P>As in all other ES trials, the included trials showed considerable variation in design, parameters used and intensity of ES: </P>
<UL>
<LI>Wille (<LINK REF="STD-Wille-2003" TYPE="STUDY">Wille 2003</LINK>), Ceresoli (<LINK REF="STD-Ceresoli-2002" TYPE="STUDY">Ceresoli 2002</LINK>), Hoffmann (<LINK REF="STD-Hoffmann-2005" TYPE="STUDY">Hoffmann 2005</LINK>) and Yamanishi (<LINK REF="STD-Yamanishi-2010" TYPE="STUDY">Yamanishi 2010</LINK>) added ES to PFMT;</LI>
<LI>
<LINK REF="STD-Yokoyama-2004" TYPE="STUDY">Yokoyama 2004</LINK> used ES only; and</LI>
<LI>Moore (<LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>) alternated PFMT with ES.</LI>
</UL>
<P>As described above, the variety in the duration of each session of stimulation and the number of sessions was considerable. Frequencies used in the different studies varied between:</P>
<UL>
<LI>14 Hz (<LINK REF="STD-Hoffmann-2005" TYPE="STUDY">Hoffmann 2005</LINK>),</LI>
<LI>20 Hz (<LINK REF="STD-Yokoyama-2004" TYPE="STUDY">Yokoyama 2004</LINK>),</LI>
<LI>27 Hz (<LINK REF="STD-Wille-2003" TYPE="STUDY">Wille 2003</LINK>), and</LI>
<LI>50 Hz in two other studies (<LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>; <LINK REF="STD-Yamanishi-2010" TYPE="STUDY">Yamanishi 2010</LINK>).</LI>
</UL>
<P>Also, intensity differed between trials:</P>
<UL>
<LI>in the Wille study patients could control intensity, from 10% to 100% of maximal intensity (<LINK REF="STD-Wille-2003" TYPE="STUDY">Wille 2003</LINK>);</LI>
<LI>whereas patients in the Moore study used &#8216;comfortable&#8217; intensity (<LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>);</LI>
<LI>Yokoyama (<LINK REF="STD-Yokoyama-2004" TYPE="STUDY">Yokoyama 2004</LINK>) reported a maximal output current of 24 mA;</LI>
<LI>in two studies an intensity of maximal output of 70 mA (<LINK REF="STD-Hoffmann-2005" TYPE="STUDY">Hoffmann 2005</LINK>; <LINK REF="STD-Yamanishi-2010" TYPE="STUDY">Yamanishi 2010</LINK>) was reported;</LI>
<LI>Ceresoli (<LINK REF="STD-Ceresoli-2002" TYPE="STUDY">Ceresoli 2002</LINK>) used daily TENS, with intensity below the sensory threshold.  </LI>
</UL>
<P>In four trials a biphasic pulse shape was used, only Ceresoli (<LINK REF="STD-Ceresoli-2002" TYPE="STUDY">Ceresoli 2002</LINK>) and Yokoyama (<LINK REF="STD-Yokoyama-2004" TYPE="STUDY">Yokoyama 2004</LINK>) did not specify this. Pulse width was between 1 sec (<LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>; <LINK REF="STD-Wille-2003" TYPE="STUDY">Wille 2003</LINK>) and 250 msec (<LINK REF="STD-Hoffmann-2005" TYPE="STUDY">Hoffmann 2005</LINK>). Yamanishi (<LINK REF="STD-Yamanishi-2010" TYPE="STUDY">Yamanishi 2010</LINK>) and Yokoyama (<LINK REF="STD-Yokoyama-2004" TYPE="STUDY">Yokoyama 2004</LINK>) reported a pulse duration of 300 &#956;sec.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2013-04-25 22:30:06 +0100" MODIFIED_BY="[Empty name]">
<P>Fourteen studies needed to be excluded, mainly because in these trials both men and women were included without separate reporting of results according to gender. Reasons for exclusion can be found in the table <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-04-25 22:31:31 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>Specific characteristics, details of assessment, methodological quality and risk of bias of the included studies are presented in the table <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.</P>
<ALLOCATION MODIFIED="2013-04-25 22:30:18 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Random sequence generation (selection bias)</HEADING>
<P>The method used for random sequence generation was unclear in 3/6 trials (<LINK REF="STD-Ceresoli-2002" TYPE="STUDY">Ceresoli 2002</LINK>; <LINK REF="STD-Wille-2003" TYPE="STUDY">Wille 2003</LINK>; <LINK REF="STD-Yokoyama-2004" TYPE="STUDY">Yokoyama 2004</LINK>). Three trials were judged to be at low risk of bias: <LINK REF="STD-Hoffmann-2005" TYPE="STUDY">Hoffmann 2005</LINK> and <LINK REF="STD-Yamanishi-2010" TYPE="STUDY">Yamanishi 2010</LINK> used computer-generated randomization; whereas <LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK> used a computer-generated random-number list.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Allocation concealment (selection bias)</HEADING>
<P>Security of allocation concealment was unclear in 4/6 trials (<LINK REF="STD-Ceresoli-2002" TYPE="STUDY">Ceresoli 2002</LINK>; <LINK REF="STD-Hoffmann-2005" TYPE="STUDY">Hoffmann 2005</LINK>; <LINK REF="STD-Wille-2003" TYPE="STUDY">Wille 2003</LINK>; <LINK REF="STD-Yokoyama-2004" TYPE="STUDY">Yokoyama 2004</LINK>). It was considered adequate in two trials: <LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK> reported that the "participants were assigned using a computer-generated random-number list placed in sealed envelopes at the end of the assessment visit, with patient and researcher opening the sealed envelope" whereas <LINK REF="STD-Yamanishi-2010" TYPE="STUDY">Yamanishi 2010</LINK> reported that "none of the patients, doctors or medical staff knew which type of stimulation had been assigned until the key code was opened".</P>
</SUBSECTION>
</ALLOCATION>
<BLINDING MODIFIED="2013-04-25 22:30:30 +0100" MODIFIED_BY="[Empty name]">
<P>The doctors, nurses and medical staff were blinded in the trial conducted by Yamansihi and colleagues (<LINK REF="STD-Yamanishi-2010" TYPE="STUDY">Yamanishi 2010</LINK>). <LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK> reported that the physiotherapists and the outcome assessors were blinded. Blinding of participants, personnel and outcome assessors was unclear in the other four trials (<LINK REF="STD-Ceresoli-2002" TYPE="STUDY">Ceresoli 2002</LINK>; <LINK REF="STD-Hoffmann-2005" TYPE="STUDY">Hoffmann 2005</LINK>; <LINK REF="STD-Wille-2003" TYPE="STUDY">Wille 2003</LINK>; <LINK REF="STD-Yokoyama-2004" TYPE="STUDY">Yokoyama 2004</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2013-04-25 22:30:30 +0100" MODIFIED_BY="[Empty name]">
<P>There were no missing data in one trial (<LINK REF="STD-Yokoyama-2004" TYPE="STUDY">Yokoyama 2004</LINK>). Three trials reported dropouts resulting in incomplete outcome data, but these were evenly distributed across the groups (<LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>; <LINK REF="STD-Yamanishi-2010" TYPE="STUDY">Yamanishi 2010</LINK>) or the information about the group distribution was not supplied (<LINK REF="STD-Wille-2003" TYPE="STUDY">Wille 2003</LINK>). In one trial we assumed that there were no missing data but the information was not provided (<LINK REF="STD-Ceresoli-2002" TYPE="STUDY">Ceresoli 2002</LINK>). One trial was judged to be at high risk of bias because there was differential dropout (<LINK REF="STD-Hoffmann-2005" TYPE="STUDY">Hoffmann 2005</LINK>).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2013-04-25 22:30:40 +0100" MODIFIED_BY="[Empty name]">
<P>It was unclear if there was selective reporting of the outcomes in all six trials because the protocols were not available (<LINK REF="STD-Ceresoli-2002" TYPE="STUDY">Ceresoli 2002</LINK>; <LINK REF="STD-Hoffmann-2005" TYPE="STUDY">Hoffmann 2005</LINK>; <LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>; <LINK REF="STD-Wille-2003" TYPE="STUDY">Wille 2003</LINK>; <LINK REF="STD-Yamanishi-2010" TYPE="STUDY">Yamanishi 2010</LINK>; <LINK REF="STD-Yokoyama-2004" TYPE="STUDY">Yokoyama 2004</LINK>).</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2013-04-25 22:31:31 +0100" MODIFIED_BY="[Empty name]">
<P>Information about other potential sources of bias was unclear in 3/6 trials (<LINK REF="STD-Ceresoli-2002" TYPE="STUDY">Ceresoli 2002</LINK>; <LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>; <LINK REF="STD-Wille-2003" TYPE="STUDY">Wille 2003</LINK>). No other potential source of bias was found in 1/6 trials (<LINK REF="STD-Yokoyama-2004" TYPE="STUDY">Yokoyama 2004</LINK>), whereas 2/6 trials were judged to be at high risk of bias (<LINK REF="STD-Hoffmann-2005" TYPE="STUDY">Hoffmann 2005</LINK>; <LINK REF="STD-Yamanishi-2010" TYPE="STUDY">Yamanishi 2010</LINK>). Support for these judgements are detailed under <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and summarised in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="4">Outcome measures</HEADING>
<P>Outcome measures in the included studies showed a lack of consistency. With regard to the primary outcomes of the included studies, objective measures were reported by Moore (<LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>), Ceresoli (<LINK REF="STD-Ceresoli-2002" TYPE="STUDY">Ceresoli 2002</LINK>), Yokoyama (<LINK REF="STD-Yokoyama-2004" TYPE="STUDY">Yokoyama 2004</LINK>) and Yamanishi (<LINK REF="STD-Yamanishi-2010" TYPE="STUDY">Yamanishi 2010</LINK>) using a 24-hr pad test; Wille (<LINK REF="STD-Wille-2003" TYPE="STUDY">Wille 2003</LINK>) used a 20-min provocative pad test and Hoffmann (<LINK REF="STD-Hoffmann-2005" TYPE="STUDY">Hoffmann 2005</LINK>) a 1-hr standardised pad test. Self report of cure or improvement using a visual analogue scale (VAS) was done only by Ceresoli (<LINK REF="STD-Ceresoli-2002" TYPE="STUDY">Ceresoli 2002</LINK>) and Hoffmann (<LINK REF="STD-Hoffmann-2005" TYPE="STUDY">Hoffmann 2005</LINK>). Micturition charts were used in the Wille (<LINK REF="STD-Wille-2003" TYPE="STUDY">Wille 2003</LINK>), Ceresoli (<LINK REF="STD-Ceresoli-2002" TYPE="STUDY">Ceresoli 2002</LINK>) and Moore (<LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>) trials.  </P>
<P>Quality of life (QOL) as a secondary outcome measure, using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ), was measured by Hoffmann (<LINK REF="STD-Hoffmann-2005" TYPE="STUDY">Hoffmann 2005</LINK>) and Moore (<LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>) while the latter also used the Incontinence Impact Questionaire (IIQ-7). In the study of Yokoyama (<LINK REF="STD-Yokoyama-2004" TYPE="STUDY">Yokoyama 2004</LINK>) the Incontinence Quality of Life (I-QOL) was scored. The Incontinence Consultation on Incontinence Questionnaire Short Form (ICIQ-SF) and King's Health Questionnaire (KHQ) were secondary endpoints in Yamanishi (<LINK REF="STD-Yamanishi-2010" TYPE="STUDY">Yamanishi 2010</LINK>).</P>
<P>Adherence to the protocol was measured by Moore (<LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>) and compliance was measured by Wille (<LINK REF="STD-Wille-2003" TYPE="STUDY">Wille 2003</LINK>) and Hoffmann (<LINK REF="STD-Hoffmann-2005" TYPE="STUDY">Hoffmann 2005</LINK>).</P>
<P>There was no reporting of economic measures in any of the included studies. </P>
</SUBSECTION>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-04-25 22:33:27 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>The specific characteristics and outcomes of the included studies are in the table '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>'. Data, when available, are summarised in the paragraph 'Comparisons and data'.</P>
<SUBSECTION>
<HEADING LEVEL="3">1. Electrical stimulation (ES) with non-implanted devices versus no active treatment</HEADING>
<P>One trial addressed this comparison (<LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>). All the men had stress urinary incontinence at baseline. Moore compared anal electrical nerve stimulation with PFMT. The trial was too small to reliably detect differences between the groups (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. Electrical stimulation (ES) with non-implanted devices versus placebo treatments</HEADING>
<P>One RCT compared ES against placebo treatment (sham stimulation) (<LINK REF="STD-Yamanishi-2010" TYPE="STUDY">Yamanishi 2010</LINK>). All the men had stress urinary incontinence.</P>
<SUBSECTION>
<HEADING LEVEL="4">Urinary incontinence</HEADING>
<P>ES resulted in statistically significantly fewer incontinent men at 3 and 6 months (for example RR at 6 months 0.38, 95% CI 0.16 to 0.87, <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>), but not at 12 months. Pad tests also showed less urine loss at 3, but not at 6 or 12 months (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>). These findings were reflected in the ICI-Questionaire (Short Form) data: the total score (range 0 to 21) was significantly less (better) at 3 and 6 months (MD -3.9, 95% CI -7.15 to -0.65, <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>.2) although the QOL score (range 0 to 10) was only better at 3 months (MD -1.5, 95% CI -2.9 to -0.1, <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>.1).</P>
<P>Adverse effects in the active ES group occurred in 2 of 26 men, and in 4 out of 30 men in the sham ES group (discomfort or anal pain) (<LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3. Electrical stimulation with non-implanted devices versus other 'single' treatments</HEADING>
<P>One small trial addressed this comparison (<LINK REF="STD-Yokoyama-2004" TYPE="STUDY">Yokoyama 2004</LINK>) but it provided no useable data. There were no statistically significant differences between the groups but the trial was too small to detect them.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">4. Electrical stimulation with non-implanted devices in combination with another therapy versus the other therapy alone</HEADING>
<P>Four small trials addressed this comparison (<LINK REF="STD-Ceresoli-2002" TYPE="STUDY">Ceresoli 2002</LINK>; <LINK REF="STD-Hoffmann-2005" TYPE="STUDY">Hoffmann 2005</LINK>; <LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>; <LINK REF="STD-Wille-2003" TYPE="STUDY">Wille 2003</LINK>). All the men had stress urinary incontinence at baseline. The following interventions were compared:</P>
<UL>
<LI>transcutaneous (anal) electrical nerve stimulation plus PFMT (<LINK REF="STD-Hoffmann-2005" TYPE="STUDY">Hoffmann 2005</LINK>; <LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>; <LINK REF="STD-Wille-2003" TYPE="STUDY">Wille 2003</LINK>);</LI>
<LI>transcutaneous (perineal) electrical nerve stimulation plus PFMT (<LINK REF="STD-Ceresoli-2002" TYPE="STUDY">Ceresoli 2002</LINK>; <LINK REF="STD-Hoffmann-2005" TYPE="STUDY">Hoffmann 2005</LINK>);</LI>
<LI>PFMT alone (<LINK REF="STD-Ceresoli-2002" TYPE="STUDY">Ceresoli 2002</LINK>; <LINK REF="STD-Hoffmann-2005" TYPE="STUDY">Hoffmann 2005</LINK>; <LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>; <LINK REF="STD-Wille-2003" TYPE="STUDY">Wille 2003</LINK>);</LI>
<LI>PFMT plus biofeedback (<LINK REF="STD-Wille-2003" TYPE="STUDY">Wille 2003</LINK>).</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="5">Transcutaneous (anal) ES plus PFMT versus PFMT alone</HEADING>
<P>All four trials provided information about the number of men with urinary incontinence at three months after treatment. There was no evidence of a difference in the number of men with urinary incontinence (RR 0.98, 95% CI 0.84 to 1.15, <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>.1), nor in the pad test data (<LINK REF="CMP-004.07" TYPE="ANALYSIS">Analysis 4.7</LINK>). However, one small trial suggested that men reported better QOL scores with PFMT alone (MD 2.34, 95% CI 0.07 to 4.61, <LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK>.1). Overall, men reported more adverse effects with anal ES (20/79, 25% versus 2/99, 2% with PFMT alone; RR 9.77, 95% CI 2.42 to 39.44,<I> </I>
<LINK REF="CMP-004.08" TYPE="ANALYSIS">Analysis 4.8</LINK>.1).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Transcutaneous (perineal) ES plus PFMT versus PFMT alone</HEADING>
<P>One trial used perineal ES (<LINK REF="STD-Hoffmann-2005" TYPE="STUDY">Hoffmann 2005</LINK>). There was no statistically significant difference in the incontinence rate (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>2). However, men reported better quality of life with PFMT (MD 6.51, 95% CI 4.70 to 8.32, <LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK>.2) (<LINK REF="STD-Hoffmann-2005" TYPE="STUDY">Hoffmann 2005</LINK>). There were too few adverse effects for meaningful analysis (<LINK REF="CMP-004.08" TYPE="ANALYSIS">Analysis 4.8</LINK>.2).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Transcutaneous (any) ES plus PFMT versus PFMT alone</HEADING>
<P>
<LINK REF="STD-Ceresoli-2002" TYPE="STUDY">Ceresoli 2002</LINK> did not specify the method of transcutaneous ES. There was no statistically significant difference in the incontinence rate (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>3). Men used fewer pads per day in the PFMT group (MD 1, 95% CI 0.53 to 1.47, <LINK REF="CMP-004.06" TYPE="ANALYSIS">Analysis 4.6</LINK>,1) (<LINK REF="STD-Ceresoli-2002" TYPE="STUDY">Ceresoli 2002</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Transcutaneous (anal or perineal) ES plus PFMT versus PFMT alone</HEADING>
<P>Overall, there was no evidence of a statistically significant difference in the number of men with urinary incontinence at 3 months (146/239, 61% for combined treatment versus 98/156, 63% with PFMT alone; RR 0.93, 95% CI 0.82 to 1.06, <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>.3). However, there were more adverse effects (23/139, 17% versus 2/99, 2% with PFMT alone; RR 7.04, 95% CI 1.51 to 32.94, <LINK REF="CMP-004.08" TYPE="ANALYSIS">Analysis 4.8</LINK>.3) and QOL also seemed better with PFMT alone (<LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK>).</P>
<P>Based on these six trials there seems to be no additional value of the addition of ES to PFMT in men with stress urinary incontinence after a radical prostatectomy.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">5. One method of providing electrical stimulation (ES) with non-implanted devices versus another method</HEADING>
<P>One trial compared transcutaneous (anal) ES with PFMT versus transcutaneous (perineal) ES with PFMT (<LINK REF="STD-Hoffmann-2005" TYPE="STUDY">Hoffmann 2005</LINK>). All the men had stress urinary incontinence at baseline.</P>
<P>This small trial did not detect statistically significant differences between the two methods of administration of transcutaneous ES (anal versus perineal) (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>; <LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>) but the QOL score was lower (better) in the anal stimulation group (<LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>). </P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-05-06 22:02:03 +0100" MODIFIED_BY="Bary CM Berghmans">
<SUBSECTION>
<HEADING LEVEL="5">Value and benefits of electrical stimulation</HEADING>
<P>Today, it is still very difficult to clarify the real value, potentials and benefits of electrical stimulation (ES) in the treatment of male urinary incontinence (<LINK REF="REF-Smith-2009" TYPE="REFERENCE">Smith 2009</LINK>). There are several reasons for this. First, the nomenclature used to describe electrical stimulation has been inconsistent, leading to confusion how to categorize ES. Stimulation has sometimes been described on the basis of the type of current being used (for example faradic stimulation, interferential therapy) but is also described on the basis of the structures being targeted (for example neuromuscular electrical stimulation), the current intensity (for example low-intensity stimulation, or maximal stimulation) and the proposed mechanism of action (for example neuromodulation). Second, in electrical stimulation studies many combinations of current types, amplitudes, types of waveforms, frequencies, intensities, electrode placements etc. are reported (<LINK REF="REF-Smith-2009" TYPE="REFERENCE">Smith 2009</LINK>). Third, although it has been suggested that ES as an intervention for urinary incontinence is using the natural neural pathways and micturition reflexes (<LINK REF="REF-Fall-1998" TYPE="REFERENCE">Fall 1998</LINK>; <LINK REF="STD-Yamanishi-1998a" TYPE="STUDY">Yamanishi 1998a</LINK>), and the understanding of both the neuro-anatomy and neurophysiology of the central and peripheral nervous systems is increasing, there is still lack of a well-substantiated biological rationale supporting the use of ES (<LINK REF="REF-Smith-2009" TYPE="REFERENCE">Smith 2009</LINK>).</P>
<P>Comparing ES in combination with another treatment modality with that treatment modality alone, there seems to be little to no additional value of the addition of ES to PFMT in men with stress urinary incontinence after a radical prostatectomy. However, this conclusion should be taken with caution because in all four included RCTs the number of included participants was relatively small. There were too few data to draw final conclusions about the effects of ES with non-implantable devices.</P>
</SUBSECTION>
<SUMMARY_OF_RESULTS MODIFIED="2013-04-25 22:34:12 +0100" MODIFIED_BY="[Empty name]">
<P>One small trial showed that ES was more effective than sham treatment in the first few months in both urinary outcomes and quality of life (QOL), but this did not persist after six months (<LINK REF="STD-Yamanishi-2010" TYPE="STUDY">Yamanishi 2010</LINK>).</P>
<P>There was not enough evidence from four small trials to suggest that supplementing ES with PFMT resulted in better urinary outcomes than with PFMT alone (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>), but there were more adverse effects (<LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK>). However, the QOL score was lower (better) in the anal stimulation group than in the perineal group (<LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>).</P>
<P>Of the included trials, Ceresoli (<LINK REF="STD-Ceresoli-2002" TYPE="STUDY">Ceresoli 2002</LINK>) and Wille (<LINK REF="STD-Wille-2003" TYPE="STUDY">Wille 2003</LINK>) did not report any adverse event or side effect. It remains unclear whether these were not reported or that there were no adverse events or side effects in these trials. The other four trials reported that a minority of ES patients suffered from discomfort from the electrode, pain or an increase in incontinence symptoms in such way that they dropped out. Most reported side effects were pain, soreness or local irritation and psychological distress.</P>
<P>Therefore there was not enough evidence for or against ES, partly due to the variability in the interventions of the included trials and their small size.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2013-04-25 22:34:49 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">Patient selection and electrical stimulation protocols</HEADING>
<P>There were many differences in the populations, the intervention protocols and the timing of the outcome measures in the included trials, as summarised above. As all the trials included men with stress urinary incontinence, it was not possible to determine the effect of ES on other types of incontinence such as urgency. The trials were also confined to men who had undergone a prostatectomy.</P>
<P>Five of the six included studies used surface anal electrodes, Hoffmann et al (<LINK REF="STD-Hoffmann-2005" TYPE="STUDY">Hoffmann 2005</LINK>) also used transcutaneous (anal and perineal) ES. Ceresoli (<LINK REF="STD-Ceresoli-2002" TYPE="STUDY">Ceresoli 2002</LINK>) used  a transcutaneous electrode. Although both anal and surface electrodes have been reported to be safe (<LINK REF="STD-Yamanishi-2000a" TYPE="STUDY">Yamanishi 2000a</LINK>), sometimes patients do not tolerate anal plug electrode because of pain, discomfort, mucosal injury or exacerbation of haemorrhoids (<LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>).</P>
<P>Most often intensity of stimulation is used up to the maximum tolerable level, because many authors report that the stronger the intensity the better the outcome (<LINK REF="REF-Geirsson-1997" TYPE="REFERENCE">Geirsson 1997</LINK>; <LINK REF="REF-Sand-1995" TYPE="REFERENCE">Sand 1995</LINK>; <LINK REF="STD-Yamanishi-1997a" TYPE="STUDY">Yamanishi 1997a</LINK>; <LINK REF="STD-Yamanishi-1998a" TYPE="STUDY">Yamanishi 1998a</LINK>; <LINK REF="STD-Yamanishi-2000a" TYPE="STUDY">Yamanishi 2000a</LINK>; <LINK REF="REF-Yashuda-1999" TYPE="REFERENCE">Yashuda 1999</LINK>). In the included studies frequencies and duration of the stimulation and the number of sessions varied depending on the investigators. Hoffmann (<LINK REF="STD-Hoffmann-2005" TYPE="STUDY">Hoffmann 2005</LINK>) and Yamanishi (<LINK REF="STD-Yamanishi-2010" TYPE="STUDY">Yamanishi 2010</LINK>) used a maximal amplitude of 70 mA, Moore (<LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>) reported the use of intensities "adequate to induce a visual lifting of the levator ani and pubococcygeus muscle, considering the level of comfort of the patients", Wille (<LINK REF="STD-Wille-2003" TYPE="STUDY">Wille 2003</LINK>) instructed patients to control intensity of current &#8216;from 10% to 100%&#8217;. Although it is not clear yet whether or not maximal tolerable intensity of current really is necessary to get an optimal result of ES therapy, it might be that in the included studies intensity of current was not adequate or sufficient to reach an optimal result.</P>
<P>All six trials reported some of the primary outcome measures of interest, that is patient perceived urinary incontinence, pad tests and condition specific QOL. However, none of the trials used the same subjective outcome measures. Regarding pad tests, Moore (<LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>), Ceresoli (<LINK REF="STD-Ceresoli-2002" TYPE="STUDY">Ceresoli 2002</LINK>), Yamanishi (<LINK REF="STD-Yamanishi-2010" TYPE="STUDY">Yamanishi 2010</LINK>) and Yokoyama (<LINK REF="STD-Yokoyama-2004" TYPE="STUDY">Yokoyama 2004</LINK>) used a 24-hr pad test, while Hoffmann (<LINK REF="STD-Hoffmann-2005" TYPE="STUDY">Hoffmann 2005</LINK>) used a 1-hr pad test and Wille (<LINK REF="STD-Wille-2003" TYPE="STUDY">Wille 2003</LINK>) a 20-min pad test. As a result, the amount of data available for meta-analysis was very limited, making interpretation of results difficult.</P>
<P>In all but one (<LINK REF="STD-Yokoyama-2004" TYPE="STUDY">Yokoyama 2004</LINK>) of the six RCTs, ES was combined with PFMT. Because of this, it is difficult to assess any specific effect of ES (as could have been the case if ES was provided as a stand-alone therapy). Especially when ES is combined with PFMT, any effect may be partly due to the attention and support given to patients during their clinic sessions (<LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>). Both Moore et al (<LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>) and Hoffman et al (<LINK REF="STD-Hoffmann-2005" TYPE="STUDY">Hoffmann 2005</LINK>) discussed that these non-specific effects might have contributed to the effect of ES.</P>
</SUBSECTION>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2013-05-06 22:02:03 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Study quality and methodological assessment</HEADING>
<P>Various conservative treatment modalities for the management of stress, mixed, and urgency urinary incontinence are available. ES is used alone or as an adjunct to one of other eligible physiotherapeutic treatment modalities such as PFMT. All but one of the included trials in this review used ES as an adjunct to PFMT.</P>
<P>Only a small number of RCTs investigating the effect of ES could be identified.<BR/>When assessing methodological quality, the primary goal is to assess the reported effects of interventions and the influence, risk and direction of bias on the results of these treatments as methodological quality plays an important role in weighing the conclusions of different trials. In order to explore the possibility that an increasing likelihood of bias was reflected in the results of the trials (through an increasing number of methodological shortcomings), the 'Risk of bias' criteria presented in <I>The Cochrane Handbook for Systematic Reviews of Intervention</I>, were assessed.</P>
<P>The risk of bias in the six included studies appeared to range from low to high risk of bias. Allocation concealment and blinding were unclear in more than half of the studies while incomplete outcome reporting and selective reporting were identified in about 40% and 14% respectively, and other potential bias in 40% of the studies. So, bias with respect to measurement, intervention or allocation might have been introduced. None of the studies reported whether or not they had performed an intention-to-treat analysis. A power calculation was only performed by Moore et al (<LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>) and Yamanishi et al (<LINK REF="STD-Yamanishi-2010" TYPE="STUDY">Yamanishi 2010</LINK>). It might be that studies were underpowered to find any statistical differences between study groups.</P>
<P>Because of small numbers per group in the included RCTs, occurrence of type II-errors was more likely than would have been the case in RCTs with larger groups.<BR/>
<BR/>Apart from Ceresoli et al (<LINK REF="STD-Ceresoli-2002" TYPE="STUDY">Ceresoli 2002</LINK>), all included RCTs had sufficient descriptions of the content, the duration and the intensity of the interventions.</P>
</SUBSECTION>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2013-02-15 13:27:02 +0000" MODIFIED_BY="[Empty name]">
<P>None known</P>
</POTENTIAL_BIASES>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-04-25 22:35:18 +0100" MODIFIED_BY="Bary CM Berghmans">
<IMPLICATIONS_PRACTICE MODIFIED="2013-04-25 22:35:11 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>The six small included trials were of disparate populations and interventions, limiting our ability to combine the data. There was some evidence that electrical stimulation (ES) enhanced the effect of PFMT in the short term but not after six months. There were, however, more adverse effects with ES.</P>
<P>There was a marked lack of consistency in the ES protocols, which implies a lack of consensus about the physiological principles of rehabilitating urinary incontinence in men through ES in clinical practice.</P>
<P>Since no RCTs on ES were available for any type of urinary incontinence other than post-prostatectomy stress urinary incontinence, at the moment it is not possible to reach any conclusion on effects, side effects or adverse events of ES as a-stand alone therapy or in combination with other treatments on men with other types of urinary incontinence. </P>
<P>In men with stress urinary incontinence after radical prostatectomy, up till now there is no convincing evidence from RCTs that ES is a useful treatment. So far, it is impossible to recommend the optimal ES regimen and protocol.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-04-25 22:35:18 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>Because of the scanty evidence of an effect of ES on incontinence in men, and the lack of agreement about the correct mode of administration, duration and frequency of treatment, there is a need to design rigorous trials to determine whether there is a place for ES in the management of men with stress urinary incontinence. Any trialists should use the recommendations and principles set out in the CONSORT statement when designing and reporting their trials.</P>
<P>There is a need for more research to determine the best ES protocol(s) and important standardised outcome measures for these men. Future trials should follow the recommendations and principles of the CONSORT statement and should include primary and secondary outcomes which are most suitable (with respect to sensitivity, responsiveness, validity, and reliability).<BR/>
<BR/>
</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-05-06 21:53:26 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>The authors would like to acknowledge the team of the Cochrane Incontinence Review Group for their help.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2013-02-15 12:34:29 +0000" MODIFIED_BY="Bary CM Berghmans">
<P>None known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-05-06 21:53:09 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>All review authors contributed in the writing of the protocol. Authors Bary Berghmans, Erik Hendriks and Rob de Bie independently assessed the pertinence and quality of eligible studies and selected which to include in the review. The first two review authors independently extracted data from trial reports of identified studies and interpreted the results. Muhammad Imran Omar re-checked extracted data and risk of bias assessments and offered methodological advice and help. In the case of  disagreement Rob de Bie and Muhammad Imran Omar acted as consultants and helped to make final decisions. All review authors contributed in the writing of the final version of the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-04-25 22:58:16 +0100" MODIFIED_BY="Bary CM Berghmans">
<STUDIES MODIFIED="2013-04-25 22:54:36 +0100" MODIFIED_BY="Bary CM Berghmans">
<INCLUDED_STUDIES MODIFIED="2013-04-25 22:41:27 +0100" MODIFIED_BY="Bary CM Berghmans">
<STUDY DATA_SOURCE="PUB" ID="STD-Ceresoli-2002" MODIFIED="2012-05-31 11:21:18 +0100" MODIFIED_BY="Bary CM Berghmans" NAME="Ceresoli 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-05-31 11:21:18 +0100" MODIFIED_BY="Bary CM Berghmans" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Ceresoli A, Kartalas Goumas J, Colombo F, Barbetti E, Dell'Aglio F, Bonacina P, et al</AU>
<TI>Daily transcutaneous electrical nerve stimulation (DTENS) after radical perineal prostatectomy: a free cost effective biofeedback technique in the treatment of postoperative urinary incontinence (Abstract number 426)</TI>
<SO>Proceedings of the International Continence Soceity (ICS), 32nd Annual Meeting, Heidelberg, Germany, 28-30 August</SO>
<YR>2002</YR>
<PG>289</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hoffmann-2005" NAME="Hoffmann 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hoffman W, Liedke S, Dombo O, Otto U</AU>
<TI>Electrical stimulation for post-operative stress urinary incontinence</TI>
<TO>Die Elektrostimulation in der Therapie der Postoperativen Harninkontinenz</TO>
<SO>Der Urologe</SO>
<YR>2005</YR>
<VL>1</VL>
<PG>33-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moore-1999" MODIFIED="2011-09-29 20:53:42 +0100" MODIFIED_BY="Bary CM Berghmans" NAME="Moore 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moore KN, Griffiths D, Hughton A</AU>
<TI>Urinary incontinence after radical prostatectomy: a randomized controlled trial comparing pelvic muscle exercises with or without electrical stimulation</TI>
<SO>British Journal of Urology International</SO>
<YR>1999</YR>
<VL>83</VL>
<PG>57-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wille-2003" MODIFIED="2013-04-15 13:48:36 +0100" MODIFIED_BY="[Empty name]" NAME="Wille 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-04-15 13:48:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wille S, Sobottka A, Heidenreich A, Hofmann R</AU>
<TI>Pelvic floor exercises, electrical stimulation and biofeedback after radical prostatectomy: results of a prospective randomized trial</TI>
<SO>Journal of Urology</SO>
<YR>2003</YR>
<VL>170</VL>
<PG>490-3</PG>
<IDENTIFIERS MODIFIED="2013-04-15 11:34:16 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-04-15 11:34:16 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12853806"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yamanishi-2010" MODIFIED="2013-04-25 22:41:17 +0100" MODIFIED_BY="Bary CM Berghmans" NAME="Yamanishi 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-04-25 22:41:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yamanishi T, Mizuno T, Sakakibara R, Uchiyama T, Ito T, Yamamoto T, et al</AU>
<TI>A randomized,placebo-controlled, double-blind study of electrical stimulation with pelvic floor muscle training for the treatment of urinary incontinence after radical prostatectomy</TI>
<SO>Neurourology and Urodynamics (Abstract number 30)</SO>
<YR>2006</YR>
<VL>25</VL>
<NO>6</NO>
<PG>545-6</PG>
<IDENTIFIERS MODIFIED="2013-04-15 11:34:59 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-04-15 11:34:59 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SR-INCONT26613"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-04-25 22:41:17 +0100" MODIFIED_BY="Bary CM Berghmans" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yamanishi T, Mizuno T, Watanabe M, Honda M, Yoshida K</AU>
<TI>Randomized, placebo controlled study of electrical stimulation with pelvic floor muscle training for severe urinary incontinence after radical prostatectomy</TI>
<SO>Journal of Urology</SO>
<YR>2010</YR>
<VL>184</VL>
<PG>2007-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yokoyama-2004" MODIFIED="2013-04-25 22:41:27 +0100" MODIFIED_BY="Bary CM Berghmans" NAME="Yokoyama 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-04-25 22:41:27 +0100" MODIFIED_BY="Bary CM Berghmans" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yokoyama T, Nishiguchi J, Watanabe T, Nose H, Nozaki K, Fujita O, et al</AU>
<TI>Comparative study of effects of extracorporeal magnetic innervation versus electrical stimulation for urinary incontinence after radical prostatectomy</TI>
<SO>Urology</SO>
<YR>2004</YR>
<VL>63</VL>
<NO>2</NO>
<PG>264-7</PG>
<IDENTIFIERS MODIFIED="2013-04-15 11:34:29 +0100" MODIFIED_BY="Bary CM Berghmans"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-04-25 22:54:36 +0100" MODIFIED_BY="Bary CM Berghmans">
<STUDY DATA_SOURCE="PUB" ID="STD-Bocker-2002" MODIFIED="2013-04-15 13:55:12 +0100" MODIFIED_BY="[Empty name]" NAME="Bocker 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-04-15 13:55:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bocker B, Smolenski UC</AU>
<TI>Physical therapy for pelvic floor insufficiency-comparison of methods</TI>
<TO>Physikalische Therapie der Beckenbodeninsuffizienz</TO>
<SO>Journal fur Urologie und Urogynäkologie</SO>
<YR>2002</YR>
<VL>2</VL>
<PG>20-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goode-2009" MODIFIED="2013-04-25 22:52:29 +0100" MODIFIED_BY="Bary CM Berghmans" NAME="Goode 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-04-25 22:52:29 +0100" MODIFIED_BY="Bary CM Berghmans" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goode P, Burgio K, Johnson T, Roth D, Clay O, Burkhardt J, et al</AU>
<TI>Behavioral therapy with or without biofeedback and pelvic floor electrical stimulation for persistent post-prostatectomy incontinence - a randomized controlled trial</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2009</YR>
<VL>28</VL>
<PG>681-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hasan-1994" MODIFIED="2012-05-31 11:40:12 +0100" MODIFIED_BY="Bary CM Berghmans" NAME="Hasan 1994" YEAR="1994">
<REFERENCE MODIFIED="2012-05-31 11:40:12 +0100" MODIFIED_BY="Bary CM Berghmans" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hasan ST, Robson WA, Pridie AK, Neal DE</AU>
<TI>Outcome of transcutaneous electrical stimulation in patients with detrusor instability (Abstract)</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>1994</YR>
<VL>13</VL>
<NO>4</NO>
<PG>349-50</PG>
<IDENTIFIERS MODIFIED="2012-05-31 11:40:12 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-05-31 11:40:12 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SR-INCONT2686"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lin-2004" MODIFIED="2013-04-15 13:49:35 +0100" MODIFIED_BY="Bary CM Berghmans" NAME="Lin 2004" YEAR="">
<REFERENCE MODIFIED="2013-04-15 13:49:35 +0100" MODIFIED_BY="Bary CM Berghmans" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lin LS, Song YF, Song J, Chen MF</AU>
<TI>A clinical study of pelvic floor electrical stimulation in treatment of overactive bladder</TI>
<SO>Chinese Journal of Obstetrics &amp; Gynecology</SO>
<YR>2004</YR>
<VL>39</VL>
<NO>12</NO>
<PG>801-3</PG>
<IDENTIFIERS MODIFIED="2013-04-15 11:35:16 +0100" MODIFIED_BY="Bary CM Berghmans"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mariotti-2009" MODIFIED="2013-04-25 22:53:56 +0100" MODIFIED_BY="Bary CM Berghmans" NAME="Mariotti 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-04-25 22:53:56 +0100" MODIFIED_BY="Bary CM Berghmans" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mariotti G, Sciarra A, Gentilucci A, Salciccia S, Alfarone A, Pierro GD, et al</AU>
<TI>Early recovery of urinary continence after radical prostatectomy using early pelvic floor electrical stimulation and biofeedback associated treatment</TI>
<SO>Journal of Urology</SO>
<YR>2009</YR>
<VL>181</VL>
<NO>4</NO>
<PG>1788-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McClurg-2008" MODIFIED="2013-04-25 22:41:40 +0100" MODIFIED_BY="Bary CM Berghmans" NAME="McClurg 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-04-25 22:41:40 +0100" MODIFIED_BY="Bary CM Berghmans" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McClurg D, Ashe RG, Lowe-Strong AS</AU>
<TI>Neuromuscular electrical stimulation and the treatment of lower urinary tract dysfunction in multiple sclerosis: a double-blind, placebo controlled, randomised clinical trial</TI>
<SO>Neurourology and Urodynamics </SO>
<YR>2008</YR>
<VL>27</VL>
<PG>231-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Petersen-1994" MODIFIED="2013-04-25 22:41:49 +0100" MODIFIED_BY="[Empty name]" NAME="Petersen 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-04-25 22:41:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Petersen T, Just-Christensen JE, Kousgaard P, Holmboe B, Klemar B</AU>
<TI>Anal sphincter maximum functional electrical stimulation in detrusor hyperreflexia</TI>
<SO>Journal of Urology</SO>
<YR>1994</YR>
<VL>152</VL>
<PG>1460-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Soomro-2001" MODIFIED="2013-04-25 22:41:58 +0100" MODIFIED_BY="[Empty name]" NAME="Soomro 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-04-25 22:41:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Soomro NA, Khadra MH, Robson W, Neal DE</AU>
<TI>A crossover randomized trial of transcutaneous electrical nerve stimulation and oxybutynin in patients with detrusor instability</TI>
<SO>Journal of Urology</SO>
<YR>2001</YR>
<VL>166</VL>
<PG>146-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Walsh-2001" MODIFIED="2013-04-25 22:54:21 +0100" MODIFIED_BY="[Empty name]" NAME="Walsh 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-04-25 22:54:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Walsh IK, Johnston RS, Keane, PF</AU>
<TI>Transcutaneous sacral neuro stimulation for irritative voiding dysfunction</TI>
<SO>European Urology</SO>
<YR>1999</YR>
<VL>35</VL>
<PG>192-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Webb-1992" MODIFIED="2012-05-31 11:39:29 +0100" MODIFIED_BY="[Empty name]" NAME="Webb 1992" YEAR="1992">
<REFERENCE MODIFIED="2012-05-31 11:39:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Webb RJ, Powell PH</AU>
<TI>Transcutaneous electrical nerve stimulation in patients with idiopathic detrusor instability</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>1992</YR>
<VL>11</VL>
<NO>4</NO>
<PG>327-8</PG>
<IDENTIFIERS MODIFIED="2012-05-31 11:39:29 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-05-31 11:39:29 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SR-INCONT4626"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yamanishi-1997a" MODIFIED="2013-04-15 13:50:29 +0100" MODIFIED_BY="[Empty name]" NAME="Yamanishi 1997a" YEAR="1997">
<REFERENCE MODIFIED="2013-04-15 13:50:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yamanishi T, Yasuda K, Sakakibara R, Hattori T, Ito H, Murakami S</AU>
<TI>Pelvic floor electrical stimulation in the treatment of stress incontinence: an investigational study and a placebo controlled double-blind trial</TI>
<SO>Journal of Urology</SO>
<YR>1997</YR>
<VL>158</VL>
<NO>6</NO>
<PG>2127-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yamanishi-1998a" MODIFIED="2013-04-15 13:50:43 +0100" MODIFIED_BY="[Empty name]" NAME="Yamanishi 1998a" YEAR="1998">
<REFERENCE MODIFIED="2013-04-15 13:50:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yamanishi T, Yasuda K, Sakakibara R, Hattori T, Suda S</AU>
<TI>Randomized, double-blind study of electrical stimulation for urinary incontinence due to detrusor overactivity</TI>
<SO>Urology</SO>
<YR>2000</YR>
<VL>55</VL>
<PG>353-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yamanishi-2000a" MODIFIED="2013-04-15 13:51:02 +0100" MODIFIED_BY="[Empty name]" NAME="Yamanishi 2000a" YEAR="2000">
<REFERENCE MODIFIED="2013-04-15 13:51:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Yamanishi T, Sakakibara R, Uchiyama T, Suda S, Hattori T, Ito H, Yasuda K</AU>
<TI>Comparative study of the effects of magnetic versus electrical stimulation on inhibition of detrusor overactivity</TI>
<SO>Urology</SO>
<YR>2000</YR>
<VL>56</VL>
<PG>777-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yasuda-1994" MODIFIED="2013-04-25 22:54:36 +0100" MODIFIED_BY="Bary CM Berghmans" NAME="Yasuda 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-04-25 22:54:36 +0100" MODIFIED_BY="Bary CM Berghmans" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Yasuda K, Kawabe K, Suzuki T, Kageyama K, Yokoyama A, Takimoto Y, et al</AU>
<TI>Interferential therapy for the treatment of pollakisuria, urinary urgency and incontinence (Abstract)</TI>
<SO>Proceedings of the International Continence Society (ICS), 24th Annual Meeting, 1994 Aug 30-Sep 2</SO>
<YR>1994</YR>
<PG>222</PG>
<IDENTIFIERS MODIFIED="2012-05-31 11:44:45 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-05-31 11:44:45 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SR-INCONT10944"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-04-25 22:58:16 +0100" MODIFIED_BY="Bary CM Berghmans">
<ADDITIONAL_REFERENCES MODIFIED="2013-04-25 22:58:16 +0100" MODIFIED_BY="Bary CM Berghmans">
<REFERENCE ID="REF-Abrams-2002" MODIFIED="2013-04-25 22:54:49 +0100" MODIFIED_BY="[Empty name]" NAME="Abrams 2002" TYPE="JOURNAL_ARTICLE">
<AU>Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al</AU>
<TI>The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>2</NO>
<PG>167-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Abrams-2009" MODIFIED="2013-04-25 22:42:14 +0100" MODIFIED_BY="Bary CM Berghmans" NAME="Abrams 2009" TYPE="BOOK">
<AU>Abrams P, Cardozo L, Khoury S, Wein A (editors)</AU>
<SO>Incontinence: 4th International Consultation on Incontinence. Recommendations of the International Scientific Committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse and faecal incontinence: Paris, France, July 5-9, 2008</SO>
<YR>2009</YR>
<PB>Health Publication Ltd</PB>
<CY>Plymouth, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Amarenco-2003" MODIFIED="2013-04-15 13:46:04 +0100" MODIFIED_BY="[Empty name]" NAME="Amarenco 2003" TYPE="JOURNAL_ARTICLE">
<AU>Amarenco G, Ismael SS, Even-Schneider A, Raibaut P, Demaille-Wlodyka S, Parratte B, Kerdraon J</AU>
<TI>Urodynamic effect of acute transcutaneous posterior tibial nerve stimulation in overactive bladder</TI>
<SO>Journal of Urology</SO>
<YR>2003</YR>
<VL>169</VL>
<PG>2210-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Appell-1998" MODIFIED="2013-04-25 22:42:24 +0100" MODIFIED_BY="[Empty name]" NAME="Appell 1998" TYPE="JOURNAL_ARTICLE">
<AU>Appell RA</AU>
<TI>Electrical stimulation for the treatment of urinary incontinence</TI>
<SO>Urology</SO>
<YR>1988</YR>
<VL>51 Suppl 2A</VL>
<PG>24-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bent-1993" MODIFIED="2013-04-15 13:45:37 +0100" MODIFIED_BY="[Empty name]" NAME="Bent 1993" TYPE="JOURNAL_ARTICLE">
<AU>Bent AE, Sand PK, Ostergard DR, Brubaker LT</AU>
<TI>Transvaginal electrical stimulation in the treatment of genuine stress incontinence and detrusor instability</TI>
<SO>International Journal of Urogynecology</SO>
<YR>1993</YR>
<VL>4</VL>
<PG>9-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Berghmans-1998a" MODIFIED="2013-04-15 13:38:54 +0100" MODIFIED_BY="[Empty name]" NAME="Berghmans 1998a" TYPE="JOURNAL_ARTICLE">
<AU>Berghmans LCM, Bernards ATM, Bluyssen AMW, Grupping-Morel MHM, Hendriks HJM, de Jong-van Ierland MJEA, et al</AU>
<TI>Dutch physiotherapy guidelines for stress urinary incontinence</TI>
<TO>KNGF-richtlijn Stress urine-incontinentie</TO>
<SO>Nederland Tijdschrift voor Fysiotherapie</SO>
<YR>1998</YR>
<VL>108 Suppl</VL>
<NO>4</NO>
<PG>1-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Berghmans-1998b" MODIFIED="2013-04-25 22:43:05 +0100" MODIFIED_BY="[Empty name]" NAME="Berghmans 1998b" TYPE="JOURNAL_ARTICLE">
<AU>Berghmans LCM, Hendriks HJM, Bø K, Hay-Smith EJ, de Bie RA, Waalwijk V, van Doorn ESC</AU>
<TI>Conservative treatment of stress urinary incontinence in women: a systematic review of randomized clinical trials</TI>
<SO>British Journal of Urology</SO>
<YR>1998</YR>
<VL>82</VL>
<PG>181-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Berghmans-2002" MODIFIED="2013-04-25 22:42:40 +0100" MODIFIED_BY="Bary CM Berghmans" NAME="Berghmans 2002" TYPE="JOURNAL_ARTICLE">
<AU>Berghmans LCM, Van Waalwijk van Doorn ESC, Nieman FHM, De Bie RA, Van den Brandt PA, Van Kerrebroeck PhEV</AU>
<TI>Efficacy of physical therapeutic modalities in women with proven bladder overactivity</TI>
<SO>European Urology</SO>
<YR>2002</YR>
<VL>41</VL>
<PG>581-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brubaker-2000" MODIFIED="2013-04-25 22:42:48 +0100" MODIFIED_BY="[Empty name]" NAME="Brubaker 2000" TYPE="JOURNAL_ARTICLE">
<AU>Brubaker L</AU>
<TI>Electrical stimulation in overactive bladder</TI>
<SO>Urology</SO>
<YR>2000</YR>
<VL>55 Suppl 5A</VL>
<PG>17-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Buckley-2008" MODIFIED="2013-04-25 22:42:56 +0100" MODIFIED_BY="Bary CM Berghmans" NAME="Buckley 2008" TYPE="JOURNAL_ARTICLE">
<AU>Buckley BS, Lapitan MC et al</AU>
<TI>Prevalence of urinary incontinence in men, women, and children&#8212;Current evidence: Findings of the Fourth International Consultation on Incontinence</TI>
<SO>Urology</SO>
<YR>2010 Aug</YR>
<VL>76</VL>
<NO>2</NO>
<PG>270-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Campbell-2012" MODIFIED="2012-05-31 11:57:59 +0100" MODIFIED_BY="Bary CM Berghmans" NAME="Campbell 2012" NOTES="&lt;p&gt;at 31 may 2012 latest version is:&lt;/p&gt;&lt;p&gt;Campbell SE, Glazener CMA, Hunter KF, Cody JD, Moore KN. Conservative management for postprostatectomy urinary incontinence. Cochrane Database of Systematic Reviews 2012, Issue 1. Art. No.: CD001843. DOI: 10.1002/14651858.CD001843.pub4&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2012-05-31 11:57:59 +0100" NOTES_MODIFIED_BY="Bary CM Berghmans" TYPE="COCHRANE_REVIEW">
<AU>Campbell SE, Glazener CMA, Hunter KF, Cody JD, Moore KN</AU>
<TI>Conservative management for postprostatectomy urinary incontinence</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2012-05-31 11:56:15 +0100" MODIFIED_BY="Bary CM Berghmans">
<IDENTIFIER MODIFIED="2012-05-31 11:56:15 +0100" MODIFIED_BY="Bary CM Berghmans" TYPE="DOI" VALUE="10.1002/14651858.CD001843.pub4"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Carlson-2001" MODIFIED="2013-04-15 13:44:58 +0100" MODIFIED_BY="[Empty name]" NAME="Carlson 2001" TYPE="JOURNAL_ARTICLE">
<AU>Carlson KV, Kitti VW</AU>
<TI>Prevention and management of incontinence following radical prostatectomy</TI>
<SO>Urological Clinics of North America</SO>
<YR>2001</YR>
<VL>28</VL>
<PG>595-612</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Coyne-2012" MODIFIED="2012-05-31 12:19:15 +0100" MODIFIED_BY="Bary CM Berghmans" NAME="Coyne 2012" NOTES="&lt;p&gt;epub was July 2011 but now available in print so updated the citation&lt;/p&gt;" NOTES_MODIFIED="2012-05-31 12:19:15 +0100" NOTES_MODIFIED_BY="Bary CM Berghmans" TYPE="JOURNAL_ARTICLE">
<AU>Coyne KS, Kvasz M, Ireland AM, Milsom I, Kopp ZS, Chapple CR</AU>
<TI>Urinary incontinence and its relationship to mental health and health-related quality of life in men and women in Sweden, the United Kingdom, and the United States</TI>
<SO>European Urology</SO>
<YR>2012</YR>
<VL>61</VL>
<NO>1</NO>
<PG>88-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-De-Nunzio-2003" MODIFIED="2013-04-15 13:44:46 +0100" MODIFIED_BY="[Empty name]" NAME="De Nunzio 2003" TYPE="JOURNAL_ARTICLE">
<AU>De Nunzio C, Franco G, Rocchgiani A, Iori F, Leonardo C, Laurenti C</AU>
<TI>The evolution of detrusor overactivity after watchful waiting, medical therapy and surgery in patients with bladder outlet obstruction</TI>
<SO>Journal of Urology</SO>
<YR>2003</YR>
<VL>169</VL>
<PG>535-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dmochowski-2002" MODIFIED="2013-04-15 13:44:36 +0100" MODIFIED_BY="[Empty name]" NAME="Dmochowski 2002" TYPE="JOURNAL_ARTICLE">
<AU>Dmochowski RR, Staskin DR</AU>
<TI>Overactive bladder in men: special considerations for evaluation and management</TI>
<SO>Urology</SO>
<YR>2002</YR>
<VL>60</VL>
<NO>5a</NO>
<PG>56-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Eriksen-1989" NAME="Eriksen 1989" NOTES="&lt;p&gt;Eriksen BC, Eik-Nes SH. Long-term electrostimulation of the pelvic floor: primary therapy in female stress incontinence? Urol Int 1989, 44:90-95.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Eriksen BC, Eik-Nes SH</AU>
<TI>Long-term electrostimulation of the pelvic floor: primary therapy in female stress incontinence?</TI>
<SO>Urologia Internationalis</SO>
<YR>1989</YR>
<VL>44</VL>
<NO>2</NO>
<PG>90-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Everaert-1999" MODIFIED="2012-05-31 12:25:18 +0100" MODIFIED_BY="Bary CM Berghmans" NAME="Everaert 1999" TYPE="CONFERENCE_PROC">
<AU>Everaert K, Lefevere F, Hagens P, Vanderstraeten G, Oosterlinck W</AU>
<TI>Influence of FES parameters on urethral pressure (Abstract)</TI>
<SO>Proceedings of the International Continence Society (ICS), 29th Annual Meeting, Denver, Colorado, USA</SO>
<YR>1999</YR>
<PG>390</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fall-1991" NAME="Fall 1991" NOTES="&lt;p&gt;Fall M, Lindstrom S. Electrical stimulation; a physiologic approach to the treatment of urinary incontinence. Urol Clin North Am 1991; 18:393-407.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Fall M, Lindstrom S</AU>
<TI>Electrical stimulation; a physiologic approach to the treatment of urinary incontinence</TI>
<SO>The Urologic Clinics of North America</SO>
<YR>1991</YR>
<VL>18</VL>
<NO>2</NO>
<PG>393-407</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fall-1994" NAME="Fall 1994" NOTES="&lt;p&gt;Fall M, Lindstrom S. Functional electrical stimulation: physiological basis and clinical principles. Int Urogynecol J 1994; 5:296-304.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Fall M, Lindstrom S</AU>
<TI>Functional electrical stimulation: physiological basis and clinical principles</TI>
<SO>International Urogynecology Journal and Pelvic Floor Dysfunction</SO>
<YR>1994</YR>
<VL>5</VL>
<PG>296-304</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fall-1998" MODIFIED="2013-04-25 22:43:23 +0100" MODIFIED_BY="[Empty name]" NAME="Fall 1998" NOTES="&lt;p&gt;Fall M. Advantages and pitfallsof functional electrical stimualtion. Acta Obstet Gynecol Scand 1998; 77(suppl 168):16-21&lt;/p&gt;" NOTES_MODIFIED="2013-04-25 22:43:23 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Fall M</AU>
<TI>Advantages and pitfalls of functional electrical stimulation</TI>
<SO>Acta Obstetricia et Gynecologica Scandinavica</SO>
<YR>1998</YR>
<VL>77 Suppl 168</VL>
<PG>16-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gacci-2003" NAME="Gacci 2003" TYPE="JOURNAL_ARTICLE">
<AU>Gacci M, Bartoletti R, Figlioli S, Sarti E, Eisner B, Boddi V, Rizzo M</AU>
<TI>Urinary symptoms, quality of life and sexual function in patients with benign prostatic hypertrophy before and after prostatectomy: a prospective study.</TI>
<SO>British Journal of Urology International</SO>
<YR>2003</YR>
<VL>91</VL>
<PG>196-200</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Geirsson-1997" MODIFIED="2013-04-15 13:15:00 +0100" MODIFIED_BY="[Empty name]" NAME="Geirsson 1997" TYPE="JOURNAL_ARTICLE">
<AU>Geirsson G, Fall M</AU>
<TI>Maximal functional electrical stimulation in routine practice</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>1997</YR>
<VL>16</VL>
<PG>559-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goldberg-2000" NAME="Goldberg 2000" NOTES="&lt;p&gt;Goldberg RP, Sand PK. Electromagnetic pelvic floor stimulation: applications for the gynecologist. Obstetrical and Gynecological Survey 2000;55(11):715-720.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Goldberg RP, Sand PK</AU>
<TI>Electromagnetic pelvic floor stimulation: applications for the gynecologist</TI>
<SO>Obstetrical and Gynecological Survey</SO>
<YR>2000</YR>
<VL>55</VL>
<NO>11</NO>
<PG>715-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Govier-2001" NAME="Govier 2001" NOTES="&lt;p&gt;Govier FE, Litwiller S, Nitti V, Kreder KJ Jr, Rosenblatt P. Percutaneous afferent neuromodulation for the refractory overactive bladder: results of a multicenter study. Journal of Urology 2001;165:1193-1198.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Govier FE, Litwiller S, Nitti V, Kreder KJ Jr, Rosenblatt P</AU>
<TI>Percutaneous afferent neuromodulation for the refractory overactive bladder: results of a multicenter study</TI>
<SO>Journal of Urology</SO>
<YR>2001</YR>
<VL>165</VL>
<NO>4</NO>
<PG>1193-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Groutz-2000" MODIFIED="2013-04-25 22:43:37 +0100" MODIFIED_BY="[Empty name]" NAME="Groutz 2000" TYPE="JOURNAL_ARTICLE">
<AU>Groutz A, Blaivas JG, Chaikin DC, Weiss JP, Verhaaren M</AU>
<TI>The pathophysiology of post-radical prostatectomy incontinence: a clinical and video urodynamic study</TI>
<SO>Journal of Urology</SO>
<YR>2000</YR>
<VL>163</VL>
<PG>1767-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gudziak-1996" MODIFIED="2013-04-15 13:15:30 +0100" MODIFIED_BY="[Empty name]" NAME="Gudziak 1996" TYPE="JOURNAL_ARTICLE">
<AU>Gudziak MR, McGuire EJ, Gormley EA</AU>
<TI>Urodynamic assessment of urethral sphincter function in post-prostatectomy incontinence: urodynamic findings and treatment outcomes</TI>
<SO>Journal of Urology</SO>
<YR>1996</YR>
<VL>156</VL>
<PG>1131-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hasan-1998" MODIFIED="2013-04-15 13:44:16 +0100" MODIFIED_BY="[Empty name]" NAME="Hasan 1998" NOTES="&lt;p&gt;Hasan ST, Neal DE. Neuromodulation in bladder dysfunction. Current Opinion in Obstetrics and Gynecology 1998;10:395-399.&lt;/p&gt;" NOTES_MODIFIED="2013-04-15 13:44:16 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Hasan ST, Neal DE</AU>
<TI>Neuromodulation in bladder dysfunction</TI>
<SO>Current Opinion in Obstetrics and Gynecology</SO>
<YR>1998</YR>
<VL>10</VL>
<NO>5</NO>
<PG>395-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Haylen-2010" MODIFIED="2013-04-25 22:43:48 +0100" MODIFIED_BY="Bary CM Berghmans" NAME="Haylen 2010" TYPE="JOURNAL_ARTICLE">
<AU>Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, et al</AU>
<TI>An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2010</YR>
<VL>29</VL>
<PG>4-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Herbison-2009" MODIFIED="2012-05-31 12:30:02 +0100" MODIFIED_BY="G Peter Herbison" NAME="Herbison 2009" NOTES="&lt;p&gt;at 31.5.2012 latest version is:&lt;/p&gt;&lt;p&gt;Herbison GP, Arnold EP. Sacral neuromodulation with implanted devices for urinary storage and voiding dysfunction in adults. Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No.: CD004202. DOI: 10.1002/14651858.CD004202.pub2&lt;/p&gt;&lt;p&gt;Herbison P, Arnold E. Neuromodulation with implanted electrodes for urinary storage and voiding dysfunction in adults (Protocol for a Cochrane Review). In: The Cochrane Library, Issue 4, 2003. Chichester, UK: John Wiley &amp;amp; Sons, Ltd.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;span class=&quot;inserted&quot; modified=&quot;2012-03-19 15:01:00 +1300&quot; modified_by=&quot;G Peter Herbison&quot;&gt;The full review is not published.&lt;/span&gt;&lt;/p&gt;" NOTES_MODIFIED="2012-05-31 12:30:02 +0100" NOTES_MODIFIED_BY="G Peter Herbison" TYPE="COCHRANE_REVIEW">
<AU>Herbison GP, Arnold EP</AU>
<TI>Sacral neuromodulation with implanted devices for urinary storage and voiding dysfunction in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>2</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester, UK</CY>
<MD>Art. No.: CD004202. DOI: 10.1002/14651858.CD004202.pub2.</MD>
<IDENTIFIERS MODIFIED="2012-05-31 12:30:02 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-05-31 12:30:02 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004202.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2013-04-25 22:43:57 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2012-05-31 12:37:49 +0100" MODIFIED_BY="Bary CM Berghmans" NAME="Higgins 2011" NOTES="&lt;p&gt;at 31 may 2012 latest version is:&lt;/p&gt;&lt;p&gt;Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.&lt;/p&gt;" NOTES_MODIFIED="2012-05-31 12:37:49 +0100" NOTES_MODIFIED_BY="Bary CM Berghmans" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<YR>2011</YR>
<IDENTIFIERS MODIFIED="2011-09-30 12:43:00 +0100" MODIFIED_BY="Bary CM Berghmans"/>
</REFERENCE>
<REFERENCE ID="REF-Hirakawa-1993" NAME="Hirakawa 1993" TYPE="JOURNAL_ARTICLE">
<AU>Hirakawa S, Hassouna M, Deleon R, ElHilali M</AU>
<TI>The role of combined pelvic floor stimulation and biofeedback in post-prostatectomy urinary incontinence</TI>
<SO>Journal of Urology</SO>
<YR>1993</YR>
<VL>149</VL>
<PG>235A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hu-2003" MODIFIED="2013-04-15 13:16:01 +0100" MODIFIED_BY="[Empty name]" NAME="Hu 2003" TYPE="JOURNAL_ARTICLE">
<AU>Hu JC, Gold KF, Pashos CL, Metha SS, Litwin MS</AU>
<TI>Temporal trends in radical prostatectomy complications from 1991 to 1998</TI>
<SO>Journal of Urology</SO>
<YR>2003</YR>
<VL>169</VL>
<PG>1443-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jabs-2001" NAME="Jabs 2001" NOTES="&lt;p&gt;Jabs CFI, Stanton SL. Urge incontinence and detrusor instability. International Urogynecology Journal 2001;12:58-68.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Jabs CFI, Stanton SL</AU>
<TI>Urge incontinence and detrusor instability</TI>
<SO>International Urogynecology Journal and Pelvic Floor Dysfunction</SO>
<YR>2001</YR>
<VL>12</VL>
<PG>58-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Janknegt-1997" NAME="Janknegt 1997" NOTES="&lt;p&gt;Janknegt RA, Weil EJH, Ferdmans PHA. Improving neuromodulation technique for refractory voiding dysfunctions: two-stage implant. Urology 1997;49:358-362.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Janknegt RA, Weil EH, Eerdmans PH</AU>
<TI>Improving neuromodulation technique for refractory voiding dysfunctions: two-stage implant</TI>
<SO>Urology</SO>
<YR>1997</YR>
<VL>49</VL>
<NO>3</NO>
<PG>358-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Meaglia-1990" MODIFIED="2013-04-25 22:55:42 +0100" MODIFIED_BY="[Empty name]" NAME="Meaglia 1990" TYPE="JOURNAL_ARTICLE">
<AU>Meaglia JP, Joseph AC, Chang M, Schmidt JD</AU>
<TI>Post-prostatectomy urinary incontinence: response to behavioral training</TI>
<SO>Journal of Urology</SO>
<YR>1990</YR>
<VL>144</VL>
<PG>674-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Messelink-2005" MODIFIED="2012-06-01 10:27:56 +0100" MODIFIED_BY="[Empty name]" NAME="Messelink 2005" NOTES="&lt;p&gt;at 31 May 2012 - the 2001 version is old. ?Better to cite the newer and revised version:&lt;/p&gt;&lt;p&gt;B. Messelink, T. Benson, B. Berghmans, K. Bo, J. Corcos, C. Fowler, et al. Standardization of terminology of pelvic floor muscle function and dysfunction: report from the pelvic floor clinical assessment group of the International Continence Society. Neurourol.Urodyn. 24 (4):374-380, 2005.&lt;/p&gt;&lt;p&gt;rather than the older ICS PFCA 2001&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2012-06-01 10:27:56 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Messelink B, Benson T, Berghmans B, Bo K, Corcos J, Fowler C, et al</AU>
<TI>Standardization of terminology of pelvic floor muscle function and dysfunction: report from the pelvic floor clinical assessment group of the International Continence Society</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2005</YR>
<VL>24</VL>
<NO>4</NO>
<PG>374-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Okada-1998" MODIFIED="2013-04-25 22:58:16 +0100" MODIFIED_BY="[Empty name]" NAME="Okada 1998" TYPE="JOURNAL_ARTICLE">
<AU>Okada N, Igawa Y, Ogawa A, Nishizawa O</AU>
<TI>Transcutaneous electrical stimulation of thigh muscles in the treatment of detrusor overactivity</TI>
<SO>British Journal of Urology International</SO>
<YR>1998</YR>
<VL>81</VL>
<PG>560-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Palmer-2003" MODIFIED="2013-04-15 13:16:33 +0100" MODIFIED_BY="[Empty name]" NAME="Palmer 2003" TYPE="JOURNAL_ARTICLE">
<AU>Palmer MH, Fogarty LA, Somerfield MR, Powel, LL</AU>
<TI>Incontinence after prostatectomy: coping with incontinence after prostate cancer surgery</TI>
<SO>Oncological Nursing Forum</SO>
<YR>2003</YR>
<VL>30</VL>
<PG>229-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Plevnik-1986" MODIFIED="2013-04-25 22:57:55 +0100" MODIFIED_BY="[Empty name]" NAME="Plevnik 1986" TYPE="JOURNAL_ARTICLE">
<AU>Plevnik S, Janez J, Vrtacnik P, Trsinar B, Vodusek DB</AU>
<TI>Short-term electrical stimulation: home treatment for urinary incontinence</TI>
<SO>World Journal of Urology</SO>
<YR>1986</YR>
<VL>4</VL>
<PG>24-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Plevnik-1991" NAME="Plevnik 1991" NOTES="&lt;p&gt;Plevnik S, Janez J, Vodusek DB. Electrical stimulation. In: Krane KJ, Siroky MB (ed). Clinical neuro-urology. Boston: Little-Brown, 1991.&lt;/p&gt;" TYPE="BOOK_SECTION">
<AU>Plevnik S, Janez J, Vodusek DB</AU>
<TI>Electrical stimulation</TI>
<SO>Clinical Neuro-urology</SO>
<YR>1991</YR>
<ED>Krane KJ, Siroky MB</ED>
<PB>Little-Brown</PB>
<CY>Boston</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Primus-1996" MODIFIED="2013-04-15 13:43:47 +0100" MODIFIED_BY="[Empty name]" NAME="Primus 1996" TYPE="JOURNAL_ARTICLE">
<AU>Primus G, Kramer G</AU>
<TI>Maximal external electrical stimulation for treatment of neurogenic or non-neurogenic urgency and/or urge incontinence</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>1996</YR>
<VL>15</VL>
<PG>187-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Salinas-1993" MODIFIED="2013-04-15 13:40:47 +0100" MODIFIED_BY="[Empty name]" NAME="Salinas 1993" TYPE="JOURNAL_ARTICLE">
<AU>Salinas CJ, Viseda CM, Salomon MS, Bravo Derueda C, Aristizabal JM, Resel EL</AU>
<TI>Results of electrical stimulation in the treatment of post-prostatectomy incontinence</TI>
<SO>Actas Urologia Espanol</SO>
<YR>1996</YR>
<VL>20</VL>
<PG>544-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sand-1995" MODIFIED="2013-04-25 22:44:19 +0100" MODIFIED_BY="Bary CM Berghmans" NAME="Sand 1995" TYPE="JOURNAL_ARTICLE">
<AU>Sand PK, Richardson DA, Staskin DR, Swift SE, et al</AU>
<TI>Pelvic floor electrical stimulation in the treatment of genuine stress incontinence: A multicenter,placebo-controlled trial</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1995</YR>
<VL>173</VL>
<PG>72-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Scheepens-2003" NAME="Scheepens 2003" NOTES="&lt;p&gt;Scheepens WA. Progress in sacral neuromodulation of the lower urinary tract. Thesis University of Maastricht, Maastricht, the Netherlands 2003&lt;/p&gt;" TYPE="OTHER">
<AU>Scheepens WA</AU>
<TI>Progress in sacral neuromodulation of the lower urinary tract</TI>
<SO>Thesis: University of Maastricht, Maastricht, The Netherlands</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Siegel-1992" NAME="Siegel 1992" NOTES="&lt;p&gt;Siegel SW. Management of voiding dysfunction with an implantable neuroprosthesis. Urological Clinics of North America 1992;19:163-170.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Siegel SW</AU>
<TI>Management of voiding dysfunction with an implantable neuroprosthesis</TI>
<SO>Urological Clinics of North America</SO>
<YR>1992</YR>
<VL>19</VL>
<NO>1</NO>
<PG>163-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smith-2009" MODIFIED="2013-04-25 22:57:12 +0100" MODIFIED_BY="Bary CM Berghmans" NAME="Smith 2009" TYPE="BOOK_SECTION">
<AU>Hay-Smith J, Berghmans B, Burgio K, Dumoulin C, Hagen S, Moore K, et al</AU>
<TI>Adult conservative management</TI>
<SO>Incontinence: 4th International Consultation on Incontinence. Recommendations of the International Scientific Committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse and faecal incontinence: Paris, France, July 5-9, 2008</SO>
<YR>2009</YR>
<PG>1025-120</PG>
<ED>Abrams P, Cardozo L, Khoury S, Wein A</ED>
<PB>Health Publication,Ltd</PB>
<CY>Plymouth, UK</CY>
<IDENTIFIERS MODIFIED="2013-04-15 13:27:44 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-04-15 13:27:44 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SRINCONT43527"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Steers-2002" MODIFIED="2013-04-25 22:44:36 +0100" MODIFIED_BY="[Empty name]" NAME="Steers 2002" TYPE="JOURNAL_ARTICLE">
<AU>Steers WD</AU>
<TI>Overactive bladder (OAB): what we thought we knew and what we know today</TI>
<SO>European Urology</SO>
<YR>2002</YR>
<VL>Suppl 1</VL>
<PG>3-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-Balken-2001" MODIFIED="2013-04-25 22:56:47 +0100" MODIFIED_BY="[Empty name]" NAME="van Balken 2001" NOTES="&lt;p&gt;van Balken MR, Vandoninck V, Gisolf KWH, Vergunst H, Kiemeney LALM, Debruyne FMJ, Bemelmans BLH. Posterior tibial nerve stimulation as neuromodulative treatment of lower urinary tract dysfunction. Journal of Urology 2001;166:914-918.&lt;/p&gt;" NOTES_MODIFIED="2013-04-25 22:56:47 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>van Balken MR, Vandoninck V, Gisolf KWH, Vergunst H, Kiemeney LALM, Debruyne FMJ, et al</AU>
<TI>Posterior tibial nerve stimulation as neuro modulative treatment of lower urinary tract dysfunction</TI>
<SO>Journal of Urology</SO>
<YR>2001</YR>
<VL>166</VL>
<NO>3</NO>
<PG>914-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-Kampen-2000" MODIFIED="2013-04-15 13:22:26 +0100" MODIFIED_BY="[Empty name]" NAME="van Kampen 2000" TYPE="JOURNAL_ARTICLE">
<AU>Van Kampen M, De Weerdt W, Van Poppel H, De Ridder D, Feys H, Baert L</AU>
<TI>Effect of pelvic-floor re-education on duration and degree of incontinence after radical prostatectomy: a randomised controlled trial</TI>
<SO>Lancet</SO>
<YR>2000</YR>
<VL>355</VL>
<PG>98-102</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-Kerrebroeck-1998" MODIFIED="2013-04-25 22:44:46 +0100" MODIFIED_BY="[Empty name]" NAME="van Kerrebroeck 1998" NOTES="&lt;p&gt;Van Kerrebroeck PEV. The role of electrical stimulation in voiding dysfunction. European Urology 1998;34 (Suppl 1):27-30&lt;/p&gt;" NOTES_MODIFIED="2013-04-25 22:44:46 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Van Kerrebroeck PEV</AU>
<TI>The role of electrical stimulation in voiding dysfunction</TI>
<SO>European Urology</SO>
<YR>1998</YR>
<VL>34 Suppl 1</VL>
<PG>27-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vodusek-1986" NAME="Vodusek 1986" NOTES="&lt;p&gt;Vodusek DB, Light JK, Libby JM. Detrusor inhibition induced by stimulation of pudendal nerve afferents. Neurourol Urodyn 1986;5:2381-2389&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Vodusek DB, Light JK, Libby JM</AU>
<TI>Detrusor inhibition induced by stimulation of pudendal nerve afferents</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>1986</YR>
<VL>5</VL>
<PG>2381-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Walsh-1999" MODIFIED="2013-04-25 22:44:58 +0100" MODIFIED_BY="Bary CM Berghmans" NAME="Walsh 1999" TYPE="JOURNAL_ARTICLE">
<AU>Walsh IK, Johnston RS, Keane PF</AU>
<TI>Transcutaneous sacral neuro stimulation for irritative voiding dysfunction</TI>
<SO>European Urology</SO>
<YR>1999</YR>
<VL>35</VL>
<PG>192-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ware-1993" NAME="Ware 1993" NOTES="&lt;p&gt;Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey Manual and Interpretation Guide. The Health Institute, New England Medical Centre, Boston, Massachusetts 1993.&lt;br&gt;&lt;/p&gt;" TYPE="BOOK">
<AU>Ware JE, Snow KK, Kosinski M, Gandek B</AU>
<SO>SF-36 Health Survey Manual and Interpretation Guide</SO>
<YR>1993</YR>
<PB>The Health Institute, New England Medical Centre</PB>
<CY>Boston</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weil-2000" NAME="Weil 2000" NOTES="&lt;p&gt;Weil EH. Ruiz Cerda JL, Eerdmans PH. Sacral root neuromodulation in the treatment of refractory urinary urge incontinence : a prospective randomized clinical trial Eur Urol 2000;37:161-171.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Weil EH, Ruiz Cerda JL, Eerdmans PH</AU>
<TI>Sacral root neuromodulation in the treatment of refractory urinary urge incontinence: a prospective randomized clinical trial</TI>
<SO>European Urology</SO>
<YR>2000</YR>
<VL>37</VL>
<NO>2</NO>
<PG>161-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wolin-2009" MODIFIED="2013-04-15 13:21:40 +0100" MODIFIED_BY="Bary CM Berghmans" NAME="Wolin 2009" TYPE="JOURNAL_ARTICLE">
<AU>Wolin KY , Luly J, Sutcliffe S, Andriole GL, Kibel AS</AU>
<TI>Risk of urinary incontinence following prostatectomy: The role of physical activity and obesity</TI>
<SO>Journal of Urology</SO>
<YR>2009</YR>
<VL>83</VL>
<PG>629-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yamanishi-1997" MODIFIED="2013-04-25 22:56:23 +0100" MODIFIED_BY="Bary CM Berghmans" NAME="Yamanishi 1997" TYPE="JOURNAL_ARTICLE">
<AU>Yamanishi T, Yasuda K, Sakakibara R, Hattori T, Ito H, Murakami S</AU>
<TI>Pelvic floor electrical stimulation in the treatment of stress incontinence: an investigational study and a placebo controlled double-blind trial</TI>
<SO>Journal of Urology</SO>
<YR>1997</YR>
<VL>158</VL>
<NO>6</NO>
<PG>2127-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yamanishi-1998" MODIFIED="2012-06-01 12:02:11 +0100" MODIFIED_BY="[Empty name]" NAME="Yamanishi 1998" NOTES="&lt;p&gt;Yamanishi T, Yasuda K. Electrical stimulation for stress incontinence. Int Urogynecol J 1998;9:281-290&lt;/p&gt;" NOTES_MODIFIED="2012-06-01 12:02:11 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Yamanishi T, Yasuda K</AU>
<TI>Electrical stimulation for stress incontinence</TI>
<SO>International Urogynecology Journal and Pelvic Floor Dysfunction</SO>
<YR>1998</YR>
<VL>9</VL>
<NO>5</NO>
<PG>281-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yashuda-1999" MODIFIED="2013-04-25 22:45:10 +0100" MODIFIED_BY="Bary CM Berghmans" NAME="Yashuda 1999" TYPE="JOURNAL_ARTICLE">
<AU>Yashuda K, Yamanishi T</AU>
<TI>Critical evaluation of electrical stimulation for management of female urinary incontinence</TI>
<SO>Current Opinion in Obstetrics and Gynecology</SO>
<YR>1999</YR>
<VL>11</VL>
<PG>503-7</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-04-26 13:34:01 +0100" MODIFIED_BY="Bary CM Berghmans">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-04-26 13:34:01 +0100" MODIFIED_BY="Bary CM Berghmans" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-04-26 13:34:01 +0100" MODIFIED_BY="Bary CM Berghmans" STUDY_ID="STD-Ceresoli-2002">
<CHAR_METHODS MODIFIED="2013-04-26 13:34:01 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>2-arm Randomized Controlled Trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-25 22:35:49 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>Participants underwent post-radical perineal prostatectomy for localized prostate cancer with post-operative (stress) incontinence</P>
<P>Age: not specified</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-05 13:01:43 +0000" MODIFIED_BY="Bary CM Berghmans">
<P>A (n=34): Daily Transcutaneous Electrical Nerve Stimulation (DTENS) + PFMT based on Kegel's exercises</P>
<P>B (n=36): PFMT based on Kegel's exercises (control group)</P>
<P>Length of follow-up: not reported</P>
<P>Number of dropouts not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-04-25 22:35:49 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>Continence described according to Catalona's definition and measured with</P>
<P>- subjective visual analogue scale of improvement</P>
<P>- mean number of pads used daily</P>
<P>- 24-hour pad test: maximal speed of recovery from incontinence, grams/month</P>
<P>Data collected at 1, 4, and 6 months post-operatively</P>
<P>Number of men dry at 4 months: A 82%, B 65% (wet: A 6/34, B 13/36)</P>
<P>Number of men dry at 6 months: A 87%, B 76% (wet: A 4/34, B 9/36)</P>
<P>Number of pads (mean per day): A 1, B 1.5 (no SDs given)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-01 20:43:41 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>Only abstract available.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-25 22:36:42 +0100" MODIFIED_BY="Bary CM Berghmans" STUDY_ID="STD-Hoffmann-2005">
<CHAR_METHODS MODIFIED="2013-04-25 22:36:32 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>3-arm Randomized Controlled Trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-29 12:34:16 +0000" MODIFIED_BY="Bary CM Berghmans">
<P>Participants underwent radical retropubic prostatectomy with post-operative grade 3 SUI<BR/>Mean age: 65.0 years</P>
<P>Inclusion: between 12 and 35 days post-surgery</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-04-25 22:36:32 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>A (n=60): Transcutaneous (perineal) ES (20 minutes, max amp 70 mA, pulse width 250 ms, frequency 14 Hz, biphasic) + PMFT<BR/>B (n=60): Transcutaneous (anal) ES (same parameters as perineal ES) + PMFT<BR/>C (n=60): PMFT thrice a week, group training 30 minutes (control group)</P>
<P>Length of follow-up: 3 months after discharge<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-04-25 22:36:32 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>Incontinence defined as "self reports of incontinence" and measured with:</P>
<UL>
<LI>1-hour ICS pad test</LI>
<LI>VAS-incontinence</LI>
<LI>Uroflowmetry</LI>
</UL>
<P>Quality of life measured with EORTC QLQ C30</P>
<P>Number of men with incontinence at end of treatment: A 54/56, B 37/38, C 54/55</P>
<P>Adverse effects leading to dropout: A 2/60 (discomfort) + 2/60 (pain); B 16/60 (discomfort) + 4/60 (pain); C 0/60</P>
<P>Deterioration in SUI: A 1/60, B 2/60, C 0/60</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-04-25 22:36:42 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>Authors state that additional use of ES was only significantly superior to PFMT alone in a highly compliant subgroup. Dropouts: 22 out of 60 in anal ES group, 4 out of 60 in perineal ES group. No reasons for dropouts given. High score on device errors and lack of patient compliance.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-25 22:38:30 +0100" MODIFIED_BY="Bary CM Berghmans" STUDY_ID="STD-Moore-1999">
<CHAR_METHODS MODIFIED="2013-04-25 22:38:06 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>3-arm Randomized Controlled Trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-25 22:38:06 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>Particpants were post-radical prostatectomy patients with incontinence based on 24-hour pad test and questionnaires (Incontinence Impact Questionnaire IIQ7 and EORTC QLQ C30)<BR/>Age: mean 67 years (range 49 to 77 years)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-04-01 22:26:15 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>A (n=21): PFMT in outpatient clinic 2 per week for 12 weeks + home exercises<BR/>B (n=21): PFMT in outpatient clinic 2 per week for 12 weeks + ES via surface anal electrode + home exercise</P>
<P>C (n=21): pre and post-operative oral and written information about PFMT</P>
<P>Home exercises: 12-20 contractions of 5-10 seconds, 8-10 contractions of 20-30 seconds and repetitive contractions in 10 seconds 3 per day<BR/>
</P>
<P>Length of follow up was 24 weeks<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-04-25 22:38:13 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>Reported following outcomes:</P>
<UL>
<LI>Continence defined as less than or equal to 2 gm urine per 24 hours</LI>
<LI>Urine loss (measured by 24-hour pad test)</LI>
<LI>Quality of life:</LI>
<UL>
<LI>Incontinence Impact Questionnaire</LI>
<LI>European Organization for the Research and Treatment of Cancer-EORTC QLQ C-30</LI>
<LI>Physical symptom inventor</LI>
</UL>
</UL>
<P>Data collection: baseline and at 12 weeks, 16 weeks and 24 weeks</P>
<P>Number of incontinent men at 3 months: A 12/18, B 11/19, C 14/21</P>
<P>Number of incontinent men at 6 months: A 8/18, C 7/21 (B not given)</P>
<P>24 hour pad test (grams urine lost, mean (SD) n):</P>
<UL>
<LI>At 3 months: A 87 (123) 18, B 156 (168) 19, C 104 (176) 21</LI>
<LI>At 6 months: A 74 (131) 18, B 202 (242) 19, C 67 (137) 21</LI>
<LI>At 12 months: A 70 (114) 17, B 98 (132) 19, C 54 (103) 21</LI>
</UL>
<P>Adverse effects: A 2/18 (anal pain), B 0/19, C 0/21</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-04-25 22:38:30 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>Power calculation performed.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-25 22:39:12 +0100" MODIFIED_BY="Bary CM Berghmans" STUDY_ID="STD-Wille-2003">
<CHAR_METHODS MODIFIED="2013-04-25 22:39:12 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>3-arm Randomized Controlled Trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-15 16:29:56 +0000" MODIFIED_BY="Bary CM Berghmans">
<P>Participants undergoing radical prostatectomy with post-operative urinary incontinence<BR/>Age: mean 64.6 (in group A and B) and 65.9 (group C)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-04-25 22:39:12 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>A (n=47): PFMT</P>
<P>B (n=46): PFMT + ES via surface anal electrode with a bio-impulser for 15 minutes</P>
<P>C (n=46): PFMT + ES + biofeedback 15 minutes sessions two times per day for 3 months</P>
<P>All groups received instructions about PFMT by physiotherapist</P>
<P>They were instructed to perform PFMT for 20 to 30 minutes, two times per day for 3 months plus 3 weeks of rehabilitation programme after discharge. There was regular interaction with the healthcare professional and the patient during the first 6 weeks after surgery.</P>
<P>Length of follow up was 12 months<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-04-25 22:39:12 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>The following outcomes were reported at baseline, 3 months and 12 months post-operatively:</P>
<UL>
<LI>Urine loss measure by questionnaire (subjective) and 20 minutes provocative mean pad test (objective)</LI>
<LI>Quality of life EORCT QLQ-C30: scores for physical; role; emotional; social; and global quality of life were not significantly different between the groups at 3 or 12 months (no SDs provided)</LI>
</UL>
<P>
<B>Continence defined as reported use of 0 to1 pads by questionnaire (subjective outcome)</B>
</P>
<P>Wet at 3 months: A 19/47, B 16/46, C 22/46</P>
<P>Wet at 12 months: A 6/47, B 9/46, C 5/46</P>
<P>
<B>Number of participants with loss of &lt;1 gram of urine on pad test (objective outcome)</B>
</P>
<P>Wet at 12 months: A 9/47, B 8/46, C 4/46</P>
<P>Willingness to undergo surgery again (satisfaction): A 73%, B 83%, C 73%</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-01 20:43:44 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-26 13:33:41 +0100" MODIFIED_BY="Bary CM Berghmans" STUDY_ID="STD-Yamanishi-2010">
<CHAR_METHODS MODIFIED="2013-04-25 22:39:30 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>2-arm Randomized Controlled Trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-25 22:39:30 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>Men with severe urinary incontinence (&gt; 200 gram daily) after radical prostatectomy<BR/>Mean age: mean (SD) 66.2 (6.2) Range [50 to 76]</P>
<P>Inclusion criteria: UI &gt; 200 gram daily after removal of catheter, no residual cancer after radical prostatectomy on pathological examination</P>
<P>Exclusion criteria: Participants on anticholinergics or tricyclic antidepressants, neurological disorders and urethral strictures</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-04-25 22:39:30 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>Participants were taught by nurses about PFMT before the surgery and continued at the follow-up visits</P>
<P>A (n=26) intervention: PFMT plus anal electrical stimulation for 15 minutes twice daily (50 Hz square waves with 300 &#956;sec pulse duration, maximum output 70mA (5 seconds on, 5 seconds off-duty cycle)</P>
<P>B (n=30) control: PFMT plus sham stimulation (output 3mA, 2 seconds on, 13 seconds off-duty cycle)</P>
<P>Length of follow up: 1 months, 3 months , 6 months and 12 months after treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-04-26 13:33:41 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>Number of incontinent men</P>
<P>24 hour pad test weights</P>
<P>ICIQ-SF score</P>
<P>ICIQ-QoL score</P>
<P>Time until continent in months</P>
<P>Adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-04-25 22:39:30 +0100" MODIFIED_BY="Bary CM Berghmans"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-04-25 22:40:03 +0100" MODIFIED_BY="Bary CM Berghmans" STUDY_ID="STD-Yokoyama-2004">
<CHAR_METHODS MODIFIED="2013-04-25 22:40:03 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>3-arm Randomized Controlled Trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-25 22:40:03 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>Recruitment: Post-operative</P>
<P>Included: 36 men with urinary incontinence after retropubic radical prostatectomy with incontinence defined as &gt;100 gram on 24-hour pad test, one day after catheter removal</P>
<P>Mean age (SD): Group A 67.2 (6.7) years, Group B 68.2 (4.9) years, Group C 66.2 (7.6) years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-04-25 22:40:03 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>A (n=12) intervention: anal electrode for 15 minutes twice a day for 1 month</P>
<P>B (n=12) intervention: extracorporeal magnetic innervation, neocontrol system, treatment sessions 20 minutes, twice a week for 2 weeks</P>
<P>C (n=12) control: PFMT, digital anal teaching of correct contractions, then verbal and written instructions for home practice</P>
<P>Length of follow up: 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-04-25 22:40:03 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>24-hour pad test weight (grams):</P>
<P>3 months: A 34 gram, B 7.3 gram, C 50 gram</P>
<P>6 months: For all groups less than 10 gram</P>
<P>Quality of Life measured by I-QOL: Improvement in all groups over time, no statistically significant difference between the groups</P>
<P>Remaining UI at 6 months: A 2/12, B 1/12, C 2/12</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-04-25 22:40:03 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>Dropouts: It appears that there are no drop outs but this was not specifically mentioned.</P>
<P>Side effects: No complaints about discomfort or irritation from the probe.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>
<B>List of abbreviations<BR/>
</B>
</P>
<P>(D)TENS: (Daily) Transcutaneous electrical nerve stimulation<BR/>
</P>
<P>ES: Electrical stimulation</P>
<P>GSI: Genuine stress incontinence</P>
<P>Hz: Hertz</P>
<P>ICS: International Continence Society<BR/>IEF: Incontinence episodes frequency<BR/>IFT: Interferential therapy<BR/>Imax: Maximal tolerable intensity</P>
<P>I-QOL: Incontinence Quality of Life</P>
<P>MES: Magnetic electrical stimulation<BR/>
<BR/>MUI: Mixed urinary incontinence</P>
<P>PFM: Pelvic floor muscle(s)</P>
<P>PFMT: Pelvic floor muscle training<BR/>OAB: Overactive bladder<BR/>QOL: Quality of life<BR/>RCT: Randomized clinical trial<BR/>SUI: Stress urinary incontinence<BR/>USUI: Urodynamic stress urinary incontinence<BR/>UUI: Urgency urinary incontinence<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-04-25 22:52:02 +0100" MODIFIED_BY="Bary CM Berghmans" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2013-04-25 22:40:42 +0100" MODIFIED_BY="Bary CM Berghmans" STUDY_ID="STD-Bocker-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-25 22:40:42 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>Men (post-prostatectomy) and women (with post-polio syndrome) included, no separate reporting of results</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-30 10:00:15 +0100" MODIFIED_BY="Bary CM Berghmans" STUDY_ID="STD-Goode-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-30 10:00:15 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>No analysis of separate results of ES possible, because ES always combined with biofeedback</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-30 10:29:49 +0100" MODIFIED_BY="Bary CM Berghmans" STUDY_ID="STD-Hasan-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-30 10:29:49 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>Both men and women included, without separate reporting of results</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-25 22:51:59 +0100" MODIFIED_BY="Bary CM Berghmans" STUDY_ID="STD-Lin-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-25 22:51:59 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>Both full-text report and abstract only available in the Chinese language</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-30 10:05:20 +0100" MODIFIED_BY="Bary CM Berghmans" STUDY_ID="STD-Mariotti-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-30 10:05:20 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>No analysis of separate results of ES possible, because ES always combined with biofeedback</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-30 10:08:04 +0100" MODIFIED_BY="Bary CM Berghmans" STUDY_ID="STD-McClurg-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-30 10:08:04 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>Both men and women included, without separate reporting of results</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-25 22:52:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Petersen-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-25 22:52:02 +0100" MODIFIED_BY="[Empty name]">
<P>Not an RCT, consecutive patients. Neurogenic urinary incontinence due to neurogenic detrusor overactivity in both men and women without separate reporting</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-30 10:08:15 +0100" MODIFIED_BY="Bary CM Berghmans" STUDY_ID="STD-Soomro-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-30 10:08:15 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>Both men and women included, without separate reporting of results</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-30 10:08:45 +0100" MODIFIED_BY="Bary CM Berghmans" STUDY_ID="STD-Walsh-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-30 10:08:45 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>Both men and women included, without separate reporting of results</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-30 10:29:36 +0100" MODIFIED_BY="Bary CM Berghmans" STUDY_ID="STD-Webb-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-30 10:29:36 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>Both men and women included, without separate reporting of results</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-30 10:16:28 +0100" MODIFIED_BY="Bary CM Berghmans" STUDY_ID="STD-Yamanishi-1997a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-30 10:16:28 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>Both men and women included, without separate reporting of results</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-30 10:08:55 +0100" MODIFIED_BY="Bary CM Berghmans" STUDY_ID="STD-Yamanishi-1998a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-30 10:08:55 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>Both men and women included, without separate reporting of results</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-30 10:09:01 +0100" MODIFIED_BY="Bary CM Berghmans" STUDY_ID="STD-Yamanishi-2000a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-30 10:09:01 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>Both men and women included, without separate reporting of results</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-30 13:30:09 +0100" MODIFIED_BY="Bary CM Berghmans" STUDY_ID="STD-Yasuda-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-30 13:30:09 +0100" MODIFIED_BY="Bary CM Berghmans">
<P>Both men and women included, without separate reporting of results</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-04-25 22:51:53 +0100" MODIFIED_BY="Bary CM Berghmans">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-04-25 22:40:17 +0100" MODIFIED_BY="Bary CM Berghmans" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-25 22:36:08 +0100" MODIFIED_BY="Bary CM Berghmans" RESULT="UNKNOWN" STUDY_ID="STD-Ceresoli-2002">
<DESCRIPTION>
<P>Reported as "randomized trial" but method of sequence generation not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-25 22:36:57 +0100" MODIFIED_BY="Bary CM Berghmans" RESULT="YES" STUDY_ID="STD-Hoffmann-2005">
<DESCRIPTION>
<P>Computer-generated randomization</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-25 22:38:40 +0100" MODIFIED_BY="Bary CM Berghmans" RESULT="YES" STUDY_ID="STD-Moore-1999">
<DESCRIPTION>
<P>"Participants were assigned using a computer-generated random-number list placed in sealed envelopes at the end of the assessment visit, with patient and researcher opening the sealed envelope"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-01 20:43:44 +0100" MODIFIED_BY="Bary CM Berghmans" RESULT="UNKNOWN" STUDY_ID="STD-Wille-2003">
<DESCRIPTION>
<P>Reported as "prospective randomized trial" but method of sequence generation not specified </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-28 16:33:43 +0000" MODIFIED_BY="Bary CM Berghmans" RESULT="YES" STUDY_ID="STD-Yamanishi-2010">
<DESCRIPTION>
<P>"Randomisation was done by computer"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-25 22:40:17 +0100" MODIFIED_BY="Bary CM Berghmans" RESULT="UNKNOWN" STUDY_ID="STD-Yokoyama-2004">
<DESCRIPTION>
<P>".........randomly assigned to three groups....." no further details about sequence generation provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-04-25 22:40:17 +0100" MODIFIED_BY="Bary CM Berghmans" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-25 22:36:08 +0100" MODIFIED_BY="Bary CM Berghmans" RESULT="UNKNOWN" STUDY_ID="STD-Ceresoli-2002">
<DESCRIPTION>
<P>Reported as "randomized trial" but method of allocation concealment not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-25 22:36:57 +0100" MODIFIED_BY="Bary CM Berghmans" RESULT="UNKNOWN" STUDY_ID="STD-Hoffmann-2005">
<DESCRIPTION>
<P>Method of allocation concealment not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-25 22:38:56 +0100" MODIFIED_BY="Bary CM Berghmans" RESULT="YES" STUDY_ID="STD-Moore-1999">
<DESCRIPTION>
<P>"participants were assigned using a computer-generated random-number list placed in sealed envelopes at the end of the assessment visit, with patient and researcher opening the sealed envelope"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-01 20:43:44 +0100" MODIFIED_BY="Bary CM Berghmans" RESULT="UNKNOWN" STUDY_ID="STD-Wille-2003">
<DESCRIPTION>
<P>Reported as "prospective randomized trial" but method of sequence generation not specified </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-28 16:33:43 +0000" MODIFIED_BY="Bary CM Berghmans" RESULT="YES" STUDY_ID="STD-Yamanishi-2010">
<DESCRIPTION>
<P>"None of the patients, doctors or medical staff knew which type of stimulation had been assigned until the key code was opened"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-25 22:40:17 +0100" MODIFIED_BY="Bary CM Berghmans" RESULT="UNKNOWN" STUDY_ID="STD-Yokoyama-2004">
<DESCRIPTION>
<P>".........randomly assigned to three groups....." no further details about allocation concealment provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2013-04-25 22:40:17 +0100" MODIFIED_BY="Bary CM Berghmans" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-04-25 22:36:08 +0100" MODIFIED_BY="Bary CM Berghmans" RESULT="UNKNOWN" STUDY_ID="STD-Ceresoli-2002">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-04-25 22:36:57 +0100" MODIFIED_BY="Bary CM Berghmans" RESULT="UNKNOWN" STUDY_ID="STD-Hoffmann-2005">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-10-01 20:43:42 +0100" MODIFIED_BY="Bary CM Berghmans" RESULT="UNKNOWN" STUDY_ID="STD-Moore-1999">
<DESCRIPTION>
<P>Blinding to intervention not possible, however outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-10-01 20:43:44 +0100" MODIFIED_BY="Bary CM Berghmans" RESULT="UNKNOWN" STUDY_ID="STD-Wille-2003">
<DESCRIPTION>
<P>Not specified </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-04-25 22:39:45 +0100" MODIFIED_BY="Bary CM Berghmans" RESULT="YES" STUDY_ID="STD-Yamanishi-2010">
<DESCRIPTION>
<P>Seems to be adequate, but no report when key-code was broken</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-04-25 22:40:17 +0100" MODIFIED_BY="Bary CM Berghmans" RESULT="UNKNOWN" STUDY_ID="STD-Yokoyama-2004">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2013-04-25 22:40:17 +0100" MODIFIED_BY="Bary CM Berghmans" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-04-25 22:36:08 +0100" MODIFIED_BY="Bary CM Berghmans" RESULT="UNKNOWN" STUDY_ID="STD-Ceresoli-2002">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-04-25 22:36:57 +0100" MODIFIED_BY="Bary CM Berghmans" RESULT="UNKNOWN" STUDY_ID="STD-Hoffmann-2005">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-04-25 22:38:46 +0100" MODIFIED_BY="Bary CM Berghmans" RESULT="YES" STUDY_ID="STD-Moore-1999">
<DESCRIPTION>
<P>Physiotherapists were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-10-01 20:43:44 +0100" MODIFIED_BY="Bary CM Berghmans" RESULT="UNKNOWN" STUDY_ID="STD-Wille-2003">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-04-25 22:39:45 +0100" MODIFIED_BY="Bary CM Berghmans" RESULT="YES" STUDY_ID="STD-Yamanishi-2010">
<DESCRIPTION>
<P>Blinding of doctors, nurses and medical staff</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-04-25 22:40:17 +0100" MODIFIED_BY="Bary CM Berghmans" RESULT="UNKNOWN" STUDY_ID="STD-Yokoyama-2004">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2013-04-25 22:40:17 +0100" MODIFIED_BY="Bary CM Berghmans" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-04-25 22:36:08 +0100" MODIFIED_BY="Bary CM Berghmans" RESULT="UNKNOWN" STUDY_ID="STD-Ceresoli-2002">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-04-25 22:36:57 +0100" MODIFIED_BY="Bary CM Berghmans" RESULT="UNKNOWN" STUDY_ID="STD-Hoffmann-2005">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-10-01 20:43:44 +0100" MODIFIED_BY="Bary CM Berghmans" RESULT="YES" STUDY_ID="STD-Moore-1999">
<DESCRIPTION>
<P>Outcome assessors were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-10-01 20:43:44 +0100" MODIFIED_BY="Bary CM Berghmans" RESULT="UNKNOWN" STUDY_ID="STD-Wille-2003">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-04-25 22:39:41 +0100" MODIFIED_BY="Bary CM Berghmans" RESULT="YES" STUDY_ID="STD-Yamanishi-2010">
<DESCRIPTION>
<P>Blinding of assessors, medical staff</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-04-25 22:40:17 +0100" MODIFIED_BY="Bary CM Berghmans" RESULT="UNKNOWN" STUDY_ID="STD-Yokoyama-2004">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-04-25 22:40:17 +0100" MODIFIED_BY="Bary CM Berghmans" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-25 22:36:08 +0100" MODIFIED_BY="Bary CM Berghmans" RESULT="UNKNOWN" STUDY_ID="STD-Ceresoli-2002">
<DESCRIPTION>
<P>No information or reporting about attrition and exclusions (we assumed there were no dropouts)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-25 22:36:57 +0100" MODIFIED_BY="Bary CM Berghmans" RESULT="NO" STUDY_ID="STD-Hoffmann-2005">
<DESCRIPTION>
<P>Dropouts: 22 out of 60 in anal ES group, 4 out of 60 in perineal ES group. No reasons for dropouts given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-25 22:38:46 +0100" MODIFIED_BY="Bary CM Berghmans" RESULT="UNKNOWN" STUDY_ID="STD-Moore-1999">
<DESCRIPTION>
<P>"Five dropouts, three with bladder neck contractures requiring dilatation, one with rectal pain when doing the exercise and one unable to complete therapy while on vacation." However, there was no differential dropout from one group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-03-29 13:00:16 +0000" MODIFIED_BY="Bary CM Berghmans" RESULT="UNKNOWN" STUDY_ID="STD-Wille-2003">
<DESCRIPTION>
<P>"Resuts at baseline after catheter removal, at 3 and 12 months postoperatively were available for 139, 120 and 128 (questionnaires at three different time points) and 116, 79 and 124 (pad test at three different time points) patients, respectively". However, no information about individual groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-03-29 13:57:02 +0000" MODIFIED_BY="Bary CM Berghmans" RESULT="UNKNOWN" STUDY_ID="STD-Yamanishi-2010">
<DESCRIPTION>
<P>It is reported that "In the active ES group 2 patients discontinued after 2 and 3 months, respectively, due to urethral stricture at the bladder neck. In the sham group 1 patient discontinued treatment at 7 months because of an increase in prostate specific antigen and he then underwent radiation therapy." However, there is no evidence that dropout was related to trial interventions.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-25 22:40:17 +0100" MODIFIED_BY="Bary CM Berghmans" RESULT="YES" STUDY_ID="STD-Yokoyama-2004">
<DESCRIPTION>
<P>No missing data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-04-25 22:40:17 +0100" MODIFIED_BY="Bary CM Berghmans" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-25 22:36:17 +0100" MODIFIED_BY="Bary CM Berghmans" RESULT="UNKNOWN" STUDY_ID="STD-Ceresoli-2002">
<DESCRIPTION>
<P>Assessment is based upon the published abstract. Complete report of the trial and the protocol not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-25 22:36:57 +0100" MODIFIED_BY="Bary CM Berghmans" RESULT="UNKNOWN" STUDY_ID="STD-Hoffmann-2005">
<DESCRIPTION>
<P>Protocol not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-25 22:38:41 +0100" MODIFIED_BY="Bary CM Berghmans" RESULT="UNKNOWN" STUDY_ID="STD-Moore-1999">
<DESCRIPTION>
<P>Protocol not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-01 20:43:45 +0100" MODIFIED_BY="Bary CM Berghmans" RESULT="UNKNOWN" STUDY_ID="STD-Wille-2003">
<DESCRIPTION>
<P>Protocol not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-28 16:33:43 +0000" MODIFIED_BY="Bary CM Berghmans" RESULT="UNKNOWN" STUDY_ID="STD-Yamanishi-2010">
<DESCRIPTION>
<P>Protocol not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-25 22:40:17 +0100" MODIFIED_BY="Bary CM Berghmans" RESULT="UNKNOWN" STUDY_ID="STD-Yokoyama-2004">
<DESCRIPTION>
<P>Protocol not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2013-04-25 22:51:53 +0100" MODIFIED_BY="Bary CM Berghmans" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-25 22:36:09 +0100" MODIFIED_BY="Bary CM Berghmans" RESULT="UNKNOWN" STUDY_ID="STD-Ceresoli-2002">
<DESCRIPTION>
<P>Information not provided about the method of statistical analysis; lost to follow-up (if any); dropouts (if any), and whether or not intention-to-treat analysis (ITT) performed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-25 22:36:57 +0100" MODIFIED_BY="Bary CM Berghmans" RESULT="NO" STUDY_ID="STD-Hoffmann-2005">
<DESCRIPTION>
<P>No intention-to-treat analysis; insufficient information on methods of statistical analysis; interventions unclear and insufficiently specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-25 22:38:46 +0100" MODIFIED_BY="Bary CM Berghmans" RESULT="UNKNOWN" STUDY_ID="STD-Moore-1999">
<DESCRIPTION>
<P>Intention-to-treat-analysis not performed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-25 22:51:53 +0100" MODIFIED_BY="Bary CM Berghmans" RESULT="UNKNOWN" STUDY_ID="STD-Wille-2003">
<DESCRIPTION>
<P>Reasons for dropouts not provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-25 22:39:52 +0100" MODIFIED_BY="Bary CM Berghmans" RESULT="NO" STUDY_ID="STD-Yamanishi-2010">
<DESCRIPTION>
<P>Number of dropouts given, but reasons not specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-04-25 22:40:17 +0100" MODIFIED_BY="Bary CM Berghmans" RESULT="YES" STUDY_ID="STD-Yokoyama-2004">
<DESCRIPTION>
<P>It appears that there are no dropouts but this was not specifically mentioned. Study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2013-04-26 13:33:53 +0100" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-03-29 14:51:15 +0000" MODIFIED_BY="Bary CM Berghmans">
<COMPARISON ID="CMP-001" MODIFIED="2013-01-28 14:48:25 +0000" MODIFIED_BY="Bary CM Berghmans" NO="1">
<NAME>ES with non-implanted devices versus no active treatment</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-01-28 14:47:57 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="14.276442666482795" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="19" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Number of men with urinary incontinence</NAME>
<GROUP_LABEL_1>Electrical stimulation</GROUP_LABEL_1>
<GROUP_LABEL_2>No active treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ES</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="14" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-01-28 14:47:31 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>3 months: Anal ES + PFMT vs standard treatment</NAME>
<DICH_DATA CI_END="1.4152283907546668" CI_START="0.532885808100266" EFFECT_SIZE="0.868421052631579" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" LOG_CI_END="0.15082653232705753" LOG_CI_START="-0.2733658458049029" LOG_EFFECT_SIZE="-0.06126965673892266" MODIFIED="2012-12-14 14:18:53 +0000" MODIFIED_BY="[Empty name]" ORDER="433" O_E="0.0" SE="0.24917270270085023" STUDY_ID="STD-Moore-1999" TOTAL_1="19" TOTAL_2="21" VAR="0.0620870357712463" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-01-28 14:47:41 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>6 months: Anal ES + PFMT vs standard treatment</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-01-28 14:47:57 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>12 months: Anal ES + PFMT vs standard treatment</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2013-01-28 14:48:25 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="57" TOTAL_2="63" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>24-hr pad test (grams of urine lost)</NAME>
<GROUP_LABEL_1>Electrical stimulation</GROUP_LABEL_1>
<GROUP_LABEL_2>No active treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ES</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.02.01" MODIFIED="2013-01-28 14:48:07 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>&lt;3 months: Anal ES + PFMT vs standard treatment</NAME>
<CONT_DATA CI_END="158.64295885924147" CI_START="-54.642958859241475" EFFECT_SIZE="52.0" ESTIMABLE="YES" MEAN_1="156.0" MEAN_2="104.0" MODIFIED="2012-12-14 14:33:42 +0000" MODIFIED_BY="[Empty name]" ORDER="70" SD_1="168.0" SD_2="176.0" SE="54.41067269624724" STUDY_ID="STD-Moore-1999" TOTAL_1="19" TOTAL_2="21" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.02.02" MODIFIED="2013-01-28 14:48:16 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>3 months: Anal ES + PFMT vs standard treatment</NAME>
<CONT_DATA CI_END="258.5877774308061" CI_START="11.4122225691939" EFFECT_SIZE="135.0" ESTIMABLE="YES" MEAN_1="202.0" MEAN_2="67.0" MODIFIED="2012-12-14 14:33:59 +0000" MODIFIED_BY="[Empty name]" ORDER="70" SD_1="242.0" SD_2="137.0" SE="63.0561471566063" STUDY_ID="STD-Moore-1999" TOTAL_1="19" TOTAL_2="21" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.02.03" MODIFIED="2013-01-28 14:48:25 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>6 months: Anal ES + PFMT vs standard treatment</NAME>
<CONT_DATA CI_END="117.91541335548547" CI_START="-29.91541335548547" EFFECT_SIZE="44.0" ESTIMABLE="YES" MEAN_1="98.0" MEAN_2="54.0" MODIFIED="2012-12-14 14:34:15 +0000" MODIFIED_BY="[Empty name]" ORDER="70" SD_1="132.0" SD_2="103.0" SE="37.71263856811697" STUDY_ID="STD-Moore-1999" TOTAL_1="19" TOTAL_2="21" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2012-12-14 10:35:14 +0000" MODIFIED_BY="Bary CM Berghmans" NO="2">
<NAME>ES with non-implanted devices versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="18" EVENTS_2="48" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-12-14 10:35:14 +0000" MODIFIED_BY="Bary CM Berghmans" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="14.276442666482795" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="69" TOTAL_2="80" WEIGHT="0.0" Z="0.0">
<NAME>Number of men with urinary incontinence</NAME>
<GROUP_LABEL_1>Electrical stimulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Control (sham ES)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ES</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="25" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-12-14 09:54:30 +0000" MODIFIED_BY="Bary CM Berghmans" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Urinary incontinence at 3 months</NAME>
<DICH_DATA CI_END="0.7931111714304633" CI_START="0.29455027179830007" EFFECT_SIZE="0.48333333333333334" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="25" LOG_CI_END="-0.10066593278980833" LOG_CI_START="-0.5308405721795667" LOG_EFFECT_SIZE="-0.31575325248468755" MODIFIED="2012-12-14 09:54:30 +0000" MODIFIED_BY="Bary CM Berghmans" ORDER="16" O_E="0.0" SE="0.25268671257635156" STUDY_ID="STD-Yamanishi-2010" TOTAL_1="24" TOTAL_2="29" VAR="0.0638505747126437" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="15" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-12-14 09:54:39 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="26" WEIGHT="0.0" Z="0.0">
<NAME>Urinary incontinence at 6 months</NAME>
<DICH_DATA CI_END="0.8749223671627098" CI_START="0.16228522992980532" EFFECT_SIZE="0.37681159420289856" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="15" LOG_CI_END="-0.058030480701815816" LOG_CI_START="-0.7897210048310588" LOG_EFFECT_SIZE="-0.42387574276643736" MODIFIED="2012-12-14 09:54:39 +0000" MODIFIED_BY="[Empty name]" ORDER="16" O_E="0.0" SE="0.42979863580002553" STUDY_ID="STD-Yamanishi-2010" TOTAL_1="23" TOTAL_2="26" VAR="0.18472686733556298" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="8" I2="0.0" ID="CMP-002.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-12-14 09:54:49 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>Urinary incontinence at 12 months</NAME>
<DICH_DATA CI_END="1.4103425801529417" CI_START="0.1287575110960138" EFFECT_SIZE="0.42613636363636365" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.14932461804455557" LOG_CI_START="-0.8902274268894552" LOG_EFFECT_SIZE="-0.3704514044224498" MODIFIED="2012-12-14 09:54:49 +0000" MODIFIED_BY="[Empty name]" ORDER="16" O_E="0.0" SE="0.6106380170598518" STUDY_ID="STD-Yamanishi-2010" TOTAL_1="22" TOTAL_2="25" VAR="0.37287878787878787" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.02" MODIFIED="2012-12-14 09:59:52 +0000" MODIFIED_BY="Bary CM Berghmans" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="512.7428355898913" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="69" TOTAL_2="80" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>24-hr Pad test (grams loss of urine)</NAME>
<GROUP_LABEL_1>Electrical stimulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Control (sham ES)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ES</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.02.01" MODIFIED="2012-12-14 09:57:39 +0000" MODIFIED_BY="Bary CM Berghmans" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Urine loss at 3 months</NAME>
<CONT_DATA CI_END="-15.500561285071143" CI_START="-286.49943871492883" EFFECT_SIZE="-151.0" ESTIMABLE="YES" MEAN_1="81.0" MEAN_2="232.0" MODIFIED="2012-12-14 09:57:39 +0000" MODIFIED_BY="Bary CM Berghmans" ORDER="18" SD_1="140.0" SD_2="339.0" SE="69.13363703809414" STUDY_ID="STD-Yamanishi-2010" TOTAL_1="24" TOTAL_2="29" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.02.02" MODIFIED="2012-12-14 09:58:14 +0000" MODIFIED_BY="Bary CM Berghmans" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="26" WEIGHT="0.0" Z="0.0">
<NAME>Urine loss at 6 months</NAME>
<CONT_DATA CI_END="2.389985040536587" CI_START="-226.3899850405366" EFFECT_SIZE="-112.0" ESTIMABLE="YES" MEAN_1="20.0" MEAN_2="132.0" MODIFIED="2012-12-14 09:58:14 +0000" MODIFIED_BY="[Empty name]" ORDER="21" SD_1="49.0" SD_2="293.0" SE="58.363309705091616" STUDY_ID="STD-Yamanishi-2010" TOTAL_1="23" TOTAL_2="26" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.02.03" MODIFIED="2012-12-14 09:58:30 +0000" MODIFIED_BY="Bary CM Berghmans" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>Urine loss at 12 months</NAME>
<CONT_DATA CI_END="30.495676842449242" CI_START="-190.49567684244926" EFFECT_SIZE="-80.0" ESTIMABLE="YES" MEAN_1="18.0" MEAN_2="98.0" MODIFIED="2012-12-14 09:58:30 +0000" MODIFIED_BY="[Empty name]" ORDER="22" SD_1="49.0" SD_2="277.0" SE="56.37638125701545" STUDY_ID="STD-Yamanishi-2010" TOTAL_1="22" TOTAL_2="25" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.03" MODIFIED="2012-12-14 10:06:40 +0000" MODIFIED_BY="Bary CM Berghmans" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="30.54" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="69" TOTAL_2="80" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Urinary incontinence score (Short Form International Consultation of Incontinence Score</NAME>
<GROUP_LABEL_1>Electrical stimulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Control (sham ES)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ES</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.03.01" MODIFIED="2012-12-14 10:02:51 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Score at 3 months</NAME>
<CONT_DATA CI_END="-2.317122545629692" CI_START="-8.482877454370307" EFFECT_SIZE="-5.3999999999999995" ESTIMABLE="YES" MEAN_1="5.8" MEAN_2="11.2" MODIFIED="2012-12-14 10:02:51 +0000" MODIFIED_BY="[Empty name]" ORDER="23" SD_1="5.7" SD_2="5.7" SE="1.5729255632693515" STUDY_ID="STD-Yamanishi-2010" TOTAL_1="24" TOTAL_2="29" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.03.02" MODIFIED="2012-12-14 10:03:33 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="26" WEIGHT="0.0" Z="0.0">
<NAME>Score at 6 months</NAME>
<CONT_DATA CI_END="-0.6487694884040551" CI_START="-7.151230511595944" EFFECT_SIZE="-3.8999999999999995" ESTIMABLE="YES" MEAN_1="4.3" MEAN_2="8.2" MODIFIED="2012-12-14 10:03:09 +0000" MODIFIED_BY="[Empty name]" ORDER="23" SD_1="6.2" SD_2="5.3" SE="1.658821558580278" STUDY_ID="STD-Yamanishi-2010" TOTAL_1="23" TOTAL_2="26" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.03.03" MODIFIED="2012-12-14 10:03:39 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>Score at 12 months</NAME>
<CONT_DATA CI_END="2.2337503542914416" CI_START="-5.03375035429144" EFFECT_SIZE="-1.3999999999999995" ESTIMABLE="YES" MEAN_1="4.2" MEAN_2="5.6" MODIFIED="2012-12-14 10:03:24 +0000" MODIFIED_BY="[Empty name]" ORDER="23" SD_1="6.2" SD_2="6.5" SE="1.8539883298642221" STUDY_ID="STD-Yamanishi-2010" TOTAL_1="22" TOTAL_2="25" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.04" MODIFIED="2012-12-14 10:07:21 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="30.54" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="69" TOTAL_2="80" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Quality of life score: International Consultation of Incontinence Questionnaire</NAME>
<GROUP_LABEL_1>Electrical stimulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Control (sham ES)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ES</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.04.01" MODIFIED="2012-12-14 10:06:55 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Score at 3 months</NAME>
<CONT_DATA CI_END="-0.09973409439636782" CI_START="-2.900265905603632" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="2.2" MEAN_2="3.7" MODIFIED="2012-12-14 10:06:55 +0000" MODIFIED_BY="[Empty name]" ORDER="23" SD_1="2.3" SD_2="2.9" SE="0.7144345083117603" STUDY_ID="STD-Yamanishi-2010" TOTAL_1="24" TOTAL_2="29" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.04.02" MODIFIED="2012-12-14 10:07:08 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="26" WEIGHT="0.0" Z="0.0">
<NAME>Score at 6 months</NAME>
<CONT_DATA CI_END="0.623208469504116" CI_START="-2.423208469504116" EFFECT_SIZE="-0.8999999999999999" ESTIMABLE="YES" MEAN_1="1.6" MEAN_2="2.5" MODIFIED="2012-12-14 10:07:08 +0000" MODIFIED_BY="[Empty name]" ORDER="23" SD_1="3.1" SD_2="2.2" SE="0.7771614588426062" STUDY_ID="STD-Yamanishi-2010" TOTAL_1="23" TOTAL_2="26" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.04.03" MODIFIED="2012-12-14 10:07:21 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>Score at 12 months</NAME>
<CONT_DATA CI_END="1.2243102421515901" CI_START="-2.02431024215159" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="1.9" MODIFIED="2012-12-14 10:07:21 +0000" MODIFIED_BY="[Empty name]" ORDER="23" SD_1="3.1" SD_2="2.5" SE="0.8287449437662844" STUDY_ID="STD-Yamanishi-2010" TOTAL_1="22" TOTAL_2="25" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-12-14 10:08:25 +0000" MODIFIED_BY="Bary CM Berghmans" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="26" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Electrical stimulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Control (sham ES)</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ES</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="4" I2="0.0" ID="CMP-002.05.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-12-14 10:08:25 +0000" MODIFIED_BY="Bary CM Berghmans" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>During treatment</NAME>
<DICH_DATA CI_END="2.8980755964159766" CI_START="0.11484870756926112" EFFECT_SIZE="0.5769230769230769" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.46210970987156236" LOG_CI_START="-0.9398738877018358" LOG_EFFECT_SIZE="-0.23888208891513676" MODIFIED="2012-12-14 10:07:45 +0000" MODIFIED_BY="Bary CM Berghmans" ORDER="21" O_E="0.0" SE="0.8235321051453478" STUDY_ID="STD-Yamanishi-2010" TOTAL_1="26" TOTAL_2="30" VAR="0.6782051282051282" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2012-05-15 12:04:23 +0100" MODIFIED_BY="Bary CM Berghmans" NO="3">
<NAME>ES with non-implanted devices versus other single treatments</NAME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2013-03-29 14:51:15 +0000" MODIFIED_BY="Bary CM Berghmans" NO="4">
<NAME>ES with non-implanted devices combined with other therapy versus other therapy without ES</NAME>
<DICH_OUTCOME CHI2="14.862096106464687" CI_END="1.0143242224271116" CI_START="0.8618561980928963" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9349874961594747" ESTIMABLE="YES" EVENTS_1="292" EVENTS_2="250" I2="46.17179203598223" I2_Q="4.625749228372273" ID="CMP-004.01" LOG_CI_END="0.006176796717636061" LOG_CI_START="-0.06456519076993388" LOG_EFFECT_SIZE="-0.029194197026148876" METHOD="MH" MODIFIED="2013-03-29 14:51:15 +0000" MODIFIED_BY="Bary CM Berghmans" NO="1" P_CHI2="0.061883126969214164" P_Q="0.36973125871292556" P_Z="0.10572776494912456" Q="3.1455030846674297" RANDOM="NO" SCALE="6.943131266944789" SORT_BY="EFFECT_SIZE" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="478" TOTAL_2="367" WEIGHT="400.0" Z="1.6176976859427983">
<NAME>Number of men with urinary incontinence (subjective): at 3 months</NAME>
<GROUP_LABEL_1>ES + Other</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ES + other</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.34900977049046694" CI_END="1.1472050231086752" CI_START="0.8411821092974738" DF="2" EFFECT_SIZE="0.9823483807362908" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="85" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="0.05964103991333762" LOG_CI_START="-0.07510997269043637" LOG_EFFECT_SIZE="-0.007734466388549387" MODIFIED="2013-03-29 14:50:42 +0000" MODIFIED_BY="Bary CM Berghmans" NO="1" P_CHI2="0.839872785014498" P_Z="0.8219817379256422" STUDIES="3" TAU2="0.0" TOTAL_1="149" TOTAL_2="120" WEIGHT="100.0" Z="0.22499683331905163">
<NAME>Transcutaneous (Anal) ES + PFMT vs PFMT alone</NAME>
<DICH_DATA CI_END="1.437141582914502" CI_START="0.5247604923686948" EFFECT_SIZE="0.868421052631579" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.15749955564261792" LOG_CI_START="-0.28003886912046333" LOG_EFFECT_SIZE="-0.06126965673892266" MODIFIED="2012-12-14 14:16:49 +0000" MODIFIED_BY="[Empty name]" ORDER="429" O_E="0.0" SE="0.2570122365559669" STUDY_ID="STD-Moore-1999" TOTAL_1="19" TOTAL_2="18" VAR="0.06605528973950028" WEIGHT="15.102517670424675"/>
<DICH_DATA CI_END="1.056676482446599" CI_START="0.9307479159058463" EFFECT_SIZE="0.9917153996101364" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="54" LOG_CI_END="0.023942041806537296" LOG_CI_START="-0.031167927563616943" LOG_EFFECT_SIZE="-0.0036129428785398273" MODIFIED="2013-01-22 12:00:36 +0000" MODIFIED_BY="Bary CM Berghmans" ORDER="18" O_E="0.0" SE="0.0323718688067766" STUDY_ID="STD-Hoffmann-2005" TOTAL_1="38" TOTAL_2="55" VAR="0.001047937890043156" WEIGHT="54.07675681990771"/>
<DICH_DATA CI_END="1.5612967306890586" CI_START="0.6686434616441497" EFFECT_SIZE="1.0217391304347827" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="19" LOG_CI_END="0.1934854503104038" LOG_CI_START="-0.17480539780211696" LOG_EFFECT_SIZE="0.009340026254143432" MODIFIED="2012-12-14 11:08:18 +0000" MODIFIED_BY="Bary CM Berghmans" ORDER="17" O_E="0.0" SE="0.2163358672503949" STUDY_ID="STD-Wille-2003" TOTAL_1="92" TOTAL_2="47" VAR="0.046801207458980476" WEIGHT="30.82072550966762"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0448792669040454" CI_START="0.9231732530159557" DF="0" EFFECT_SIZE="0.9821428571428571" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="54" I2="0.0" ID="CMP-004.01.02" LOG_CI_END="0.019066111742259705" LOG_CI_START="-0.034716786766172895" LOG_EFFECT_SIZE="-0.007825337511956592" MODIFIED="2013-03-29 14:51:15 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5684443316126301" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="55" WEIGHT="100.0" Z="0.5703441099553404">
<NAME>Transcutaneous (Perineal) ES + PFMT vs PFMT</NAME>
<DICH_DATA CI_END="1.0448792669040454" CI_START="0.9231732530159557" EFFECT_SIZE="0.9821428571428571" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="54" LOG_CI_END="0.019066111742259705" LOG_CI_START="-0.034716786766172895" LOG_EFFECT_SIZE="-0.007825337511956592" MODIFIED="2013-01-22 12:00:51 +0000" MODIFIED_BY="[Empty name]" ORDER="20" O_E="0.0" SE="0.03159234081349462" STUDY_ID="STD-Hoffmann-2005" TOTAL_1="56" TOTAL_2="55" VAR="9.98075998075998E-4" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1390164558922744" CI_START="0.20966839225883285" DF="0" EFFECT_SIZE="0.48868778280542985" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="13" I2="0.0" ID="CMP-004.01.03" LOG_CI_END="0.056529998575661794" LOG_CI_START="-0.6784670349719838" LOG_EFFECT_SIZE="-0.310968518198161" MODIFIED="2013-03-29 14:30:48 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.09722163310958482" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="36" WEIGHT="100.0" Z="1.6584749820073241">
<NAME>ES (not specified) + PFMT vs PFMT</NAME>
<DICH_DATA CI_END="1.1390164558922744" CI_START="0.20966839225883285" EFFECT_SIZE="0.48868778280542985" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="13" LOG_CI_END="0.056529998575661794" LOG_CI_START="-0.6784670349719838" LOG_EFFECT_SIZE="-0.310968518198161" MODIFIED="2013-03-29 14:27:37 +0000" MODIFIED_BY="[Empty name]" ORDER="237" O_E="0.0" SE="0.43174089579988073" STUDY_ID="STD-Ceresoli-2002" TOTAL_1="34" TOTAL_2="36" VAR="0.18640020110608346" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.7759179084537715" CI_END="1.0565551436967262" CI_START="0.8155046141202433" DF="3" EFFECT_SIZE="0.9282378977165051" ESTIMABLE="YES" EVENTS_1="146" EVENTS_2="98" I2="61.4193457888942" ID="CMP-004.01.04" LOG_CI_END="0.023892168665404247" LOG_CI_START="-0.08857357738116521" LOG_EFFECT_SIZE="-0.032340704357880466" MODIFIED="2013-03-29 14:29:16 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.05087716203117976" P_Z="0.2596510235840196" STUDIES="4" TAU2="0.0" TOTAL_1="239" TOTAL_2="156" WEIGHT="100.0" Z="1.1272163837308535">
<NAME>Transcutaneous ES (any) + PFMT vs PFMT alone</NAME>
<DICH_DATA CI_END="1.1390164558922744" CI_START="0.20966839225883285" EFFECT_SIZE="0.48868778280542985" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="13" LOG_CI_END="0.056529998575661794" LOG_CI_START="-0.6784670349719838" LOG_EFFECT_SIZE="-0.310968518198161" MODIFIED="2013-01-22 12:33:39 +0000" MODIFIED_BY="[Empty name]" ORDER="237" O_E="0.0" SE="0.43174089579988073" STUDY_ID="STD-Ceresoli-2002" TOTAL_1="34" TOTAL_2="36" VAR="0.18640020110608346" WEIGHT="10.680618530961032"/>
<DICH_DATA CI_END="1.437141582914502" CI_START="0.5247604923686948" EFFECT_SIZE="0.868421052631579" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.15749955564261792" LOG_CI_START="-0.28003886912046333" LOG_EFFECT_SIZE="-0.06126965673892266" MODIFIED="2013-01-22 12:31:45 +0000" MODIFIED_BY="[Empty name]" ORDER="429" O_E="0.0" SE="0.2570122365559669" STUDY_ID="STD-Moore-1999" TOTAL_1="19" TOTAL_2="18" VAR="0.06605528973950028" WEIGHT="10.423301440267707"/>
<DICH_DATA CI_END="1.0380057428673963" CI_START="0.9366237812379358" EFFECT_SIZE="0.9860126083530338" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="54" LOG_CI_END="0.016199756295407354" LOG_CI_START="-0.028434819510066867" LOG_EFFECT_SIZE="-0.006117531607329743" MODIFIED="2013-01-22 12:33:12 +0000" MODIFIED_BY="[Empty name]" ORDER="18" O_E="0.0" SE="0.026218570772849177" STUDY_ID="STD-Hoffmann-2005" TOTAL_1="94" TOTAL_2="55" VAR="6.874134533709012E-4" WEIGHT="57.624546394076255"/>
<DICH_DATA CI_END="1.5612967306890586" CI_START="0.6686434616441497" EFFECT_SIZE="1.0217391304347827" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="19" LOG_CI_END="0.1934854503104038" LOG_CI_START="-0.17480539780211696" LOG_EFFECT_SIZE="0.009340026254143432" MODIFIED="2013-01-22 12:31:45 +0000" MODIFIED_BY="[Empty name]" ORDER="17" O_E="0.0" SE="0.2163358672503949" STUDY_ID="STD-Wille-2003" TOTAL_1="92" TOTAL_2="47" VAR="0.046801207458980476" WEIGHT="21.271533634695007"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-03-29 14:45:06 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="689.4220235872024" SORT_BY="EFFECT_SIZE" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="34" TOTAL_2="36" WEIGHT="0.0" Z="0.0">
<NAME>Number of men with urinary incontinence (subjective): at 6 months</NAME>
<GROUP_LABEL_1>ES + Other</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ES + other</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="9" I2="0.0" ID="CMP-004.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-03-29 14:45:06 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="36" WEIGHT="0.0" Z="0.0">
<NAME>Transcutaneous ES + PFMT vs PFMT</NAME>
<DICH_DATA CI_END="1.386438668819677" CI_START="0.15972815255200767" EFFECT_SIZE="0.47058823529411764" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" LOG_CI_END="0.14190066267528603" LOG_CI_START="-0.7966185314479467" LOG_EFFECT_SIZE="-0.32735893438633035" MODIFIED="2012-12-14 12:15:09 +0000" MODIFIED_BY="[Empty name]" ORDER="19" O_E="0.0" SE="0.5512908203729234" STUDY_ID="STD-Ceresoli-2002" TOTAL_1="34" TOTAL_2="36" VAR="0.30392156862745096" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-01-28 14:38:31 +0000" MODIFIED_BY="Bary CM Berghmans" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="92" TOTAL_2="47" WEIGHT="0.0" Z="0.0">
<NAME>Number of men with urinary incontinence (subjective): at 12 months</NAME>
<GROUP_LABEL_1>ES + Other</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ES + other</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="6" I2="0.0" ID="CMP-004.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-12-14 12:08:36 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="92" TOTAL_2="47" WEIGHT="0.0" Z="0.0">
<NAME>Anal ES + PFMT vs PFMT</NAME>
<DICH_DATA CI_END="2.901187539609455" CI_START="0.4897763701552071" EFFECT_SIZE="1.1920289855072463" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" LOG_CI_END="0.4625758035303412" LOG_CI_START="-0.31000217176082806" LOG_EFFECT_SIZE="0.07628681588475658" MODIFIED="2012-12-14 12:03:30 +0000" MODIFIED_BY="[Empty name]" ORDER="17" O_E="0.0" SE="0.45381612700868834" STUDY_ID="STD-Wille-2003" TOTAL_1="92" TOTAL_2="47" VAR="0.20594907713316593" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.04" MODIFIED="2013-03-29 14:49:38 +0000" MODIFIED_BY="Bary CM Berghmans" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="18.72384443250752" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="74" TOTAL_2="110" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Quality of life (EORTC QLQ 30)</NAME>
<GROUP_LABEL_1>ES + Other</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ES + other</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.04.01" MODIFIED="2013-03-29 14:49:25 +0000" MODIFIED_BY="Bary CM Berghmans" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="55" WEIGHT="0.0" Z="0.0">
<NAME>Transcutaneous (Anal) ES + PFMT vs PFMT</NAME>
<CONT_DATA CI_END="4.61242424915509" CI_START="0.06757575084490908" EFFECT_SIZE="2.34" ESTIMABLE="YES" MEAN_1="10.67" MEAN_2="8.33" MODIFIED="2011-11-02 14:08:02 +0000" MODIFIED_BY="Bary CM Berghmans" ORDER="41" SD_1="5.44" SD_2="4.22" SE="1.1594214317608298" STUDY_ID="STD-Hoffmann-2005" TOTAL_1="29" TOTAL_2="55" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.04.02" MODIFIED="2013-03-29 14:49:38 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="45" TOTAL_2="55" WEIGHT="0.0" Z="0.0">
<NAME>Transcutaneous (Perineal) ES + PFMT vs PFMT</NAME>
<CONT_DATA CI_END="8.315582278691057" CI_START="4.704417721308942" EFFECT_SIZE="6.51" ESTIMABLE="YES" MEAN_1="14.84" MEAN_2="8.33" MODIFIED="2012-12-14 11:51:04 +0000" MODIFIED_BY="[Empty name]" ORDER="41" SD_1="4.86" SD_2="4.22" SE="0.9212323761728585" STUDY_ID="STD-Hoffmann-2005" TOTAL_1="45" TOTAL_2="55" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-004.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-01-22 13:04:16 +0000" MODIFIED_BY="Bary CM Berghmans" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="92" TOTAL_2="47" WEIGHT="0.0" Z="0.0">
<NAME>Number of men with urinary incontinence (objective): anal ES</NAME>
<GROUP_LABEL_1>ES + Other</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ES + other</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="9" I2="0.0" ID="CMP-004.05.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-01-22 13:04:16 +0000" MODIFIED_BY="Bary CM Berghmans" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="92" TOTAL_2="47" WEIGHT="0.0" Z="0.0">
<NAME>Anal ES + PFMT vs PFMT alone</NAME>
<DICH_DATA CI_END="1.5002583186770515" CI_START="0.30926551119460133" EFFECT_SIZE="0.6811594202898551" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.17616604353380091" LOG_CI_START="-0.5096685091368766" LOG_EFFECT_SIZE="-0.16675123280153784" MODIFIED="2012-12-14 11:12:37 +0000" MODIFIED_BY="Bary CM Berghmans" ORDER="14" O_E="0.0" SE="0.4028626111745445" STUDY_ID="STD-Wille-2003" TOTAL_1="92" TOTAL_2="47" VAR="0.16229828348237227" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.06" MODIFIED="2013-03-29 14:46:30 +0000" MODIFIED_BY="Bary CM Berghmans" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="34" TOTAL_2="36" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean number of pads/day (from voiding diary)</NAME>
<GROUP_LABEL_1>ES + Other</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ES + other</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.06.01" MODIFIED="2013-03-29 14:46:30 +0000" MODIFIED_BY="Bary CM Berghmans" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="36" WEIGHT="0.0" Z="0.0">
<NAME>Transcutaneous ES + PFMT vs PFMT</NAME>
<CONT_DATA CI_END="1.4687123557421093" CI_START="0.5312876442578907" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="3.5" MEAN_2="2.5" MODIFIED="2012-05-30 14:49:00 +0100" MODIFIED_BY="Bary CM Berghmans" ORDER="42" SD_1="1.0" SD_2="1.0" SE="0.23914335132647976" STUDY_ID="STD-Ceresoli-2002" TOTAL_1="34" TOTAL_2="36" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.07" MODIFIED="2013-02-01 15:52:05 +0000" MODIFIED_BY="Bary CM Berghmans" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="57" TOTAL_2="53" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>24-hr pad test (grams of urine lost)</NAME>
<GROUP_LABEL_1>ES + Other</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ES + other</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.07.01" MODIFIED="2012-12-14 14:33:01 +0000" MODIFIED_BY="Bary CM Berghmans" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>&lt;3 months: Anal ES + PFMT vs PFMT alone</NAME>
<CONT_DATA CI_END="163.52582782453132" CI_START="-25.52582782453132" EFFECT_SIZE="69.0" ESTIMABLE="YES" MEAN_1="156.0" MEAN_2="87.0" MODIFIED="2012-12-14 14:24:04 +0000" MODIFIED_BY="Bary CM Berghmans" ORDER="70" SD_1="168.0" SD_2="123.0" SE="48.22834938301876" STUDY_ID="STD-Moore-1999" TOTAL_1="19" TOTAL_2="18" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.07.02" MODIFIED="2012-12-14 14:26:11 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>3 months: Anal ES + PFMT vs PFMT alone</NAME>
<CONT_DATA CI_END="252.5110169198391" CI_START="3.4889830801609065" EFFECT_SIZE="128.0" ESTIMABLE="YES" MEAN_1="202.0" MEAN_2="74.0" MODIFIED="2012-12-14 14:26:11 +0000" MODIFIED_BY="[Empty name]" ORDER="70" SD_1="242.0" SD_2="131.0" SE="63.52719636787518" STUDY_ID="STD-Moore-1999" TOTAL_1="19" TOTAL_2="18" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.07.03" MODIFIED="2012-12-14 14:27:12 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>6 months: Anal ES + PFMT vs PFMT alone</NAME>
<CONT_DATA CI_END="108.37102839305595" CI_START="-52.37102839305595" EFFECT_SIZE="28.0" ESTIMABLE="YES" MEAN_1="98.0" MEAN_2="70.0" MODIFIED="2012-12-14 14:27:12 +0000" MODIFIED_BY="[Empty name]" ORDER="70" SD_1="132.0" SD_2="114.0" SE="41.00638023301059" STUDY_ID="STD-Moore-1999" TOTAL_1="19" TOTAL_2="17" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="9.708303901374695" CI_END="21.81169331591534" CI_START="3.0979774961723474" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="8.220227189446684" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="4" I2="58.79815835355546" I2_Q="0.0" ID="CMP-004.08" LOG_CI_END="1.338689382644803" LOG_CI_START="0.49107825870282956" LOG_EFFECT_SIZE="0.9148838206738162" METHOD="MH" MODIFIED="2013-03-29 14:48:32 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.045638678418286394" P_Q="0.9470698662022222" P_Z="2.3261072624128126E-5" Q="0.10876483233739939" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="278" TOTAL_2="258" WEIGHT="300.0" Z="4.231042486133861">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>ES + Other</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ES + other</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.412497708410662" CI_END="39.436021253912166" CI_START="2.4200684244488153" DF="1" EFFECT_SIZE="9.769230769230768" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="2" I2="81.52424160021229" ID="CMP-004.08.01" LOG_CI_END="1.5958930920035745" LOG_CI_START="0.3838276452946656" LOG_EFFECT_SIZE="0.9898603686491201" MODIFIED="2013-03-29 14:48:16 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.019993166988244493" P_Z="0.0013681048929514994" STUDIES="2" TAU2="0.0" TOTAL_1="79" TOTAL_2="99" WEIGHT="100.0" Z="3.2012968896088845">
<NAME>Transcutaneous (Anal) ES + PFMT vs PFMT alone</NAME>
<DICH_DATA CI_END="662.7782331742626" CI_START="2.536293311790188" EFFECT_SIZE="41.0" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="0" LOG_CI_END="2.8213682369718995" LOG_CI_START="0.4041994764675714" LOG_EFFECT_SIZE="1.6127838567197355" MODIFIED="2013-01-22 12:04:05 +0000" MODIFIED_BY="[Empty name]" ORDER="40" O_E="0.0" SE="1.4198568950985788" STUDY_ID="STD-Hoffmann-2005" TOTAL_1="60" TOTAL_2="60" VAR="2.015993602558977" WEIGHT="23.076923076923073"/>
<DICH_DATA CI_END="7.942695375481524" CI_START="0.020144295158782927" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.8999679064642382" LOG_CI_START="-1.6958479238083133" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2012-12-14 14:41:37 +0000" MODIFIED_BY="[Empty name]" ORDER="439" O_E="0.0" SE="1.5247950681976907" STUDY_ID="STD-Moore-1999" TOTAL_1="19" TOTAL_2="39" VAR="2.325" WEIGHT="76.92307692307692"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="132.65715755793994" CI_START="0.3693732091206503" DF="0" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-004.08.02" LOG_CI_END="2.1227306874435343" LOG_CI_START="-0.4325346074150208" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2013-03-29 14:48:32 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.19482726646137244" STUDIES="1" TAU2="0.0" TOTAL_1="60" TOTAL_2="60" WEIGHT="100.0" Z="1.2964303355632745">
<NAME>Transcutaneous (Perineal) ES + PFMT vs PFMT</NAME>
<DICH_DATA CI_END="132.65715755793994" CI_START="0.3693732091206501" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1227306874435343" LOG_CI_START="-0.4325346074150211" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2013-01-22 12:04:24 +0000" MODIFIED_BY="[Empty name]" ORDER="20" O_E="0.0" SE="1.5009754829671218" STUDY_ID="STD-Hoffmann-2005" TOTAL_1="60" TOTAL_2="60" VAR="2.2529274004683844" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.267910976728609" CI_END="32.93848111032089" CI_START="1.505706106722367" DF="1" EFFECT_SIZE="7.04241948153967" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="2" I2="76.56933320651152" ID="CMP-004.08.03" LOG_CI_END="1.5177035687069866" LOG_CI_START="0.17774021178210614" LOG_EFFECT_SIZE="0.8477218902445463" MODIFIED="2013-03-29 14:47:26 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.03883881727654981" P_Z="0.013140998733475472" STUDIES="2" TAU2="0.0" TOTAL_1="139" TOTAL_2="99" WEIGHT="99.99999999999999" Z="2.479925089292831">
<NAME>Transcutaneous (any) ES + PFMT vs PFMT alone</NAME>
<DICH_DATA CI_END="383.52757667611354" CI_START="1.4638212549334837" EFFECT_SIZE="23.694214876033058" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="0" LOG_CI_END="2.583796596362411" LOG_CI_START="0.16548804889765795" LOG_EFFECT_SIZE="1.3746423226300344" MODIFIED="2013-01-22 13:09:04 +0000" MODIFIED_BY="[Empty name]" ORDER="40" O_E="0.0" SE="1.4205264116011689" STUDY_ID="STD-Hoffmann-2005" TOTAL_1="120" TOTAL_2="60" VAR="2.0178952860564934" WEIGHT="28.515318146111543"/>
<DICH_DATA CI_END="7.942695375481524" CI_START="0.020144295158782927" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.8999679064642382" LOG_CI_START="-1.6958479238083133" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2013-01-22 13:07:41 +0000" MODIFIED_BY="[Empty name]" ORDER="439" O_E="0.0" SE="1.5247950681976907" STUDY_ID="STD-Moore-1999" TOTAL_1="19" TOTAL_2="39" VAR="2.325" WEIGHT="71.48468185388845"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2012-11-05 15:13:55 +0000" MODIFIED_BY="Bary CM Berghmans" NO="5">
<NAME>One type of ES with non-implanted devices versus other ES</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-11-05 15:13:24 +0000" MODIFIED_BY="Bary CM Berghmans" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="29" TOTAL_2="45" WEIGHT="0.0" Z="0.0">
<NAME>Patient perceived recovery (dichotomous scales)</NAME>
<GROUP_LABEL_1>Anal ES</GROUP_LABEL_1>
<GROUP_LABEL_2>Percutaneous ES</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="16" I2="0.0" ID="CMP-005.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-09-29 20:57:30 +0100" MODIFIED_BY="Bary CM Berghmans" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="45" WEIGHT="0.0" Z="0.0">
<NAME>Stress urinary incontinence</NAME>
<DICH_DATA CI_END="1.9624011223500057" CI_START="0.5799447925652835" EFFECT_SIZE="1.0668103448275863" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" LOG_CI_END="0.2927877835831004" LOG_CI_START="-0.23661334682572463" LOG_EFFECT_SIZE="0.02808721837868789" ORDER="19114" O_E="0.0" SE="0.3109728445800035" STUDY_ID="STD-Hoffmann-2005" TOTAL_1="29" TOTAL_2="45" VAR="0.09670411006617903" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-005.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-09-29 20:56:37 +0100" MODIFIED_BY="Bary CM Berghmans" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Urgency urinary incontinence</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-005.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Mixed urinary incontinence</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-005.01.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Urinary incontinence: stress, urgency or mixed UI</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.02" MODIFIED="2012-11-05 15:13:38 +0000" MODIFIED_BY="Bary CM Berghmans" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="154.66" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="59" TOTAL_2="59" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>1-hr PAD test (grams loss of urine)</NAME>
<GROUP_LABEL_1>Anal ES</GROUP_LABEL_1>
<GROUP_LABEL_2>Percutaneous ES</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.02.01" MODIFIED="2011-11-01 16:04:42 +0000" MODIFIED_BY="Bary CM Berghmans" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="59" WEIGHT="0.0" Z="0.0">
<NAME>Stress urinary incontinence</NAME>
<CONT_DATA CI_END="38.65803305992452" CI_START="-30.058033059924526" EFFECT_SIZE="4.299999999999997" ESTIMABLE="YES" MEAN_1="89.6" MEAN_2="85.3" MODIFIED="2011-11-01 16:04:42 +0000" MODIFIED_BY="Bary CM Berghmans" ORDER="19120" SD_1="89.5" SD_2="100.6" SE="17.529930820635634" STUDY_ID="STD-Hoffmann-2005" TOTAL_1="59" TOTAL_2="59" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.02.02" MODIFIED="2011-09-29 20:56:37 +0100" MODIFIED_BY="Bary CM Berghmans" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Urgency urinary incontinence</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.02.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Mixed urinary incontinence</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.02.04" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Urinary incontinence: stress, urgency or mixed UI</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.03" MODIFIED="2012-11-05 15:13:55 +0000" MODIFIED_BY="Bary CM Berghmans" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="25.009696411215767" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="29" TOTAL_2="45" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Quality of life (EORTC QLQ 30)</NAME>
<GROUP_LABEL_1>PFMT + anal ES</GROUP_LABEL_1>
<GROUP_LABEL_2>PFMT + percutaneous ES</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.03.01" MODIFIED="2011-11-02 15:06:59 +0000" MODIFIED_BY="Bary CM Berghmans" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="45" WEIGHT="0.0" Z="0.0">
<NAME>Stress urinary incontinence</NAME>
<CONT_DATA CI_END="-1.7335282856891707" CI_START="-6.606471714310829" EFFECT_SIZE="-4.17" ESTIMABLE="YES" MEAN_1="10.67" MEAN_2="14.84" MODIFIED="2011-11-02 15:06:59 +0000" MODIFIED_BY="Bary CM Berghmans" ORDER="43" SD_1="5.44" SD_2="4.86" SE="1.243120656057666" STUDY_ID="STD-Hoffmann-2005" TOTAL_1="29" TOTAL_2="45" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2013-04-25 22:51:54 +0100" MODIFIED_BY="Bary CM Berghmans">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2013-04-15 13:05:44 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>PRISMA study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZIAAAK8CAYAAADFzDkhAABD7ElEQVR42u2df4QW3d/HvyRJkljJWlmRJEliJUkSSXL/kbit5Pb1iJWsJJEkWYkkWUkkKyu3uK0kSSTJSuKWJEmsJEmWrCTJebzP88zlXKeZc+ZcP3avH68Xl9qda36cmc/5vGbmzM7nP8bhP//5D58u+rQaHBPiD9qT/7idGLrs4LfQMSf+iD9oc5FwQOnMJBTg2EMdx5EDSRD8pyvXDcQfIBJAJED8ASIBREL8EX/EACIBOjJJBIgBRAJ0ZJIIEAOASACRAPEHiAQQSTvw8uVLggaRQBmRfPv2zQwNDZlFixaZBQsWmH379pnp6emqg+9/5s2bV7WMmzdvmv7+fjv/wMCAefHiBUFOG0utW7G2Z88es3DhQhuDf/75p/n8+fOsttud7v5f8TxX+68T4xGRdLBIhoeHzeXLl82vX7/s5/jx41YmRdy+fducPHmy8vOzZ8/Mpk2bzNTUlJ1/fHzcrFmzhiCnjaXWfebMGXP69OlK/N24caMqvmZbJFzB0SaoQSRLly61HTjj58+fv52JZeh769evNzMzM5XfDQ4OmvPnzycF09OnT82yZcvMxo0bqxLKkiVL7FnpkSNHqub58eOHOXDggD1rXb16tZmcnKyaLvlpPk3ftm2b+fDhQ3B9asehQ4fM4sWLTW9vr72icvfP3bt3zfz58+2V17p168yjR4/oyE1a944dO8yrV6+q4m/Xrl2Fy3n37l3lCkbHSPEwMTFRFaOhYxubnv0/731RfhticXf9+nWzYsUKG0fa1nv37pVuByKBthKJj5K2km4eV65c+e1sUR0l5V6ytuPw4cO2Q3/8+LGyXHU6/U6JRJ373LlzlXlOnTplbt26Zf9/586dqiueCxcumNHR0coZrZYl6YTWd/HiRXP27Fn7O91G2bJlS1WQu53+/v37ZuXKlXTkJq1bCd09kcl+V4ROZHTVmx1vHXs3XmPHNja96P/+z2XiTqLI5KJ4UlyVbQcigbYWiW4tKHEXdWLdwnJR51Cy1RmVzq78MZa8YHLP3MSGDRt+SyZu8pY4/OkZa9eutfJzRdjT0xNcn65M3HmeP39eFeTq0Jm46MjNXbebXEO/C+GO2cWObWx6WZHUEnex/e+2A5FA24rky5cvdrBTVwU+r1+/tgPpecGhwfqvX79Wzsx0uyslmJQ4QgP6ocTiD/z73y9an3/Lzv2exKifJTjdv6cjN2/dseOXh25V6mRHcaaE7l9Nho5tbHpZkdQSd/7vQu1AJNCWIpE89u/fX/jEzKVLl+w94bxbE+6ZmTpm0RhLUTDldcqyiSVvWqxDxubJOrluo+3cudMcO3aMjtzEW1tlfpcxNjZmr1CvXbtmHjx4YG9XhkThrzslXkIiqSXu3N/F2oFIoO1EoisRXVX4t61c9u7daxOrjz8wKpHoFldKMGlAW1c0Raxatarw1pbm9W8xuCLLW5+eMnPn0WBv0f7Ro8yd0gFaUSQStR5Bz/j+/bsduC5CknFjRTHrLjt2bGPTy4qklrhzfxdrByKBthLJkydPzNatW82nT5+CC9CYRTZY7aKxBH2yQUNdueTdAgsFkwYuswFQffSzm0x0+a/bTeLhw4e/DbZrndm8epRZ4gmtT4OcIyMjlQHX7du3V31Py9eTW8IfJKUjN3bdelrPPfY6Qw/dTtTDHdnTTZKAYs1dduzYxqa7/9cJkcY5MmH4g+2pcef+LtYORAJtJZK+vr5S5TGVTIuuCtShNECtMzI9qfLmzZvkYNLTYDpLy5bhSktnqRrE1zboXrIGSF2yxzD10ZMzb9++ja5PjyxrcFSPHGtcx/2ebmtpPdljm5lU6MiNX7eOs5K5jrs+u3fvDj6s8fjxY3tSo+Mi4eskxl926NjGprv/15OD2XbltSE17tzfxdqBSKDtbm1B1wQBSQSIAUAkgEiA+ANEAogEiD9AJEBHJokAMYBIgI5MEgFiABAJIBIg/gCRACIB4g8QCdCRSSJADCCSWaFVSpd2awlVRNJZtFscEwMdLJJaq8fVQqh0aVZMSm/cbcR6Q/PPZQnVuex0iKT529uN/QmRIJJZPfihZfkV5Jq5rtDL+BAJImnm9nZif0IkiCSpDKkIlcQNlRcNlS4tU9Y0tN4y2+1uY9669L6worKoReWBY6VWYx1JbdI2q9yxKuT571oKbVOniKTTSi93W39CJIjkt4MbK0MaK4kbKy8auhIITYutN7bdZa5I9LLA0Hb75XrLlFoNrVftUZ2TbJs3b9782/4IbVMniaSTSi93Y39CJIgkqQxprCRurLxorYEfW29su8uIJLbd/vQypVZD61VdDPfV/XklX1NLtbarSDqp9HI39idEgkiSy5SGSuLGkmetgZ9aitff7jIiSdluUW+pVX+gNFTytdNFkrcf27X0cjf2J0SCSJLKh8ZK4jYr8GspxdtskdRbajWldni3iaSdSy93Y39CJIgkqQxprCRuswI/tt6U0rmNEklqqVW/lKoq4un+c8a///6LSEoe71YuvdyN/QmRIJKkMqSxkrixwA+VLg0Ffmy9se32CW1HWZHESq26A7Tv37+3g6ahwXa1B5GUO96tXHq5G/sTIkEkyWVKQyVxY4EfKl0au0oIrbfMdrvESqiWEYkIlVrNEo5uIyiRKRH5y1Fn1fbqEUttc+zMuVtEEjverVx6uRv7EyJBJNAiKDn29fXNSTKfS5FAVyUhdgIigUaisz0N3mbP8ussOjSIi0gAkQAigSoePHhgn9fXrQX9ZfvRo0etUBAJIBJAJEBHJokAMYBIgI5MEgFiABAJIBIg/gCRACIB4g8QCdCRSSJADCASoCM3b93dWPaYUs/QcSKZmZkxw8PD9u8a9Fe7ep20it60YnCV+WtzAr69RNKNZY/boc30K0gSyeDgoLlx40blJXh6b4/+OE6fbg1ERDJ76+7Gssft0Gb6FSSJJO8FdLpK0R/JuQEwNjZmr1r0/iJVmNMrPVxqLY3qbte7d+/se3/0PW2XvjsxMRG9IomVQp2LsqJ05Pi6O7nscdH21NLmWAwX7RPiD2ZNJHqzqV7+5r42Oi8AVNRHnUGJV0Gt22EZ9ZRGdbdr/fr19s2j2VtJ1aHVOWIiCZVCnauyonTk2q9I2r3scer2xJZfpiSvv0+IP5hVkejNqUq8ClwF89WrV83jx49/CwD3KuLbt29VLxispzRqLLiKKsaVLYU6V2VF6ci1i6Tdyx6nbk9s+bWU5CX+YFZFkqFLY52d69aSpKLXSLsB4Aeye8ZUT2nUvEp0uoLR2I06ZJE8ypZCnauyonTk2kUS+k47lD1O3Z4y1TRTS/ISfzAnInHR44n+GU+oY9RTGtVdtsZhdPVy7do1+1JDXaaXEUkmoLxSqHNVVpSOPHsiabWyx6nbE1t+LSV5iT+YVZFocDHvtpMG9dwAUInRjOnpaTswmVFPaVR3u7RMdzl+edoyj//6pVDnqqwoHXn2RNJqZY9Ttye2/FpK8hJ/MKsi0dMlGhxUOVihp7H0BIkG79wA0JMn6mwSwokTJ8zevXsr0+spjepul55ayZ7SUkJXBy8jklAp1LkqK0pHLrfuTix7HNue1DbXUpKX+INZv7Wlp7AU6LqE1qCg5OKeUWleJfjly5fbgW3VztBViUutpVHd7dIgfzbwLzloAL2MSGKlUOeirCgdudy6O7XscWh7Utsci2FEAi0hEgKga4KAJFKC2Sh7TPwBIgE6cgfF0FyUPSb+oOtE4j8eCXTkTkoic1H2mPiDrhMJ0JFJIkAMACIBRAKIBBAJIBIg/gCRACIB4g8QCdCRSSJADCCSFqZby5AiEiD+oG1F4r9VVH8BrL+gHRoasgWuZjuIOv1R49h+6NQSwiQRIAY6XCQ+Eoj+IEuVAwk2kjnHFYgBSBaJ0F/5um8AFqFyn9n0ULnSjKLSuHllSGPrLVNmtJ5SvGXK//rrj5UWjpWSdf+vFwrGSrAW7fN2EEns2NRTQjf12MRiIbatgEgQSQ6uSGLlPsuUK80Ilcb1t6cRZUbrKcVbpvyvv/5YaeFYKVn3/5JY0Xdj+7wdRBI6NvWW0E09NrFYCG0rIBJE4qFXbataovsq+Vi5zzLlSjNCpXH97WlEmdF6SvHm4Ven89cfKy0cKyVb9ruxfd4OIgkdm3pL6KYem1gshLYVEEnXi8T/6FXauqXgvm8oVu4zpVxpqDSuv52NKDNaTyleUbb8r7vMlM6UUrwrpURsO4gkdGzqLaGbemxisRDaVkAkXJH8Pzq73bVrV1U1xFCnDnXQWLnSotK4/vcaVWa01lK8KeV/Z1skqfXmW3WwvejY1FtCN/XYxGIhtK2ASBCJg65CdF/+9u3bVb+PlfuspVyp8Evj+t9rdJnR1FK8KeV/M8qWFq5XJLF93i4iCR2bekroph6bWCyEthUQCSLx0JWJ7g2rY2bEyn2mlCsNlcb1y5A2osxoPaV4U8r/ZpQtLVyvSGL7vB1EEjs29ZTQTT02sVgIbSsgEkSSgzrZ1q1bq34XK1lbtlxpqDSuX4Y0tt4ywVlPKd6U8r8ZZUsL1yuS2D5vB5HEjk09JXRTj00sFmLbCoika0XSLChXOvvE9jl/kAiIBFpaJJQrnX1S9zkiAUQCLS0SypXOPqn7HJEAIoGWFgnQkUkiQAwgEqAjk0SAGABEAogEiD9AJIBIgPgDRAJ0ZJIIEAOIBOjIJBEgBgCRACIB4g8QCSASIP4AkQAdmfgDYgCRAB2ZJALEAMeQg0gQIBJAJIBIAJEA8QeIBBAJEH/QlseQA0knZhuAYw91i4QDSidmW4BjDnWLJDuwfLrn04qJhQ/xB20uEs6MAIg/AERCRwbiDwCR0JGB+ANAJHRkAOIPEAkdGYD4A0AkdGQg/gAQCR0ZiD8AREJHBiD+AJHQkQGIPwBEQkcG4g8AkdCRgfgDQCR0ZADiDxAJHRmA+ANAJHRkIP4AEAkdGYg/AERCRwbij50AiISODED8ASKhIwMQfwCIhI4MxB8AIqEjA/EHgEjasyPz4TOXHwBEApxRAwAiAUAkAIBIAJEAACIBRAIAiAQQCQAgEgBEAgCIBBAJACASQCQAgEgAkQAAIgFAJACASACRAAAigdYTCO+MAgB6PiASAEAk0BoyAQBEAoBIAACRACIBAEQCiAQAEAl0m0wAAJEAIBIA6HyRUNubDx/qwAMi4awXgD4DiIQOAYBMANpIJHQEAPoQIBI6AQB9CBAJnQAAkQAgEgBEAoBIAIA+BIiETgBAHwJEQifoPl6+fMlOaNP9QB8CRFLQCb59+2aGhobMokWLzIIFC8y+ffvM9PR01Xz+Z968eVXLuHnzpunv77fzDwwMmBcvXpAk/p+7d++a+fPnmw0bNtiftY/arT3ushq13NnaD4gEEMksdILh4WFz+fJl8+vXL/s5fvy4lUkRt2/fNidPnqz8/OzZM7Np0yYzNTVl5x8fHzdr1qwhSfw/ksi9e/dmPRk1SyTdnJQRCSCSgk6wdOlSK4CMnz9/Fp4t6nvr1683MzMzld8NDg6a8+fPJ23H06dPzbJly8zGjRsrvz9z5oxZsmSJvTI6cuRI1Tw/fvwwBw4cMAsXLjSrV682k5OTVdMlP82n6du2bTMfPnwIrk/tOHTokFm8eLHp7e21V1Tu/smuInTltW7dOvPo0aPC9rx7987s2bPHrlvzaPsmJiYKr+by3uEUanvR/vKPS6g9ecfenz42NmZ6enrsNhw+fNh8//49ekUSOi4p+6XMfkg5JogEEMkcdwIlByWtPK5cuVJ1NSJWrFiRdL9b26FEpeT38ePHynKvX79ufyeRKRGeO3euMs+pU6fMrVu37P/v3LlTdcVz4cIFMzo6Wrmi0rKU3ELru3jxojl79qz93efPn82WLVuq9o97FXH//n2zcuXKwvZIrLoKy9avbXH3n7/f/Z9jbc/bfp9Ye8qIRLfeJGAtQwldV6oxkYSOS+p+ie2HlGOCSACRzHEnuHHjhk0QRUlTt7D8Wzfq2Drj1NmnP8aStx3uFYNQEnOvioSbKJSg/OkZa9eutfJzRagz69D6dGbvzvP8+fOq/aOElyXIWnDHkGIiibU9b/t9Yu0pIxL3akLjZn19fVGRhI5L6n6J7Yd6jwkiAUQyS53gy5cv5s8//7RnhD6vX7+2A+l5y9Vg/devXytXBLrdlbIdklFoQF/TyySnvO8Xrc+/NeR+T2LMztJPnz4d3W+69ST5qt0SWyiJ+z/H2l7muMXaU0YkfhIv2of+lVuj9ktsP6QeE0QCiGQOOoHksX//fntrJI9Lly7ZsQgf3Zd3z4aVkEJP5ORtR54MQokyNi2WRGPzZElQt2t27txpjh07Vrh+jS3ozPzatWvmwYMH9vZTikhiba9FJGX2Qco+qkUkqfslth9SjgkiAUQyB51AVyK6qvBvW7ns3bvXdmKfXbt2/XY2rFtcKduhwVNd0RSxatWqwlsomte/teWKLG99esrMnefVq1eF+0ePMof2nUTqbrv2YYpIYm0vk7xi7fGXkbeN7iPbujWpdsVEEjouqfslth9SjgkiAUQyy53gyZMnZuvWrebTp0/B+XW/Om+wV/et9ckGVXXlkncLLLQdGjDPBov10c96+ipDt0d0a0M8fPjwt8F2rTObV48yK8GF1qdB4JGRkcrg9Pbt23+796+nhIQGeENn3nrYIHsaSQlcbQ8lTElWYx5Z4o+1vUzyirXHHah+//69fZrK30atU/NqGSdOnLAnDjGRhI5LbL+k7oeUY4JIAJHMcifQoGqZ8qLquEVnn0rkGgzVlYCS1Js3b5K3Q0+D6Sw2W4YrLT2KqkF8bYPutWsw2SV7/FcfPbH19u3b6Pr0yLIG5fW4qcZ13O/pForWo9stWmeWwPJ4/Pixlay+p2QnqYZEoieR1Eb3qinU9rLJK9SeLPGqPZKs2uNvo5L+8uXL7XE8evTob3+Umvf/0HGJ7ZfU/ZByTBAJIBI6ARAb7CdAJHQCIEGynwAQCXQN7fjeK/oQIBI6AQAiAUAkAIgEAJEAAH0IEAmdAIA+BIiETgCASAAQCQAiAUAkdHYAYgsQCZ2Azg7EFiCSWe4EtZS+1Tx6Pbje7aRSvX///bd9yZ7ek+TXKBd5pXBVrlfv+XJLugq9xE9vgi2zHbESswCIBBDJLIkktfSt5vnrr7/stNu3b9tEfvDgQfuz/2bWUClcvbpe011UNlbyKLMdsRKzAIgEEMksiSS19K0/j352a0m46wqVwlXVRV2VZOvSv/39/ZVlx7YjVmIWAJEAIpklkfikln8N/RwrhataKLrqEKqrodeHl92OWIlZAEQCiGSORJJa/jX0c6wMrKourl692v5fYyMqy1p2O8qUzAVAJIBI5kAkqeVfQz/HSuEKVdPTeIdua6VsR0rJXABEAohkFkWSWv419HOsFK7QALqeunIH0stsR6zELAAiAUQyRyIRKeVfYz+HSuGKL1++2PVIBinbIUIlZgEQCSASOgEAfQgQCZ0AAJEAIBIAoA8BIqETANCHAJHQCQDoQ4BI6AQAiAQAkQAgEgBEAgD0IUAkdAIA+hAgEjoBACIBQCQAiAQAkQAAfQgQCZ0AgD4EiIROAEAfAkRCJwBAJACIBADoQ4BI6AgA9B1AJHQIAPoMIJKW7hh8+PAp9wFAJMCZLwAgEkAkAIBIABAJACASQCQAgEgAkQAAIgFEAgCIBACRAAAiAUQCAIgEEAkAIBJAJACASAAQCQAgEkAkAIBIAJEAACIBRAIAiAQQCQAgEgBEAgCIBBAJACASQCQAgEgAkQAAIgFAJACASACRAAAiAUQCAIgEEAkAIBIARAIAiAQQCQAgEkAkAIBIAJEAACIBQCQAgEgAkQAAIgFEAgCIBBAJACASQCQAgEgAahKI/wEARAKASAAAkcDcyAQAEAkAIgEARAKIBAAQCSASAEAk0G0yAQBEAoBIAACRtEJC5dM9HyDuiXtEwlk5cMzZB9CAY04U0JmAY0/boa5jTyTQmYAYoM1QVwwQDXQoIAZoMyASOhQQA7QZEAkdCogB2gyIhJ0JxABtBkQCdCggBmgzIBI6FBADtBkQSQd0qG/fvpmhoSGzaNEis2DBArNv3z4zPT1dNZ//mTdvXtUybt68afr7++38AwMD5sWLFyQc2tjWcf/169fgX0vHphMTiKSrOtTw8LC5fPmy+fXrl/0cP37cdqoibt++bU6ePFn5+dmzZ2bTpk1mamrKzj8+Pm7WrFlDh6KNbR33d+7cCfaD2HRiApF0VYdaunSp7UgZP3/+tGdoeeh769evNzMzM5XfDQ4OmvPnzydtx9OnT82yZcvMxo0bK78/c+aMWbJkiT1DPHLkSNU8P378MAcOHDALFy40q1evNpOTk1XTlQQ0n6Zv27bNfPjwIbg+tePQoUNm8eLFpre3115Rufvn7t27Zv78+fbKa926debRo0eIpMvifmRkxFy6dKlwubHpxD0i6eqzUQWvgi+PK1euVF2NiBUrVpiXL18mbcfhw4dtUH/8+LGy3OvXr9vfqUMrwM+dO1eZ59SpU+bWrVuVM0H3iufChQtmdHS0cmapZanzhdZ38eJFc/bsWfu7z58/my1btlTtH3Wme/fu2f/fv3/frFy5EpF0Wdzv3bvX7NixwyZ5JV4lbZfYdOIekXR1h7px44YN4Dx0NaJbWC4KPgWdzph0ZuTfa87bDvfMSWzYsKHq7FC4QawO5E/PWLt2rU0CbkLo6ekJrk9naO48z58/r9o/SihZB+bWVnfG/fLly+3vsjP5q1evJk0n7hFJ13aoL1++mD///NOeHfm8fv3aDqTnLVeDlhp8zM6MdLsrZTsko9CAvqYX4Q/8+98vWp9/y879nsSon9XRT58+jUi6OO7dGJE8ap1O3COSruhQ6kT79++3l7x56H5w3uW7LuvdsxwFZ9EYS9F25HWKUAeITasKnBIdKu97ur+s2wk7d+40x44dQyRdGvcpcRqaTtwjko7vUDoj01WFf9vKRfeEFWA+u3bt+u0sR7e4UrZDA3u6oili1apVhZf4mte/xHdFlrc+PWXmzvPq1avC/aNHmTslASOS8nGv20TuQyWKF92+LTuduEckXdWhnjx5YrZu3Wo+ffoUnF/3brNBOxfdU9UnG/TTlUveLbDQdmjgMBsE1Ec/6ymUDN171mW3ePjw4W+DjlpnNq8e6VQHDK1PjyjrqZts0HH79u1V39Py9QSL0OBj6MwQkXRm3B89etQ+UZXFlQbBFVtlpxP3iKSrOlRfX1+pP6xSUBWdHSmgNVCnM6I9e/aYN2/eJG+HngbTbbJsGa60vn//bgfxtQ0aZNQgoUv2GKQ+enLl7du30fXpkWWdVeqpG43ruN/T5b3Wo1sPWmfWuRBJ98S9Yu7gwYM2HvWosBK+S2w6cY9Iuu4SH4gB2gzdEANEAx0KiAHaDIiEDgXEAG0GREKHAmKANgMiYWcCMUCbAZEAHQqIAdoMiIQOBcQAbQZEQocCYmDO2xRqF3EPiIQkAsRAKZEU/WEhcQ+IhCRCu5uwL4qSb6d+2iXW5np+RAIEGe3mimSOr0gQCSLp2iQSKq8ZKvVZS+nQ2HQtUxXjVHUxe99PVrGtzPyxUqLEAGMkZWJJtUn0kkS3j2RvuY71idB63d+ViVViHZG0TRIJldcMlfqspXRobLqWqRfXZZXd/DeQxuaPlRIlBnhqq0wsKZ71BmtN04sT1SdU2K1MnygrklisEuuIpK06VKi8ZqjUZy2lQ2PT85bpbnds/lgpUWIAkZSNJSVyJWsl7+Hh4dJ9oqxIYrFKrCOStupQofKaoXoEtZYODU2Pdb7U0qR+KVFiAJGUjaUsmeuV6yqAldonysRyKFaJdUTSdkmkqLxmqkjqKUVapvPVUpqUzoVIaolFsXv3bnsFMhsiIdYRScckEb+8ZqjUZy2lQ2PTY50vNn9KKVFioLvbHIslVRzUGMW1a9eqbm2V7RP+elXO1/1dLFaJdUTSVh0qVF4zVOqzltKhsekxkcTmj5USJQYQSZlY0mD75s2bq5J6VvWzbJ9wH2J5//69fYjEnR6LVWIdkbRVhwqV1wyV+qyldGhsekwkZZYfKiVKDCCSMrGkmHcf/9X/NT2lT2QnZepXuopRv/K3JRarxDoiIYkAMUCbAZHQoYAYoM2ASIAOBYgEiHtEQocCYoA2AyKhQwExQJsBkdChgBigzYBI2JlADNBmQCRAhwJigDYDIqFDATFAmwGR0KGAGKDNgEjoUEAM0GZAJECHAmKANgMioUMBMUCbAZHQoYAYoM2ASOhQQAzQZkAkQIcCYoA2AyKhUwHHnrZDk449kUCnAo45+wDqOuZEQYN3MJ/u+QBxT9wjEuCsFAAakQPYBYBIAACRACIBAEQCiAQAEAkgEgBAJACIBAAQCSASAEAkgEgAAJEAIgEARAKASAAAkQAiAQBEAogEABAJIBIAQCQAiAQAEAkgEgBAJIBIAACRACIBAEQCgEgAAJEAIgEARAKIBAAQCSASAEAkgEgAAJEAIBIAQCSASAAAkQAiAQBEAogEABAJACIBAEQCiAQAEAkgEgBAJIBIAACRACASAEAkgEgAAJFAywnE/wAAIgFAJACASGBuZAIAiAQAkQAAIgFEAgCIBBAJACAS6DaZAAAiAUAkAIBIWiGh8umeDxD3xD0i4awcOObsA2jAMScK6EzAsaftUNexJxLoTEAM0GaoKwaIBjoUEAO0GRAJHQqIAdoMiIQOBcQAbQZEws4EYoA2AyIBOhQQA7QZEAkdKpWXL1+21HKavUxigDZ3Yhwikg7sUN++fTNDQ0Nm0aJFZsGCBWbfvn1menr6t+99//7drFq1Krqeu3fvmvnz55sNGzakH+RIp9f2NYJGLSe0zLIJbDYTHSIxNcX1rVu32mbfNSO2U/t2q+1TRDILHWp4eNhcvnzZ/Pr1y36OHz9uZeLy8+dPs3fv3lIHXoF279692g5yZPmNCrxmBHCty0Qkc9fmMnH9/v17s23btrbZd83czjJ9uxX3KSKZhQBbunSpFYgbCP5ZjQ66Dn6ZRO+/6yb3NQUF8ggtv+g9OmfOnDFLliyxV1RHjhyp/P7PP/80Dx8+rDqb2rVrV6n38bx7987s2bPHLFy40Hae1atXm4mJiaptefr0qVm2bJnZuHFjtN0/fvwwBw4csMvTsiYnJwvbXNQe94xw3rx5Zt26debRo0eIpI42l4nrnTt3mjdv3pSKfTcmyhxPzTM2NmZ6enrs9MOHD9uzeRed2GmaYkfb++HDh6Q4TI2ZovWVfX9bI/cpImnjMxUlPQWmy4MHD0ov47dXEjRIJHnTr1y5Yq5fv25FKAHevHnTnDt3zk77+PGjGRgYsNPUOVeuXGlev35daj3r16834+Pjlau00dHRqn2i+dXpNU3ribX71KlT9lJe3Llzx6xZsyb3e6H2+GeE9+/ft21CJLW3ORbXIyMj9tiXjU0/JmLHU/PoNpGStb4j6egOQcaFCxfs+rM41PJ0QpIShykxU2Z9MRq5TxFJG4vkxo0bNvHVuozZFIk6oXs1JdyOoo5w8eJF23ndDlpLAOuMzp3fPTOMtVvi8Lcz73ux9khmmZC4tdW4Nud959mzZ2bHjh1JsenHROx4ah736lTjlX19fZWf165da0/s3JM8Xb2kxGFKzJRZXz37PXWfIpI27VBfvnyxt4R09tQOItHZln/J7Sb8rDOrM6htKe3QLQMJdXBw0Haw2HaG2q3tLNOmWHt0RpmdxZ4+fRqRNEkkMzMz9lbRp0+fao7NMsdTP/uicWPFj2V/epk4TImZWtbXzH2KSNqwQ0ke+/fvN58/f25op6xFJEX3Y/1l5QW+z+7du+0VQYpIdN9a81y7ds1equu2wWyIpEx7JDjdHtN95mPHjiGSJojkr7/+Mv/880/ScvKmx45nkXxCcZMahykxU8v6mrlPEUmbdSglWT0CPDU11fBO6f+sdTTqikSDh1+/fi38vp5G0z1qCSHl1tbixYurlhva5jLt1qOQZW5txdrj8uLFi+SOiEjKx2xqkbC8abHjqXl0HDP02L1iz53fv9XkPghTViRlY6aW9TVznyKSNupQT548MVu3bq265Gxkp3QH+/Q0h56GqlUkepJE94SzYNfg4NmzZyuDg/pZT40IXUVs3ry5qpPoSZG85fisWLGi8pTWq1ev7KB9bDv9ZfqD7brFIPQkWdFge6g9QvPpKRyhfRq60kEktcdsLd/Jmx47nppHP+sugKafOHHCPjrrzn/p0qXK/Doxcv8+o0wcpsRMLetr9n5HJG3SoTS4V7pMZQ3BkQWvLvMVlArqWkWiQXOdIblnSSdPnrRncfqdJJU9vaK/hXEf/9X/Nb1oOS6PHz+2g6LabnVE/4+n8rbTX6b7HT01pu3R8jTe8vz588JlFbUnu0Wh+bUvtawsQSCS1hRJ7HhqHp2wLF++3A6KHz169Lc/Bs4ex9VHT1C9ffs2KQ5TYyZ1fYiEDgXEAG1m27oqBtjjBC0QA4gEEAlBC8QAbc5o5nuxAJGQRIAYoM2ASOhQQAzQZkAkdCggBmgzIBKgQwEiAeIekdChgBigzYBI6FBADLRPmylXi0iAJJLU9tTSwMRA57e5EY/l1vqyw3aPkbmeH5GQROak7amlgYmBzm9zI/ZTu+5rRAI1HaBYWdlQqc5YGc9ay8bWs1y9bO7QoUP2/Ua9vb22Kl3o3WF57xdLKW+KSNqzzUUxVku56FjMNbOccmqpaVG29HO97W5kX0UkLd6hYmVlQ6U6Q9PqKRtbz3JVETF746reqrply5ak13/XUt4UkbRfm0MxllpTJxZzzSqnXGup6bKln+ttd6P7KiJpsyTiFuQJleoMTaunbGw9y9VVgvt6eL1pN0UktZQ3RSTt1+ZQjKWKJBZzzSqnXGup6bKln+ttd6P7KiJp8SQSKisbKtUZmlZP2dh6luvXW1Agp4ikkeVGEUnrtjkUY6kiicVcs8op11pqumzFznrb3ei+ikhauEPFyspmoikq1Vk0rd6ysbUuN1YuNDatkeVGEUnrn0DlxVi9IgnFTCPLKddaarpZIklta2pfRSQt3KFiZWVdQqU6/WmNKhubutxNmzZVXS6rwmGKSBpZbhSRzE6bUkvgxmIstVx0LOaaVU651lLTZUs/19vuRvdVRNLCSSRWVjZUqjM0rZ6ysfUsVw8OjIyMVAbwtm/fnjzY3qhyo4hk9kRS9AReUZtDMeaXq42Vi47FXLPKKddaarps6ed6293ovopIWjiJxMrKhkp1xsp41lo2tp7livPnz9v7wnrsUAOOqWesjSo32qoxUJR8O/VTdPuoKMb8crWxctGxmGtmOeVaSk2XLf1cb7sb0Vcb/Tc9iISzUSAGGnZFAu3B//zP/yASkggQA7MjEuK+M9FtOERCEgFigDZDy8QA0UCHAmKANgMioUMBMUCbAZHQoYAYoM2ASNiZQAzQZkAkQIcCYoA2AyKhQ6VA+VNiYC7bTPwhEqijQ9X6x10p8xV91/1/I8qfEgOIpNZ5/fjjSgeRkERmOfnUKiA6LiJplTY349UdgEg6qkOFymHGSobqPTpLly61VQVDVxZ6CV5W3lMlP4ve75P3f//1F6rq6KMKbH19fWZmZoaDjUiCbe7v76+8Vj17o+2zZ8/sz58+fbLTQ/GX/U4v99RLT7P3YmUvOCzajrwSzaG+V08ZbBErGa03Axdtf2rJX0TS5UkkVg6zKMlrHtVKyN7cqTeNhoSgV0ark+r7//zzj/nrr79Ki8T/v94S6ge2tufgwYMcaEQSbfP+/fttDIq///7b3rZSP8h+zkorx14tr1ofWXKOvak3r0RzrO/VUwa7TMloSapo+1NK/iISkki0HGZRZ8rEkBEqL6r/u1cgWp/WW6tIsqI/LjrL+/fffznQiCTaZhVzGxoasv/XSwFVGVQfoRMcJfQyIvFLLsfe+eV/P9b38ihbBruWktHu9qeU/EUkJJFoOcyyg9+h8qJ56y4qX1t2Gbokf/36dUVi7u0CQCShNitustujum2jAlK6LSp0+0i3u8qIJGX/FvWBWKncWstg11IyuuyyEQlJJHiGEz0INdapzlt3UdXBsstQQZzsrFKX7FevXuUgI5LSbda4nm7JZgLRiYkKu2U/z4ZIYn2vnjLYtZSMTimxjUhIIlXEymEWBZ8qKaojZui2UkgC2dVDdpldpsOGAl/r1iCibq9psFLFegCRlG3z3r17zX//+9/KLa3s9lb282yIJNb36imDXUvJ6FpKbCMSOpQlVg6z7GC75glJYMeOHfZJGX1f60sdbPfLn2ZXIn/88YcdxAREktJmPXGlMQOVUha6olWMKa7LxF8jRBLre/WUwa6lZHTZZSMSkkguoXKYsdtLuhro7e21T4WEbldpur6r70gq/qOIsf/75U/F5OSk/Q5/dYxIUtv85MmTqsd+s4dFsrrmsfhrhEhifa+eMtgitWR0yrIRCUmkKejWknu7ajZQp9NZGyAS2gyIpA07lG4LaCAuewZeZz+zOSCn9epsrt2fKCGp0mZAJF3bofQUiR651SW5noA5evSoFcpsoXvWukXGIDtJlTYDIqFDATFAmwGR0KGAGKDNgEjoUEAM0GZAJECHAmKANgMioUMBMUCbAZHQoYAYoM2ASOhQQAzQZkAkQIcCYoC4B0RChwJigDYDIqFDATFAmwGR0KGAGKDNgEiADgWIBBAJ0KGAGKDNgEjoVMCxp+0wV8eeSKBTAcecfQB1HXOioME7mE/3fIC4J+4RCXBWCgCNyAHsAkAkAIBIAJEAACIBRAIAiAQQCQAgEgBEAgCIBBAJACASQCQAgEgAkQAAIgFAJACASACRAAAiAUQCAIgEEAkAIBIARAIAiAQQCQAgEkAkAIBIAJEAACIBQCQAgEgAkQAAIgFEAgCIBBAJACASQCQAgEgAEAkAIBJAJACASACRAAAiAUQCAIgEAJEAACIBRAIAiAQQCQAgEkAkAIBIABAJACASQCQAgEig5QTifwAAkQAgEgBAJDA3MgEARAKASAAAkQAiAQBEAogEABAJdJtMAACRACASAEAkrZBQ+XTPBwAQCWflwDEHQCQkFODYAyASEgkQAwCIhCQCxAAAIgGSCBADAIiEJALEAAAiIYkAMQCASEgiQAwAIBLo2iTy8uVLDioiAUAkrZBE8v4Set68eS3fngULFjRt2Xfv3jXz5883GzZsKPzOzZs3TX9/v92OgYEB8+LFC0QCgEg4GxW3b982J0+e7OqkKIncu3evcPqzZ8/Mpk2bzNTUlPn165cZHx83a9asQSQAiASRKCmuX7/ezMzMBJfz9OlTs2zZMrNx48bK78+cOWOWLFliFi1aZI4cOfLbPGNjY6anp8dOP3z4sPn+/XvVd44fP26nLVy40Gzbts18+PChcJ1575LKriJ0NbVu3Trz6NGjYFuL1lfmPVWDg4Pm/PnzHXsyAYBIoOYkcuXKlejViJYjEUg6Hz9+rMx3/fp1+7ufP3/a2z7nzp2rmke3iZSs9R1JZ3h4uDL9woULZnR01E7TR8s7cOBAcJ1+e9yriPv375uVK1cWtqHM+kKsWLGiLcdoEAkgEmh6EtHViG7XxJbjXi0ISUIJ2cVN5JpncnKy8vO3b99MX19f5ee1a9eaHz9+VH7W/3X1Elqn3x5drdy6davUviizvhCSlmS1evVqe0Wzb98+Mz09jUgAEEl3i+T169d20LiW5Sixhgbs9bMvGs2TkTe4707PW6f/OyX27Mrn9OnTwTbUsj5/3UNDQ+br16+VKxrd7kIkAIikq0Vy6dIlO25Qy3JiT3kVySfv/3nzlBGJ0DjKnTt3zM6dO82xY8eCVxSp63NZvHhx1RWNZNLMp8gQCQAiaYsksnfvXpuEa1mOBrd1dh6ax308VreBlIzd+f1bTW5iLiuSDK0rNL2W9bns2rWr6meJRLe4EAkAIulqkWhMIxvITl2OBq/Pnj1bGbzWz3oSyp1HP3/+/NlOP3HihBWXO7+uiLL5L1++bFatWhVcpxK3xk0yIejxWz25JTTonnfVUc/6XDQWo082v5ZV5rYgIgFAJB0tEiVefxwjZTl62ktXGTqz37NnT5WUNM/ExIRZvny5HRQ/evTob4PT2eO4+ugJqrdv3wbXqafCtK7sSkK3tTSIrttsaksmlSJS1+cjeagtWXvfvHmDSAAQSXeLhARGDAAgEkAkwHEAQCSdmUTa4YkmYgAAkQBJBIgBAERCEgFiAACRkESAGABAJCQRIAYAEAmQRIAYAEAkc59EKGdLDAAgEqgriTTisd2UlyHOdYKsdzlzPT8iAUAkLZdEGpF42il5IRIARAI1JJGiErV5JWdjb+HVu7oOHTpk37nV29trKyWGrkhC5XlTSuf661C1RlUxzN675dZf10se9W4tvfRRhancglspr66PtTXWvjLzIxIARNIWIgmVqPXniSXXixcvVt4CrDf9btmypTA5x8rzppTO9dehlyhmFRX9NwGfOnWqUklRr83XW4NrEUmsrbH2xeZHJACIpG1EEipRmyqSjRs3VtX5eP78eWFyjpXnTSmd668jVJZX4ih6y3GKSGJtjbUvNj8iAUAkbSOSUInaVJH4NUCUSIuSc6w8b0rp3BQBhOqU1LMcv62x9sXmRyQAiKRtRCKKStTWK5JQco6V5w1tVyuKJLV9sfkRCQAiaSuRZPglamMimZqaqvrdpk2bqm7XvHr1qnB5sfK8oe2qRwCqhFjLra3UtsbaF5sfkQAgkrYRSahErV/O1h0Af//+vR3Udpc7Pj5uRkZGKgPI27dvL0zOsfK8KaVzU0SiwXbdNhMPHz4sHGyvt62x9sXmRyQAiKRtRBIqUeuXs80Sur6rM3t911/u+fPnTU9Pj33sVU8uhZJ8qDxvSuncFJF8//7d7Nu3zy5Ty9cgd9736m1rrH1l5kckAIikLUQCxAAAIgGSCBADAIiEJALEAAAiIYkAMQCASEgiQAwAIBIgiQAxAIBISCJADAAgEpIIEAMAiIQk0qqklgCmZDAiAUAkTUwirZxciv5iPbUEsP/9bk2oiAQQCXRdEmmU/Eig7AcARDJLSTlWpjaP48eP2/dJqRDV2NhY0nuv3r17Z99BpZdDal0qfTsxMRG8IskrARxaTlHJ4JmZGdPX12ffveWiF1Tqzb0ZoXK5iAQAkSASk1am1kflYrM32OqFhKr6lyKS9evX27fgZm/IHR0dtUIKiSRvuSnLcX8eGhqyb+X12yR5iFi5XEQCgEgQiUkrU+uj6oXuGf3k5GSSSPJwC0KVFUnKctyfX79+ba9Ksvok+re/v7+yD2LlchEJACJBJMbUlfhTSusW/U6vi1eNkMHBQfta9zLyyFtu2eX4P2/dutVedQhd1eiKzG1fqFwuIgFAJIikwSJJXZ7GVFRY6tq1a+bBgwf29lgtIklZjv+zSvlqTEVobETz513VdHIMACASmDORbN682UxPT1d+DpXWFX65Wg3Su+Vo/ellRZKynLyf9XCBxkZ0W8slpRwwIgFAJIikBpH8888/9qmtonKxsXK1SuDZ01WS0MDAQCl5+CWAY8vxv++3SQPovb29vw2kx8rlIhIARIJI6hSJ0JNNekJq+fLlNpmnlKt9/PixHbzWd3Rr6tatW6VE4pcAji3H/77fpi9fvthpkqFPrFwuIgFAJF0vEpIVMQCASACRAMcGAJF0ThJJfQ8WIBIAREISAWIAAJGQRIAYAEAkQBIBYgAAkZBEgBgAQCQkESAGABAJSaQRUN6WGABAJCSRupjN8rYkSPYTACLpwCQSe1EiIBIARNIhSUTvv8reh6W33T569Mi8ffvWVh30UZVAFYJSmdpQWd6i8raXLl0KlvENlbXN2868toW+RwzQjQCRQBOSiJvQ79+/X6kAqDf5+klY4jh48GBleaGyvHlXJLt37y78fqysbdF2+usKfY8YoBsBIoEmJBG9uVdvy/VRwaedO3dW/U412f/999/K8kJlefNEEvp+rKxt0Xb6ywl9jxigGwEigSYkEZ21a5oS+enTp6um6TaU6pqL58+fW5GElpdSTCrvSiJU1ja0ne5yQt8jBuhGgEigSUlE9c6zK5Bjx45Vfj8yMmKGhobs/w8cOGCuXr3aNJGUKWtbtJ15deDzvkcM0I0AkUCTk8iLFy+qvqdCT6ou+OnTJzsI/v3796aJJKWsrb+dRW3zv0cMsC8AkUATkogqCupJJ+EPgGdXIn/88Yc5fPhwkhhi5W3938XK2oa2011OrD3EAAAigQYnEd0GWrt2beWR3CwJZ0xOTtp5/b9Uj4khVt4273ehsrah7XSXE2sPMQCASGCWk4iSuQbdAZEAIBKSSPI8usWkqwSefkIkAIgEakoiGufYsWNH1SA7IBIAREISAWIAAJEASQSIAQBEQhIBYgAAkZBEgBgAQCQkESAGABAJkESAGABAJCQRIAYAEAlJBIgBAERCEgFiAACRAEkEiAEAREISAWIAAJGQRIAYAEAkJBEgBgAQCZBIgGMPgEhIKMAxB0AkrZdY+HTPBwAQCXBmDgCIBBAJACASQCQAgEgAkQAAIgFAJACASACRAAAiAUQCAIgEEAkAIBIARAIAiAQQCQAgEkAkAIBIAJEAACIBQCQAgEgAkQAAIgFEAgCIBBAJACASAEQCAIgEEAkAIBJAJACASACRAAAiAUAkAIgEAJEAACIBRAIAiAQQCQAgEkAkAIBIABAJACASQCQAgEgAkQAAIgFEAgCIBACRAAAiAUQCAIgEEAkAIBLoSIH4HwBAJACIBAAQCcyNTAAAkQAgEgBAJIBIAACRACIBAEQC3SYTAEAkAIgEABBJKyRUPt3zAQBEwlk5cMwBEAkJBTj2AIiERALEAAAiIYkAMQCASIAkAsQAACIhiQAxAIBISCJADAAgEpIIEAMAiAS6Nom8fPmSg4pIABBJqySRmzdvmv7+frNgwQIzMDBgXrx40fLt0bY2i7t375r58+ebDRs25E7/+vVrW/4FOSIBRAJNSSLPnj0zmzZtMlNTU+bXr19mfHzcrFmzpquToiRy7969wul37twx+/bt44oEAJEgEjE4OGjOnz+ftJynT5+aZcuWmY0bN1Z+f+bMGbNkyRKzaNEic+TIkd/mGRsbMz09PXb64cOHzffv36u+c/z4cTtt4cKFZtu2bebDhw+F68y7EsiuIubNm2fWrVtnHj16FGxH0frKXGWMjIyYS5cuIRIARIJIxIoVK5LGG7QciUBXLx8/frS/u3Llirl+/br93c+fP+2tsnPnzlXNo9tEStb6jqQzPDxcmX7hwgUzOjpqp+mj5R04cCC4Tr897lXE/fv3zcqVKwvbUGZ9Ifbu3Wt27Nhhxbl48WIrJUQCgEi6ViRKwEq8q1evtmfnumUzPT0dXI57tSAkCSVkFzeRa57JycnKz9++fTN9fX2Vn9euXWt+/PhR+Vn/19VLaJ1+e3S1cuvWrVL7osz6QixfvtzcuHHD/l/tvnr1qjl16hQiAUAk3SkS/X5oaMgOIGdn57rdlbIcyci/JaRbTO48vmg0T4b73bzpeev0fycZZlc+p0+fDu6LWtYXQm2TXBAJACLpSpHo1ox7dq6kGHoiKm85eYm5jHzy/p83TxmRCI2jaCB8586d5tixY4XbU8v6YsT2ASIBQCQdK5Jdu3b9dnatW1wpy9Hgtq5oQvO4jxTr1pkE5s7v32pyZVZWJBlaV2h6Letz0W2wmZmZqvl1axCRACCSrhSJxhX0yQae9TSS/pYkZTkavD579mxlGfpZT0K58+jnz58/2+knTpywA9bu/FpvNv/ly5fNqlWrguuU7DRukglBjyzryS2hQfe8q4561udy9OhR+8BANr8eLNAyEAkAIulKkQglVQ1W66x8z5495s2bN8nLOXnypL3KyJaRPV2VzTMxMWHHEbQeJWJ/QD97HFcfPUH19u3b4DqVvLWu7EpCt7U0iK5bTJJIJpUiUtfnokeXDx48aNe9dOlSK9F2jwEARAItnURIYMQAACIhiZDAiAEAREISmbtd2Mz3YgEiAUAkJBEgBgAQCUkEiAEAREISAWIAAJEASQSIAQBEQhIBYgAAkXROEqGcLTEAgEigriTSiMd2630Z4mwmyHqXM9fzIxIARNJySaQRiaedkhciAUAkUEMSKSpRm1dyNvYWXr3A8NChQ/adW729vbZSYuiKJFSeN6V0rr8OVWtU5cfsvVtu/XW95FHv1tJLH/XGXrfgVsqr62NtjbWvzPyIBACRtIVIQiVq/XliyfXixYuVtwDrTb9btmwpTM6x8rwppXP9deilkVlFRf9NwKpkmFVSVO0SvTW4FpHE2hprX2x+RAKASNpGJKEStaki2bhxY1Wdj+fPnxcm51h53pTSuf46QmV5JQ5/vbWIJNbWWPti8yMSAETSNiIJlahNFYlfA0SJtCg5x8rzppTOTRFAqE5JPcvx2xprX2x+RAKASNpGJKKoRG29Igkl5zKlacuWzm0FkaS2LzY/IgFAJG0lkgy/RG1MJFNTU1W/27RpU9XtmlevXhUuL1aeN7Rd9QhAlRBrubWV2tZY+2LzIxIARNI2IgmVqPXL2boD4O/fv7eD2u5yx8fHzcjISGUAefv27YXJOVaeN6V0bopINNiu22bi4cOHhYPt9bY11r7Y/IgEAJG0jUhCJWr9crZZQtd3dWav7/rLPX/+vOnp6bGPverJpVCSD5XnTSmdmyISlcndt2+fXaaWr0HuvO/V29ZY+8rMj0gAEElbiASIAQBEAiQRIAYAEAlJBIgBAERCEgFiAACRkESAGABAJEASAWIAAJGQRIAYAEAkJBEgBgAQCUmk1QmVAk4tE9wNZYURCSASaEoSaefk4pcCdtuSWiY4tCxEAoBIoAsTY2p7uyHJIhJAJND0K5JYmdo8jh8/bt8npUJUY2NjSe+9evfunX0HlV4OqXWp9O3ExESp7QmVAs6bFlpX0bJmZmZMX1+ffT+Xi15iqbf7ZoRK6iISAETSdSIJlan1UbnY7A22eiGhqv6liGT9+vX2LbjZG3JHR0etkMpuT+g19/60MuvKW9bQ0JB9c6/fbslDxErqIhIARNJ1IgmVqfVR9UL3bH1ycjJJJHm4BaFi25MikjLrylvW69ev7VVJVsNE//b391e2K1ZSF5EAIJKuE0lK8kkprVv0O70uXjVCBgcH7WvdU+ZPFUnKutyft27daq86hK5qdJXk7oNQSV1EAoBIEEmCSFKXpzEVFZa6du2aefDggb091iyRpK7L/VnlfjWmIjQ2ovnzrmraNQYAEAnMmUg2b95spqenKz+HSusKv1ytBundcrT+9EaKJHVd/s8a8NfYiG5ruaSUDEYkAIgEkXj8888/9qmtonKxsXK1Ss7Zk1OS0MDAQNL2+KWAQ9Ni6wotS2gAvbe397eB9FhJXUQCgEgQSST56KklPf20fPlym6hTytU+fvzYDkzrO7rtdOvWraTt8UsBh6bF1hValvjy5YudJmH6xErqIhIARNLRIiFZEQMAiAQQCXBsABBJ5ySR1HdcASIBQCQkESAGABAJSQSIAQBEAiQRIAYAEAlJBIgBAERCEgFiAACRkEQaQTeUriUGABAJSaSJzGbpWhIk+wkAkXRgEom9BBEQCQAi6ZAkovdfZe/D0ptsHz16ZN6+fWsrCvqoAqCKPKkEbS1lcC9duhQs4xsqWZu3nXltC32PGKAbASKBJiQRN6Hfv3+/Ut1Pb/L1k7DEcfDgwcryUsvg7t69u/D7sZK1Rdvpryv0PWKAbgSIBJqQRPTmXr0J10fFnHbu3Fn1O9Vk//fffyvLSy2DG/p+rGRt0Xb6ywl9jxigGwEigSYkEZ21a5oS+enTp6um6TaUapaL58+fW5GElpdSKCrvSiJUsja0ne5yQt8jBuhGgEigSUlEtcyzK5Bjx45Vfj8yMmKGhobs/w8cOGCuXr3aNJGUKVlbtJ15deDzvkcM0I0AkUCTk8iLFy+qvqciTqoc+OnTJzsI/v3796aJJKVkrb+dRW3zv0cMsC8AkUATkoiqBepJJ+EPgGdXIn/88Yc5fPhwkhhipWv938VK1oa2011OrD3EAAAigQYnEd0GWrt2beWR3CwJZ0xOTtp5/b9Ur6cMbtEyQiVrQ9vpLifWHmIAAJHALCcRJXMNugMiAUAkJJHkeXSLSVcJPP2ESAAQCdSURDTOsWPHjqpBdkAkAIiEJALEAAAiAZIIEAMAiIQkAsQAACIhiQAxAIBISCJADAAgEmjlJELJXWIAAJF0QRLRG3NVK6QZ+CV3OzXBll2G/mL/4cOHiAQAkXSWSPTK9ex18d2YvGZzG7Wf3dfxIxIARNL2Inny5In9o0P/u9euXTM9PT1m6dKl5u+//7YvUdR7sFJK5OaV3H337p09K9cfO2pZq1evNhMTE8Ftj80TKvtbdv4y5YUbVe5X+1v7HZEAIJKOEMnw8LAZGxv77bt//fWXTaK3b9+2AlGJXf2cWiLXX6+S9fj4eOUtv6Ojo7aqYYjYPLGyv2XmF7Hywo0q9ytJa78jEgBE0hEiGRgYMK9evfrtu25ZXP3s1gpJKZFbJnmVKWoVmidWxrfM/CJWXrhR5X61v7XfEQkAIukIkeh2jy+CWFGqlBK5eevVq95PnTplBgcH7SvfyyS40DxlXlFfdv5QeeFGlfvV/tZtQEQCgEg6QiR5VwMpIoldTfjz6jaaik/p9s6DBw/sa+qz7+SNqcTmKSOSlPlD5YUzITWi3O9cFNxCJIBIoCWvSGIlcv15Nd7ifn9qaiqa4GLzxESSMn+ovLBLPeV+NZbEFQkAIukYkehevW7h1CqSWIlcv+Subh1lT0xlYwWxBBebJyaS1PmLygs3qtyvxlwYIwFAJB0jEj09pCevahWJCJXI9UvuPn782A7GK7kq4WpQOpbgYvPERJI6f1F54UaV+9XtMp7aAkAkHSMSJU33CgKaX154y5YtVjaIBACRdIRIhJ4u4p1Y/0ezywvr1pr2d6vFAAAigbqSiO7ja0wAml9eWPuZd20BIJKOEwkQAwCIBEgiQAwAIBKSCBADAIiEJALEAAAiIYkAMQCASIAkAsQAACIhiQAxAIBISCJADAAgEpIIEAMAiARIIkAMACASkggQAwCIhCQCxAAAIiGJADEAgEhIJMCxB0AkQEIBjjkAIpnzxMKnez4A8H/8L0XSrqQTKtKTAAAAAElFTkSuQmCC</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2013-04-25 22:51:54 +0100" MODIFIED_BY="Bary CM Berghmans" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2013-04-25 22:51:54 +0100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;6 reports of 5 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;7 reports of 6 studies included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;21 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;276 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;276 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;276 records identified through Specialised Register searching&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;0 additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;255 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;14 reports of 14 studies excluded, with reasons&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>